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Breast cancer is the most common type of cancer in women, and a major cause of 
premature death still today. The PI3K-Akt-mTOR signaling (in short: PI3K 
signaling) pathway is a growth and pro-survival pathway, and is frequently 
deregulated in breast cancer due to amplifications, mutations and deletions of the 
genes encoding these important signaling hubs. PTEN inhibits the activation of Akt, 
and acts as an endogenous tumor suppressor by negatively regulating PI3K signaling. 
Loss of PTEN protein expression is frequently observed in breast cancer, which could 
contribute to hyperactivation of the PI3K pathway. Whereas aberrations in the PI3K 
pathway are associated with resistance towards endocrine therapy, less is known of 
the role of this signaling pathway in resistance to chemotherapy. 
Epigenetic alterations like DNA methylation, histone modifications and non-coding 
RNAs can also influence cancer progression and resistance to therapy. Non-coding 
RNAs are functional RNA transcripts, but are not translated into proteins. 
MicroRNAs (miRNAs) regulate protein expression post-transcriptionally by binding 
to complementary sequences on mRNA transcripts, which is then degraded. PTEN 
and the PTEN pseudogene PTENP1 share several miRNA binding sites, and PTENP1 
acts as a competing endogenous RNA (ceRNA) by adsorbing miRNAs which would 
otherwise degrade various protein-coding mRNA transcripts. In prostate cancer it has 
been showed that PTENP1 expression protects PTEN mRNA from degradation and 
increases PTEN protein expression through ceRNA interaction. The role of the non-
coding RNA PTENP1 in breast cancer has not been addressed previously.  
Main objectives   
The first two papers presented in this thesis focused on unraveling the potential 
relationship between PI3K signaling and PTEN status, and mechanisms of resistance 
to chemotherapy in breast cancer. In the third study we examined the potential role of 
PTENP1 pseudogen in breast cancer on tumor growth. 
 IX 
Results  
In Paper 1, we explored the relationship between PI3K signaling and clinical outcome 
using data from three clinical studies. By examining breast cancer biopsies using IHC 
staining for PTEN, phosphorylated Akt (pAkt), pS6K and p4EPB expression we 
found that neither of the protein staining’s were associated with survival outcome, or 
predictive of response to chemotherapy. However, we found that patients with a high 
intratumoral PTEN mRNA expression had a worse prognosis than patients with a low 
PTEN mRNA expression. Interestingly, this was only significant for patients with 
TP53 wild type tumors. PTENP1 was expressed in most of the breast cancer biopsies 
examined and correlated to PTEN expression. However, there was no prognostic 
impact of PTENP1 gene expression, and no predictive value was observed, with 
respect to response to chemotherapy. 
In Paper 2, we created anthracycline-resistant breast cancer cell lines to compare how 
PI3K signaling was affected by an acute dose of anthracycline in anthracycline-
resistant vs. naïve cells. After 24h anthracycline exposure we observed an increase in 
phosphorylated (activated) Akt in ER positive cell lines, while no change was seen in 
ER negative cell lines. Also, the resistant cell lines showed a higher baseline 
expression of phosphorylated Akt. Accordingly, we examined the effect of Akt 
inhibition with and without doxorubicin in concert both in vitro and in vivo. A 
combination treatment with Akt inhibitor and doxorubicin reduced tumor size more 
than Akt inhibitor or chemotherapy alone in the ER positive MCF7. In contrast, in the 
ER negative MDA-MB-231 Akt inhibition had no additive benefit to the 
anthracycline. To examine the relevance of Akt and anthracycline resistance in a 
clinical setting, we examined the mRNA level of AKT1 expression in breast cancer 
biopsies from two clinical studies. We found that an initial increase in AKT1 24 hours 
after the first treatment characterized ER positive tumors that subsequently responded 
to doxorubicin treatment, although this was not observed after 16 weeks of treatment. 
Thus, analysis of biopsies after 24 hours, to dissect the acute response to 
anthracyclines, seems to be of value to predict whether the patient will subsequently 
respond to treatment.  
 X 
The third paper addressed the question of whether the non-coding RNA PTENP1 has 
a functional role in breast cancer through ceRNA interactions. We found a diverging 
role for PTENP1 that was dependent on the tumor´s ER status. PTENP1 
overexpression increased both the PTEN transcript and PTEN protein in ER negative 
cell lines, while ER positive cell lines had decreased PTEN transcript and unchanged 
PTEN expression subsequent to pseudogene transduction. By implanting PTENP1-
overexpressing breast cancer cells in mice, PTENP1 reduced tumor growth in ER 
negative breast cancer, while it increased tumor growth in ER positive breast cancer. 
This effect seemed unrelated to PI3K signaling, but rather related to AP2γ and ER-
signaling. PTENP1 overexpression increased expression of hsa-miR-26a and 
profoundly decreased the hsa-miR-26a target ESR1 and thereby ERα expression in 
the ER positive MCF7. There was also a clinical correlate to this finding, where data 
from the TCGA database demonstrated that breast tumors with upregulated PTENP1 
expression exhibited lower ERα expression than breast tumors with normal or no 
PTENP1 expression. 
Conclusion and implications 
We found a high PTEN gene expression to be associated with worse prognosis for 
patients with breast cancers harboring preserved p53 function. The finding that a high 
level of PTEN expression is a marker for bad prognosis in breast cancer is surprising, 
but indicates that PTEN transcripts may not only influence PTEN protein levels and 
PI3K signaling, but also interact with other biological mechanisms to promote tumor 
progression. The interaction between PTEN and TP53 seems essential in this context. 
Also, we demonstrate that ceRNA interactions are implicated in PTEN regulation, via 
its pseudogene PTENP1, and this interaction is fundamentally dependent on the 
tumor´s estrogen receptor status. Furthermore, in estrogen receptor positive breast 
cancers, upregulated PI3K signaling, and in particular Akt activation, seems to play a 
key role in resistance to anthracycline treatment, and potentially Akt inhibitors could 
be introduced in this setting to target chemoresistance.  
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Cancer is a family of disease characterized by cells undergoing abnormal division 
resulting in malignant growth displacing normal cells in bone marrow or blood, or 
developing solid tumors that destroy surrounding normal tissues. Cancer is a family 
of disease characterized by cells undergoing abnormal division resulting in malignant 
growth displacing normal cells in bone marrow or blood, or developing solid tumors 
that destroy surrounding normal tissues. A major obstacle to successful systemic 
cancer therapy is the fact that cancer is not a foreign intruder like a bacteria or a virus, 
it is the body’s own cells that change characteristics and become malignant. These 
characteristics are known as the 
"Hallmarks of cancer" (Figure 1) 
(Hanahan and Weinberg 2000, 
Hanahan and Weinberg 2011). 
The hallmark characteristics 
include the ability to sustain 
proliferative signaling, evade 
growth suppression, the ability to 
evade immune destruction, 
replicative immortality, activate 
invasion and metastasis, induce 
angiogenesis, resisting cell death 
and deregulate metabolism. 
Cancer is a genetic disease, but 
the development of cancer is not considered to be a single mutational event, but 
rather an accumulation of events where the cells acquire hallmark characteristics 
(Hanahan and Weinberg 2011). Enabling characteristics that facilitates 
carcinogenesis and progression include genomic instability i.e. by inactivation of 
Figure 1. Hallmarks of cancer. Modified from 
(Hanahan and Weinberg 2011) 2001. Reprinted 
with permission. 
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genes involved in DNA repair or mitotic checkpoints like TP53, ATM or BRCA1 
(Negrini, Gorgoulis et al. 2010) and modification of the tumor niche by tumor-
promoting inflammation. These characteristics span over a wide range, which reflects 
the diversity of the disease and the challenges one faces when designing effective 
cancer therapy. (Hanahan and Weinberg 2000, Hanahan and Weinberg 2011, 
Vogelstein, Papadopoulos et al. 2013, Vogelstein and Kinzler 2015) 
 
1.2 Epidemiology and cancer risk 
Globally 8.8 million people died of cancer in 2015 making cancer the second leading 
cause of death worldwide (http://www.who.int/cancer/). The number of people 
diagnosed with cancer is expected to rise approximately 70% during the next twenty 
years (Ferlay, Soerjomataram et al. 2015) This increase is in part a reflection of our 
increased lifespan, since most malignancies occur after the age of 75, but also due to 
environmental factors, lifestyle and improved detection techniques (Cancer Registry 
of Norway 2016).  With improved detection techniques one also introduce the risk of 
overdiagnosis. By identifying small non-aggressive and slow-growing malignant 
tumors that may never progress, overdiagnosis could contribute to an increase in 
incidence (Carter and Barratt 2017). Prostate cancer by prostate specific antigen 
(PSA) testing, breast cancer by mammography screening, thyroid cancer by 
ultrasound and lung cancer by computed tomography screening are the most likely 
cancers subjected to such overdiagnosis (Carter and Barratt 2017) 
A predisposition to cancer can be caused by various hereditary factors. The number 
of known breast cancer susceptibility variants is increasing, which may lead to better 
risk prediction for individuals with a familial history of breast cancer in the future 
(Michailidou, Lindstrom et al. 2017, Milne, Kuchenbaecker et al. 2017). Specifically, 
germline mutations in BRCA1/2, TP53 and PTEN are associated with a high lifetime 
risk of developing breast cancer. Germline mutations in the BRCA1/2 gene predispose 
to breast and ovarian cancer. 45-75% of carriers of these mutations will develop 
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breast cancer, and 18-40% ovarian cancer (Baretta, Mocellin et al. 2016). Germline 
mutations in the TP53 gene are responsible for the Li-Fraumeni syndrome, 
characterized by early onset of multiple cancer types, including breast cancer 
(Malkin, Li et al. 1990).  Germline inactivating PTEN mutations cause Cowden 
syndrome, which is a relatively rare disorder and is characterized by frequent non-
cancerous neoplasms, hamartomas, and an increased lifetime risk of developing 
breast, thyroid, endometrial and kidney cancer (Hollander, Blumenthal et al. 2011).  
With respect to risk factors associated with increased risk of non-hereditary breast 
cancer, these are to a large extent hormone-related. The mammary glandular tissue is 
exposed to high and cycling levels of hormones which is also dependent on the length 
of each woman´s fertile period. An increased risk is correlated to the early onset of 
first menstruation, having few or no children and high age at first birth, a short time 
breast-feeding, a late menopause and the use of postmenopausal hormone substitution 
(Bray and Soerjomataram 2015).  
Environmental factors can also increase the lifetime risk of developing breast cancer, 
such as high alcohol consumption and obesity (Lauby-Secretan, Scoccianti et al. 
2016). However, only around 30% of all cancers are considered to be preventable by 
avoiding risk factors (Bray and Soerjomataram 2015). Furthermore, hereditary and 
environmental factors can not explain the development of all cases of breast cancer.  
Apart from this, somatic mutations occur randomly in healthy non-cancerous cells 
during replication throughout a person´s lifespan. The fidelity of DNA replication 
enzymes is around 1 error per 109-10 nucleotides copied, after proofreading and 
mismatch repair (Ganai and Johansson 2016). Accordingly, cancer is also attributed 
to "bad luck" (Tomasetti and Vogelstein 2015). By mathematically correlating the 
lifetime risk of specific cancer types versus the number of stem cell divisions in the 
tissue wherein the cancer originates, Tomasetti and Vogelstein found a linear 
correlation between the number of stem cell divisions and the lifetime risk of cancer. 
They suggest that approximately 65% of the variance in cancer risk between different 
tissues could be a reflection of the total number of stem cell divisions in the specific 
tissues (Tomasetti and Vogelstein 2015). In breast cancer the proportion of driver 
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gene mutations attributed to environmental factors was found to be 15%, only 1,5% 
from hereditary factors and 83,4% from replicative "bad luck" (Tomasetti, Li et al. 
2017). In contrast, driver mutations in melanoma were almost exclusively attributed 
to environmental factors (89%) and for lung cancer as high as 66%. Therefore, the 
potential for prevention by avoiding risk factors is fundamentally dependent on the 
type of cancer and its causative risk factors.  
 
1.3 Breast Cancer 
1.3.1 Incidence and mortality of breast cancer 
Breast cancer is by far the most common cancer among females, and amount to 22% 
of all female cancers across all age groups in Norway (Cancer in Norway, 2015, The 
Norwegian Cancer Registry). In 2015, 3439 new cases of breast cancer were 
reported, whereof only 24 cases were diagnosed among males. The incidence has 
increased by 8% during the last reported 5-year period (from 2006-2010 to 2011-
2015). During the same time interval, the 5-year relative survival has increased 
slightly from 87,8% to 89% and mortality has decreased moderately (Cancer in 
Norway 2015). The reduced mortality of breast cancer in Norway in recent years 
despite an increased incidence is probably due to earlier detection of breast cancer as 
part of mammography screening, and the improved survival could be explained by 
the mammography screening program in Norway and/or the development of better 
treatment (Narod, Iqbal et al. 2015). However, the influence of mammography 
screening on breast cancer-specific survival is debated (van den Ende, Oordt-Speets 
et al. 2017). However, the mortality of breast cancer is strongly related to disease 
stage (Cancer in Norway 2015). Five-year survival for patients with stage II disease 
(2011-15) was 92,3%, while patients with stage IV experienced a 25,5% five-year 
survival. With respect to long-term outcome, the survival was 77% after 15 years for 
all stages combined (Cancer in Norway 2015). For stage III disease or locally 
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advanced breast cancer (LABC), the prognosis is still poor, where 30% experience 
disease recurrence within 5 years after primary treatment (Cancer in Norway 2015).    
1.3.2 Breast cancer treatment 
The primary curative treatment for early breast cancer is surgery, which is in itself 
enough to avoid recurrence in cases where the disease is localized to the breast alone, 
and with low-risk tumor characteristics. The risk of breast cancer recurrence and 
cancer death increases substantially if regional lymph node metastases have 
developed (Cancer in Norway 2015). Despite axillary dissection, adjuvant 
radiotherapy and systemic cancer treatment are required in these cases to increase the 
chance of cancer cure. 
Treatment of locally advanced tumors warrants a more aggressive approach than 
localized tumors, where neoadjuvant chemotherapy or endocrine therapy is 
administered prior to surgery and radiotherapy to shrink the tumor. Initial surgery in 
this patient category is strongly advised against, due to a high risk of local disease 
recurrence, either on the chest wall or the axilla, if performed prior to effective 
systemic therapy. In stead, effective neoadjuvant treatment is indicated, while 
observing prospectively that the tumor shrinks - pinpointing an effective regimen.   
Radiation therapy is frequently used in the treatment of breast cancer. Ionizing 
radiation is used in order to shrink the size of the tumor, or it can be used after 
surgery to reduce the risk of recurrence. Ionizing radiation causes double stranded 
breaks in DNA, particularly in dividing cells. Radiation also causes generation of 
ROS, which also induces further DNA damage and single strand breaks (Borrego-
Soto, Ortiz-Lopez et al. 2015). Cell death and growth arrest is then induced by the 
combined effect of the ionizing radiation-induced DNA damage and ROS generation. 
Endocrine therapy is based upon the dependence of hormones as growth stimulants 
in hormone receptor positive breast cancer tissue. The influence of estrogen on breast 
cancer has been known for almost 100 years (DeVita and Chu 2008). The estrogen 
receptor was discovered in 1961, and the first targeted drug in breast cancer, 
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tamoxifen, was discovered six years later (DeVita and Rosenberg 2012). Tamoxifen 
and other SERMs (Selective Estrogen Receptor Modulators) bind to the estrogen 
receptor, blocking the proliferative effect of estradiol on the mammary epithelium. 
The estrogen-blocking property of tamoxifen makes this drug a fundamentally 
important adjuvant therapy in hormone receptor positive breast cancer, next to 
aromatase inhibitors, to reduce the risk of breast cancer recurrence (Early Breast 
Cancer Trialists' Collaborative, Davies et al. 2011). Aromatase inhibitors have a 
different mechanism than SERM. They block the enzyme aromatase and thereby 
stops the transformation of androgens to estrogens, this reduce estrogen production 
and hormone stimulation in hormone receptor positive breast cancer (Lonning and 
Eikesdal 2013).  
Chemotherapy is a denomination for drugs that are cytotoxic to cells. The 
therapeutic agent interferes with DNA or destroys cellular compartments involved 
with cell division causing cellular stress leading to apoptosis and cell death. In 
general, cancer cells divide more rapidly than normal cells, and chemotherapy will 
therefore induce relatively more damage to cancer cells than normal cells. Modern 
chemotherapy regimens reduce breast cancer mortality by 30-35% over 10-years, and 
accumulating evidence indicates that patients with ER-negative tumors benefit more 
from chemotherapy than patients with ER-positive tumors (Berry, Cirrincione et al. 
2006, Albain, Barlow et al. 2010, Albain, Anderson et al. 2012). The different 
therapeutic agents have different mechanisms of action, and modern adjuvant 
chemotherapy consists of combination regimens to increase the efficacy and reduce 
the risk of therapy resistance. In the adjuvant and neoadjuvant setting, one typically 
uses two or more drugs in combination. This includes in most cases anthracyclines 
(doxorubicin or epirubicin), and cyclophosphamide, followed by taxanes (paclitaxel 
or docetaxel), which is combined with the anti-HER2 antibody trastuzumab for HER2 
amplified breast cancer. In advanced/metastatic disease several other drugs are also 
included. 
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The chemotherapeutics given to patients in the neoadjuvant clinical trials used in this 
work are: anthracyclines (doxorubicin and epirubicin), 5-fluorouracil (5-FU), 
mitomycin and taxanes (paclitaxel and docetaxel). 
Anthracyclines have multiple and complex mechanisms of action. One is the 
inhibition of topoisomerase II, which prevents relaxation of supercoiled DNA making 
the DNA inaccessible for DNA polymerase for further replication. It also halts 
replication by binding to and intercalating between the nucleotides in the DNA. 
Furthermore, anthracyclines cause ROS generation which leads to DNA breaks and 
fragmentation, apoptosis and cell death (Minotti, Menna et al. 2004). 5-FU is a uracil 
analogue, with a fluorine atom attached. It incorporates into RNA and DNA during 
transcription, and also inhibits thymidylase synthase causing imbalance in the dNTP 
pool (specifically dATP/dTTP ratio) resulting in disruption in DNA synthesis and 
DNA repair, and further, DNA damage and cell death (Longley, Harkin et al. 2003). 
Mitomycin alkylates and crosslinks DNA, causing permanent growth arrest due to 
DNA damage, and double-strand breaks (Tomasz 1995). Taxanes, such as paclitaxel 
arrest dividing cells in G2/M phase by disrupting the function of microtubules by 
inhibiting depolymerization, accordingly, the cell will not be able to proceed with 
metaphase (Baker and Dorr 2001). 
Targeted therapy 
The concept of targeted therapy stems from the idea that cancer cells express 
different biomarkers relative to normal cells. There might be excessive expression of 
receptors initiating proliferation pathways, or activating mutations/aberrations in 
pathways that induce cell growth. In theory, this makes it possible to create drugs that 
operate as "magic bullets", targeting only the malignant cells, and leaving the benign 
tissue unharmed based on the higher expression of these molecules in malignant cells. 
There is an immense effort being made to find the right targets and combination of 
targets, but there are still only a few therapies that have proven to be beneficial and  
implemented in the clinic for breast cancer treatment. The oldest type of targeted 
breast cancer therapy is endocrine therapy, including SERMs and aromatase 
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inhibitors as described above, and these are targeting the hormone receptor positive 
tumor cells to improve survival both in the adjuvant and metastatic setting still today. 
The HER2 targeted antibody trastuzumab provides a survival benefit to patients with 
HER2 positive breast cancer, by binding to the HER2 receptor that is profoundly 
overexpressed in these tumors. Another antibody, pertuzumab, was recently 
introduced and prevents HER2-HER3 dimerization and downstream intracellular 
signaling (Baselga, Cortes et al. 2012). By conjugating the tubulin inhibitor 
emtansine to trastuzumab a new drug was generated which delivers emtansine 
exclusively to HER2 expressing cells, which has proven beneficial to patients with 
HER2 positive breast cancer (Welslau, Dieras et al. 2014).  
The PI3K-Akt-mTOR pathway is commonly activated in hormone receptor positive 
breast cancer, and upregulation of this pathway is involved in the development of 
resistance to endocrine treatment. The mTOR inhibitor everolimus is currently used 
in the treatment of postmenopausal women after first line endocrine therapy with a 
non-steroidal aromatase inhibitor has failed. Everolimus is used to avoid endocrine 
resistance and re-sensitize the tumor to further endocrine treatment, in combination 
with a steroidal aromatase inhibitor (Baselga, Campone et al. 2012).  
Cyclin Dependent Kinases (CDKs) have an important function in regulation of the 
cell cycle. CDKs bind to various cyclins, and the cyclin-CDK complexes regulate the 
timing of the progression through the cell cycle. Cyclin D partners with CDK4 or 
CDK6, and the complex phosphorylates and inactivates Rb, which initiates DNA 
replication and the transition from G1 to S phase (Asghar, Witkiewicz et al. 2015). 
The CDK4/6 inhibitors palbociclib and ribociclib were recently approved by the US 
Food and Drug administration (Clark, Karasic et al. 2016, Hortobagyi, Stemmer et al. 
2016) as well as European (EMA) and Norwegian regulatory authorities, for use in 
combination with endocrine therapy, in patients with hormone receptor positive 
metastatic breast cancer.  
Immunotherapy 
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Immunotherapy is based on the principle of enhancing or inducing a patient’s 
immune response to treat cancer. There are three main approaches undergoing 
extensive research at the moment; cell transfer therapy (Rosenberg and Restifo 2015), 
cancer vaccination (Melief, van Hall et al. 2015) and immune checkpoint inhibition 
(Francis and Thomas 2017). Checkpoint inhibition has gained a lot of attention the 
last couple of years, and has proven to be beneficial and been implemented in clinical 
use for several solid cancer types, such as melanoma, renal cancer, non-small cell 
lung cancer (NSLC), clear-cell renal carcinoma, bladder cancer and prostate cancer 
(D'Errico, Machado et al. 2017). Although, after a great number of clinical trials in 
breast cancer, response to checkpoint inhibition are reported in only a minority of 
breast cancer patients thus far (Spellman and Tang 2016). Among these the subgroup 
of triple negative breast cancer (TNBC) seems to display a better response to 
checkpoint inhibitors. Specifically, in PD-L1 expressing, metastatic TNBC, a 
response rate of 18,5% to the PD-1 inhibitor pembrolizumab was observed (Nanda, 
Chow et al. 2016). Multiple clinical trials are currently ongoing to decipher the 
clinical potential of such therapy further in breast cancer.  
1.3.3 Prognostic and predictive factors in breast cancer 
A Predictive marker will indicate whether a specific treatment A will be more 
effective than treatment B for a specific disease, and can be used to direct which 
treatment that should be chosen. A prognostic marker will indicate the expected 
clinical outcome of the disease, pointing to the risk of recurrence (i.e. recurrence-free 
survival; RFS) and/or death from the disease (disease-specific survival; DSS). A 
prognostic marker can not be used to pinpoint whether a given patient will benefit or 
not from a particular treatment. By performing a biopsy one can characterize and 
grade the tumor histologically, and examine known biomarkers. Describing the 
subtype of breast cancer is essential to estimate the risk of recurrence. Important 
prognostic factors in breast cancer are primary tumor size, lymph node status, 
infiltration to skin or chest wall, stage (I-IV), as well as hormone receptor, HER2 and 
proliferation markers like Ki67 status.  A prognostic marker can establish the severity 
of the disease, but predictive markers are needed to provide the right therapy to the 
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right patient, i.e. personalized therapy. Currently there are few predictive biomarkers 
for breast cancer, but hormone receptor expression and HER2 overexpression are 
predictive markers for response to endocrine therapy and HER2 targeted treatment, 
respectively. However, not all patients will benefit from endocrine or HER2 targeted 
treatment despite harboring hormone or HER2 overexpressing tumors, since the 
biomarkers are not 100% positively predictive of response.  
1.3.4 Breast cancer subtypes 
Breast cancer consists of several subtypes with distinct pathological features where 
each subtype has different survival outcomes and direct different treatment options 
with respect to therapy sensitivity. The traditional histopathological-based phenotypic 
breast cancer subgroups divide breast cancer into hormone receptor positive breast 
cancer (ER+/PR+/HER2-), hormone receptor positive and HER2 positive (triple 
positive, ER+/PR+/HER2+), HER2 positive (ER-/PR-/HER2+) or triple negative 











Figure 2. Histopathological Classification of Breast Cancer. 
Representative histology staining of invasive breast cancer by H&E, 
ER, PR and HER2. (Serrano 2010, Rivenbark, O'Connor et al. 2013) 
Reprinted with permission from American Society for Investigative 
Pathology, Elsevier Inc Copyright © 2013 by 
https://creativecommons.org/licenses/by-nc-nd/4.0/ 
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Ki67 staining differentiates hormone receptor positive tumors further into Luminal A 
(Ki67 low) and Luminal B (Ki67 high) subtypes (Cheang, Chia et al. 2009, 
Goldhirsch, Wood et al. 2011, Soliman and Yussif 2016). 
Measuring gene expression levels by mRNA and comparing the expression levels in 
various panels of genes is known as gene expression profiling. Gene expression 
profiling divides breast cancer into five intrinsic molecular subtypes similar to the 
histopathological based groups; Luminal A, Luminal B, HER2 enriched, Basal-like 
and Normal-like subtypes (Perou, Sorlie et al. 2000, Sorlie, Perou et al. 2001, Sorlie, 
Tibshirani et al. 2003, Cancer Genome Atlas 2012). There are several prognostic tests 
based on gene expression profiling, and both the 21-gene expression array (Sparano, 
Gray et al. 2015) and the 70-gene array Mammaprint (van 't Veer, Dai et al. 2002, 
Cardoso, van't Veer et al. 2016) can be used to identify patients with good or poor 
prognosis to aid the physician when deciding whether adjuvant chemotherapy should 
be given or not. 
Given the recent advances in molecular subtyping, the hope is that multiple novel 
predictive markers will be identified in the years to come. However, still the only 
biomarkers to guide breast cancer treatment recommended by the ASCO guidelines 
besides disease stage are the estrogen and progesterone receptor status, HER2 status, 
and Ki67 staining. Of notice, the use of Ki67 is under debate due to lab-to-lab 
reproducibility issues and its purely prognostic value (Harris, Ismaila et al. 2016, 
Harris, Ismaila et al. 2016).  
The most frequently mutated genes detected in human breast cancer are PIK3CA 
(27%), followed by TP53 (23%), representing one oncogene and one tumor 
suppressor gene (The-Cancer-Genome-Atlas-Network 2012). Furthermore, CDH1 
(11%), ESR1 (7%), PTEN (4%), RB1 (3%) and AKT1 (3%) are frequently mutated 
genes in breast cancer (Cosmic Catalogue of Somatic mutations; 
www.cancer.sanger.ac.uk)(Forbes, Beare et al. 2017). By combining histopathology 
with gene expression profiling and mutational analyses of key driver genes, a 
comprehensive understanding of the mechanisms driving the different subtypes can 
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be acquired. This provides an opportunity to design better treatment, but still today, 
there is no clear indication that such advanced analyses add anything with respect to 


















1.4 The PI3K-Akt-mTOR signaling pathway and therapy 
resistance 
 
1.4.1 PI3K-Akt-mTOR signaling 
The PI3K-Akt-mTOR signaling pathway (Figure 3) is an important growth promoting 
pathway and regulates several critical functions in a cell, including protein synthesis, 
survival, migration, proliferation and glucose metabolism (Manning and Toker 2017). 
Through its crosstalk with the estrogen-, MAPK-, p53- and STAT3- signaling 
pathways, PI3K-Akt-mTOR signaling (in short: PI3K signaling) deregulation can 
influence a wide range of cellular processes (Toss, Venturelli et al. 2017).  
 
Figure 3. PI3K-Akt-mTOR signaling. P indicates phosphorylation, red 
color indicates that the phosphorylation has an inhibitory effect, 
whereas green indicates an activating effect of phosphorylation. ER: 
estrogen receptor, E: estradiol. Figure modified from (Manning and 
Toker 2017, Toss, Venturelli et al. 2017) 
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There are three classes of PI3Ks, Class I PI3Ks are activated by the approximately 20 
classes of receptor tyrosine kinases (RTKs) like EGFR- (HER family), insulin-, 
VEGF- and AXL-receptors, and also by G-coupled receptors. Class I is the most 
studied PI3K and is also the one referred to in this work. Class I PI3Ks are 
responsible for the canonical PI3K-Akt-mTOR signaling by converting 
Phosphatidylinositol 4,5-bisphosphate (PIP2) to Phosphatidylinositol (3,4,5)-
trisphosphate (PIP3) on the cell membrane. While class II and III PI3Ks converts 
phosphatidylinositol (PI) as a substrate to generate PIP3 and is involved in growth-
regulatory processes, only class I PI3Ks have a central role in cancer through its 
downstream signaling (Chalhoub and Baker 2009). 
PIP2 and PIP3 are phospholipid components of the cell membrane, and PIP3 interacts 
with proteins containing a pleckstrin homology (PH) domain, like Akt kinase. Akt 
localizes to PIP3 on the cell membrane where PDK1 and mTORC2 activate Akt by 
phosphorylating Akt on the T308 and S473 phosphorylation sites respectively 
(Carracedo and Pandolfi 2008). PI3K is also activated by direct binding of RAS to 
the p110α subunit of Class I PI3K, (Shaw and Cantley 2006). Also, there are 21 small 
GTPase homologs belonging to the Ras or Rho family GTPases which are able to 
activate PI3K (Yang, Shin et al. 2012) demonstrating crosstalk with MAPK signaling. 
Deregulation of PI3K-Akt-mTOR signaling is involved in type II diabetes, and 
pathway hyperactivation is known to induce tumorigenesis (Cantley 2002, Shaw and 
Cantley 2006). Sustained proliferative signaling, represented here as persistent 
activation of PI3K-Akt-mTOR signaling, is a hallmark of cancer (Hanahan and 
Weinberg 2011) and more than 70% of breast cancers harbor mutations or other 
alterations in this pathway (Miller, Rexer et al. 2011), in particular among hormone 
receptor positive breast cancers. The high prevalence of alterations makes the 
pathway highly relevant as a therapeutic target both in a first line setting and as 
secondary treatment after progression on first line endocrine treatment.  
1.4.2 PI3K-Akt-mTOR signaling and drug resistance 
Endocrine resistance can be caused by different molecular aberrations of signaling 
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pathways that are involved in crosstalk with ER signaling (Austreid, Lonning et al. 
2014). Acquired resistance to endocrine therapy may be induced by alterations in the 
RAS-RAF-MAPK pathway, PI3K-Akt-mTOR pathway or the cyclin D/CDK4/6/Rb 
(Finn, Aleshin et al. 2016, Gluck 2017). In an effort to combat endocrine resistance, 
several trials have targeted the PI3K-Akt-mTOR pathway to increase the treatment 
efficacy, and also to resensitize the tumor to endocrine treatment. In the randomized 
phase 3 BOLERO-2 trial, the mTOR inhibitor everolimus and the steroidal aromatase 
inhibitor (AI) exemestane were compared to placebo and exemestane. By adding 
everolimus to exemestane treatment in patients with advanced ER+ and HER2 
negative breast cancer that had progressed on non-steroidal AIs, a 6 months increase 
in progression-free survival was achieved (Baselga, Campone et al. 2012), 
demonstrating that inhibiting mTOR can sensitize tumors to treatment or delay the 
development of therapy resistance. Everolimus has since been implemented in routine 
clinical use, in combination with exemestane, as second line treatment for patients 
with ER positive advanced disease that progress on non-steroidal AIs in first line. 
Multiple clinical trials are now focusing on other compounds targeting the PI3K-Akt-
mTOR pathway to further improve endocrine therapy and overcome endocrine 
resistance (Maurer, Martel et al. 2017).   
Activation of RTKs like HER2 and proliferative survival pathways such as PI3K-
Akt-mTOR, enable malignant cells to divide rapidly, resist apoptosis and promote 
survival, and are also implicated in resistance to chemotherapy (Austreid, Lonning et 
al. 2014, Martin, Smith et al. 2014, Avan, Narayan et al. 2016). Resistance towards 
chemotherapy has been studied extensively in the past, but the biological mechanisms 
of resistance are to a large extent still unknown (Austreid, Lonning et al. 2014). 
1.4.3 PI3K - PIK3CA 
The PIK3CA gene encodes the catalytic p110α subunit of phosphatidylinositol 3-
kinase (PI3K), and oncogenic activating mutations in PIK3CA cause constitutive 
activation of PI3K, causing activation of Akt and downstream signaling molecules to 
promote cell proliferation and growth (Miller, Rexer et al. 2011). According to 
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Cosmic (Catalogue of somatic mutations in cancer) by the Wellcome Trust Sanger 
Institute, mutations in PIK3CA encompass the majority of somatic mutations in breast 
cancer with a frequency of 27%. Activating mutations in PIK3CA are present in more 
than 30% of hormone receptor positive tumors and are predominantly located to "hot 
spots" in exon 10 and 21, previously annotated to exons 9 and 20 (Samuels, Wang et 
al. 2004, Baselga 2011). The prevalence of oncogenic PIK3CA mutations in breast 
cancer makes drugs specific to the p110 subunit of PI3K an attractive candidate to 
improve cancer therapy in these patients. For instance, PI3K inhibition with the 
p110α specific inhibitor BYL719 sensitizes both cell lines and tumors to fulvestrant  
(Bosch, Li et al. 2015). Combining endocrine therapy with PI3K targeted treatment is 
therefore a rational approach, although side effects of PI3K inhibitors is a definite 
problem clinically (Austreid, Lonning et al. 2014). 
1.4.4 Akt 
Akt, also known as protein kinase B (PKB/AKT), belongs to a family of 
serine/threonine-specific protein kinases. Three isoforms of Akt; Akt1, Akt2 and 
Akt3 have been identified, which are transcribed from separate genes but with 
approximately 80% sequence homology (Brown and Banerji 2017). All isoforms 
contain three conserved domains; a lipid-binding PH-domain, a hydrophobic motif, 
and the central catalytic domain (Brown and Banerji 2017). The different isoforms 
can activate many of the same substrates, but there are also some subtype-specific 
substrates. AKT1 knockout mice display growth retardation and perinatal lethality, 
AKT2 knockout mice develop insulin-resistance while AKT3 knockout mice suffer 
from decreased brain size (Toker and Marmiroli 2014). AKT1 is mutated in 3% of 
breast cancers, whereas AKT2 mutations are less frequent (Forbes, Beare et al. 2017). 
AKT1 and AKT2 are among the verified "cancer genes" listed by the Cosmic Cancer 
Gene Census, while AKT3 is not (Futreal, Coin et al. 2004). Due to AKT1 having a 
more important role in breast cancer than the other isoforms, we have focused on the 
AKT1 isoform, and when mentioning Akt it is assumed Akt1 unless specified 
otherwise. 
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Akt is activated by extracellular stimuli by RTKs or G-coupled receptors through 
activation of PI3K and its conversion of PIP2 to PIP3. PI3K and the lipid PIP3 
product is the rate-limiting step in PI3K signaling, and for Akt phosphorylation 
(Manning and Toker 2017). When un-phosphorylated Akt re-localize to the plasma 
membrane, its PH domain binds to PIP3 and Akt is phosphorylated by PDK1 on 
Thr308 and mTORC2 on Ser473 (See Figure 3, PI3K-Akt-mTOR signaling).  
Akt influences more than a hundred downstream targets, including FoxO, MDM2, 
GSK3 and mTORC1 to regulate survival, proliferation, metabolism, protein 
synthesis, as well as angiogenesis and invasion (Manning and Toker 2017).  
Accordingly, Akt is a key signaling hub involved in sustaining proliferative and pro-
survival signaling, and it also interacts with several other pathways including the 
RAS-ERK pathway (Manning and Toker 2017). This makes Akt an attractive target 
in the development of targeted cancer drugs. 
Importantly, constitutive Akt activation disrupts the ability to induce senescence after 
doxorubicin treatment (Taylor, Lehmann et al. 2011), and constitutive Akt activation 
applies a selective pressure for the loss of p53 function to avoid oncogene-induced 
senescence in this setting (Astle, Hannan et al. 2012). 
Increased Akt signaling is associated with resistance to chemotherapy, HER2 targeted 
therapy (trastuzumab) as well as tamoxifen treatment (Clark, West et al. 2002). A 
meta-analysis covering 3370 papers concludes that Akt signaling is activated by and 
involved in resistance to DNA damaging treatment such as platinum, taxanes, 
antimetabolites (including 5-FU) and radiation (Avan, Narayan et al. 2016). In 
addition, preclinical studies indicate that dominant negative Akt mutations increase 
doxorubicin sensitivity in breast cancer cell lines. (Clark, West et al. 2002). This 
implies that inhibiting Akt in cells with an activated PI3K-Akt-mTOR pathway might 
sensitize cells to treatment when a cytotoxic drug is combined with an Akt inhibitor.  
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1.4.5 P53 
Germline mutations in the TP53 gene are responsible for the hereditary disorder Li-
Fraumeni syndrome characterized by predisposition to a broad spectrum of cancers. 
50% of heterozygous carriers will develop cancer before 30 years of age, and at age 
70, 90% will have developed a malignancy (Malkin, Li et al. 1990, Srivastava, Zou et 
al. 1990).  
 
Regarding somatic TP53 mutations, they are considered to be an early event in 
carcinogenesis; accordingly TP53 mutations have also been reported in premalignant 
ductal carcinoma in situ (DCIS) (Rivlin, Brosh et al. 2011). Genomic rearrangements, 
amplifications and deletions commonly occur after TP53 is mutated, due to the loss 
of DNA damage response mechanism, further destabilizing the genomic integrity 
(Hanel and Moll 2012, Zhang, Zhuang et al. 2017). Somatic mutations of TP53 are 
among the most frequent alterations in human cancers all over, occurring at rates of 
up to 50% in ovarian cancer, and up to 85% in subtypes of aggressive breast cancers 
such as the basal-like subtype, and in the advanced disease setting (Olivier, Hollstein 
et al. 2010, Cancer Genome Atlas 2012).  
 
The p53 protein is considered the most important tumor suppressor in the human 
genome and has acquired the nickname "guardian of the genome" (Lane 1992). p53 is 
important to maintain genomic stability  and acts as a "master switch" that is rapidly 
upregulated in response to cellular stress such as DNA damage, hypoxia, shortened 
telomeres, ribosomal stress, oncogene activation and ROS accumulation. When p53 
is upregulated it can induce temporary cell cycle arrest  (quiescence), permanent cell 
cycle arrest (senescence) or activate programmed cell death (apoptosis) if the DNA 
damage is irreparable (Vousden and Lane 2007). The dose and dynamics of p53 
activation controls what happens to the cell after DNA damage has occurred (Meek 
2015). Low level stress induces a low levels of p53 upregulation and temporary cell 
cycle arrest, which promotes cell survival during DNA repair, while high levels of 
stress or persistent stress induces high levels of p53 and apoptosis (Vousden and Lane 
2007). Although it appears to be a dose-response to stress-induced p53 activation, 
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more is not necessarily better in a therapeutic setting. High doses of DNA damaging 
drugs in TP53 wt cells induces very high levels of p53 which mediates cell cycle 
arrest and mTOR inhibition, causing reversible quiescence and cell survival. In 
contrast, lower doses of DNA damaging drugs induces less p53 expression which 
causes cell cycle arrest but without inhibiting mTOR, and the cell becomes senescent 






The regulation of p53 level is mostly regulated through blocking its degradation. One 
example of this is how PTEN promotes MDM2 degradation by restricting MDM2 to 
the cytoplasm and thus protects p53 from ubiquitynilation by MDM2 (Mayo, Dixon 
et al. 2002). Ubiquitylation of p53 leads to its degradation by the proteasome, and 
other post-translational mechanisms like acetylation, SUMOylation and 
phospohorylation which influences its activity, localization and protein-associations 
demonstrating p53s highly dynamic and context-dependent function (Meek 2015). 
 
Low/constitutive stress High/acute stress 
p53 levels 







Quiescence Cell death 
Figure 4. High and low degree stress induce different 
levels of p53 upregulation, resulting in different cellular 
outcome. Modified after (Vousden and Lane 2007, 
Leontieva, Gudkov et al. 2010, Olga V. Leontieva 2010) 
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1.4.6 P53 as a prognostic or predictive factor in breast cancer 
The p53 protein is a transcription factor that binds to the consensus sequence 
RRRCWWGYYY to activate the transcription of several hundred genes (Fischer 
2017). Thus, one would expect that TP53 mutations would influence cancer 
progression to a major extent and possibly affect survival outcome and response to 
therapy. However, despite the prevalence of TP53 mutations in cancer, there has been 
conflicting evidence as to the value of TP53 mutations as a prognostic and predictive 
factor. This discrepancy might be due to the lack of standardization in methodology 
and which mutations that are included or excluded in the various studies (Soussi and 
Beroud 2001). In particular, the use of IHC to detect aberrant p53 proteins in the 
tumor tissue as a surrogate for TP53 mutations is prone to methodological errors 
(Wynford-Thomas 1992, Hall and Lane 1994, Hurlimann, Chaubert et al. 1994, 
Geisler, Lonning et al. 2001, Ando, Oki et al. 2015). 
TP53 has been the focus of the research conducted by the Bergen Breast Cancer 
Group for several decades. Our group, as well as others (Bergh, Norberg et al. 1995, 
Andersson, Larsson et al. 2005, Olivier, Langerod et al. 2006, Bonnefoi, Piccart et al. 
2011, Eikesdal, Knappskog et al. 2014), have established a role for TP53 mutations 
as a negative prognostic factor in breast cancer, in particular TP53 mutations in the 
zink-binding domain L2 and L3 which binds to DNA and influences its role as a 
transcription factor (Bergh, Norberg et al. 1995, Geisler, Lonning et al. 2001, 
Chrisanthar, Knappskog et al. 2008). The prognostic impact of TP53 was not only 
evident in the analysis of short-term survival after neoadjuvant chemotherapy, but 
also for long-term survival, extending more than 10 years (Eikesdal, Knappskog et al. 
2014). In a large, pooled analysis of almost 2000 patients it was reported that 
mutations causing a truncated/non-functional protein or a complete lack of the p53 
protein had the worst prognosis, followed by patients with mutations in the L2/L3 
domain (Olivier, Langerod et al. 2006). This was independent of node status, tumor 
size, and ER status.  
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Furthermore, the Bergen Breast Cancer Group, as well as others, have established 
TP53 as a predictive factor, demonstrating that TP53 mutations are associated with 
resistance to anthracyclines (Aas, Borresen et al. 1996, Kandioler-Eckersberger, 
Ludwig et al. 2000, Geisler, Lonning et al. 2001, Chrisanthar, Knappskog et al. 2008, 
Lehmann-Che, Andre et al. 2010) and mitomycin-based chemotherapy (Geisler, 
Borresen-Dale et al. 2003). However, there is some controversy regarding the 
predictive value of TP53, and others have not found any association between a 
functional p53 and sensitivity to anthracycline or taxane-based therapy (Bonnefoi, 
Piccart et al. 2011).  
While inactivating TP53 mutations predict resistance to anthracyclines, they may at 
the same time be predictive of response to high dose epirubicin-cyclophosphamide in 
ER negative breast cancer (Lehmann-Che, Andre et al. 2010). In patients with ER 
negative status and TP53 mutations, 15 out of 28 patients had a pathological complete 
response (pCR) subsequent to high dose epirubicin-cyclophosphamide, whereas none 
of the patients harboring breast cancers with wild type TP53 experienced pCR 
(Bertheau, Turpin et al. 2007). Still, the number of studies finding a predictive value 
of TP53 mutations towards treatment resistance or sensitivity are limited and this 
issue should be explored further in larger patient cohorts. 
Patients with poor survival outcome despite preserved tumor p53 function 
Although TP53 inactivating mutations may predict a lack of response to 
anthracycline and mitomycin-based chemotherapy in patients with locally advanced 
breast cancer (Geisler, Lonning et al. 2001, Geisler, Borresen-Dale et al. 2003, 
Andersson, Larsson et al. 2005, Olivier, Langerod et al. 2006, Eikesdal, Knappskog 
et al. 2014), some patients with TP53 wt status still progress on neoadjuvant 
treatment. Importantly, there are other ways to inactivate p53 apart from inactivating 
TP53 mutations. For instance, MDM2 overexpression caused by amplifications of 
MDM2 promotes polyubiquitylation and degradation of p53 (Haupt, Maya et al. 
1997, Meek 2015, Zhang, Zhuang et al. 2017). Further upstream in the p53 pathway 
CHEK2 and ATM both influences p53 activity. ATM phosphorylates and activates 
 22 
p53 in response to genotoxic stress, and ATM mutations precludes p53 induction 
(Rotman and Shiloh 1999). Whereas ATM activates CHEK2, and both ATM and 
CHEK2 activates p53, a low expression level of ATM mRNA will complement CHK2 
and TP53 mutations in predicting response to treatment (Knappskog, Chrisanthar et 
al. 2012). Accordingly, among tumors without TP53 mutations, loss of function in 
ATM or CHEK2 in the p53 pathway or aberrations in the Rb pathways are strong 
predictors of reduced sensitivity to DNA damaging drugs and may substitute for loss 
of p53 function (Knappskog, Chrisanthar et al. 2012, Lonning and Knappskog 2013). 
This points to the importance of considering pathway activation/inactivation, instead 
of focusing on single gene dysfunction to evaluate mechanisms of therapy resistance. 
Also, by combining alterations detected in multiple pathways simultaneously one can 
predict with higher precision resistance to chemotherapy. Of notice, simultaneous 
inactivation of both the RB and p53 pathway is a better predictor of resistance to 
DNA damaging drugs than any single genetic aberrations or pathway alone 
(Knappskog, Berge et al. 2015). 
 
1.5 PTEN 
Phosphatase and tensin homolog (PTEN), is an important tumor suppressor and acts 
as a negative regulator of PI3K-Akt-mTOR signaling. By acting as a lipid 
phosphatase, PTEN dephosphorylates the 3-inositol ring of PIP3 to PIP2. This stops 
activation of Akt by PIP3 and halts downstream Akt signaling, thereby suppressing 
proliferation, protein synthesis, glucose metabolism, and pro-survival signaling 
(Figure 3) (Carracedo and Pandolfi 2008, Manning and Toker 2017). The 403 amino 
acid long PTEN protein has 5 functional domains; The PIP2 binding domain (PDB), 
the phosphatase domain, C2 domain, carboxy-terminal tail and PDZ binding domain 
(Song, Salmena et al. 2012). Additionally, a 576 amino acid translational variant of 
PTEN has been identified which is translated from an alternate start codon, and is 
designated as PTEN Long. This protein is secreted, and as a membrane-permeable 
protein it has the ability to enter other cells to inhibit PI3K signaling in a paracrine 
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fashion (Hopkins, Fine et al. 2013).  
Besides dephosphorylating PIP3 to PIP2 at the cell membrane, PTEN has lipid-
phosphatase independent activity. PTEN can dephosphorylate Focal Adhesion 
Kinase, thereby repressing the cell´s ability to survive after detachment from the 
extracellular matrix (Tamura, Gu et al. 1999). Additionally, nuclear PTEN exerts 
phosphatase-independent functions by interacting with APC/C to promote the 
formation of an APC-CDH1 tumor-suppressive complex (Song, Carracedo et al. 
2011). Furthermore, PTEN is important in maintaining genomic stability by 
interacting with centromeres, and lack of PTEN leads to centromere breakage (Shen, 
Balajee et al. 2007). Also, PTEN protects the cells DNA through Rad51, which is 
involved in DSB repair (Shen, Balajee et al. 2007). Moreover, PTEN influences cell 
cycle regulation by influencing multiple cell cycle checkpoints (Gupta, Yang et al. 
2009, Brandmaier, Hou et al. 2017). Nuclear PTEN is also involved in ATM 
regulated DNA repair, making PTEN-proficient cells less sensitive to DNA damage, 
while cells lacking nuclear PTEN has been shown to be hypersensitive to DNA 
damage (Bassi, Ho et al. 2013). Based on all these important functions, PTEN has 
been proposed as "a new guardian of the genome" (Yin and Shen 2008). 
1.5.1 PTEN aberrations and loss 
Germline mutations of PTEN give rise to the PTEN hamartoma tumor syndrome 
which also includes Cowden syndrome, and manifests itself with the appearance of 
benign neoplasms and a high risk of developing, breast, endometrium and thyroid 
cancer (Hollander, Blumenthal et al. 2011). It is estimated that approximately 1 in 
200 000 are heterozygous carriers of a germline PTEN mutation, and their lifetime 
risk of breast cancer is estimated to be 67-85% in females, which is close to the risk 
of breast cancer in patients with germline BRCA1/2 mutations (Ngeow, Sesock et al. 
2017).  
PTEN was originally named Mutated in Multiple Advanced Cancers MMAC1, and is 
located at chromosome 10q23-24. While PTEN is deleted in more than 90% of 
glioblastoma (Steck, Pershouse et al. 1997), the Cosmic database of somatic 
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mutations (Forbes, Beare et al. 2017) reports PTEN mutations to be present in 
endometrium cancer in 38% of cases, while primary breast cancers are mutated in 
only 3,6% of cases. Although other genes, such as ESR1, are more frequently mutated 
in metastatic breast cancer than in primary breast cancer, the prevalence of PTEN 
mutations are currently not known to be more or less frequent in metastatic breast 
cancer than in early breast cancer (Lefebvre, Bachelot et al. 2016). However, 
acquired loss of PTEN is common in metastatic lesions, indicating a possible role for 
PTEN mutations as a metastatic event (Wikman, Lamszus et al. 2012, Juric, Castel et 
al. 2015). 
Although a minority of sporadic breast cancers contain PTEN mutations, loss of 
PTEN protein expression is reported in 34% of breast cancer (Millis, Ikeda et al. 
2016). Importantly, the presence or absence of PTEN in cancer is not a dichotomy. 
Even small changes in PTEN levels has an impact on cancer susceptibility, and in 
PTEN hypomorphic mice there is a inverted dose - response relationship regarding 
tumor incidence where a modest decrease in PTEN dose increases the susceptibility 
to develop cancer, in particular breast cancer (Alimonti, Carracedo et al. 2010). 
Although lower PTEN levels increases growth, germline homozygous loss of PTEN 
is embryonically lethal (Suzuki, de la Pompa et al. 1998). Importantly, complete loss 
of PTEN might be less oncogenic than a partial loss due to PTEN loss-induced 
senescence. However, PTEN loss-induced senescence is dependent on functional p53, 
and by concomitantly inactivating p53 together with complete PTEN loss, the cell 
can escape senescence and induce tumorigenesis (Chen, Trotman et al. 2005).  
1.5.2 Mechanisms of non-genomic PTEN loss 
There are several non-genomic mechanisms controlling PTEN expression. The PTEN 
gene can be epigenetically silenced by hypermethylation of the CpG islands in the 
promoter region, or by histone acetylation rendering gene transcription temporarily 
inaccessible (Correia, Girio et al. 2014). Also, gene expression levels can be 
transcriptional regulated by several factors; for instance p53 induces PTEN 
transcription by binding to the PTEN promoter region (Stambolic, MacPherson et al. 
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2001, Pappas, Xu et al. 2017). Post-transcriptional regulation of the PTEN mRNA 
transcript also affects PTEN expression. Various microRNAs, such as miR-21 and 
the miR17-92 cluster, are known to bind to the 3´UTR region of the PTEN transcript, 
causing it to be degraded and thus halts further translation and protein expression 
(Correia, Girio et al. 2014). 
PTEN plasticity is common, and modifications of the PTEN protein cause transient 
suppression, or nuclear translocalization. In addition, PTEN protein levels can 
decrease in cancer tissue compared to normal tissue despite normal RNA levels due 
to post-translational mechanisms causing loss of PTEN expression (Leslie and Foti 
2011, Naguib and Trotman 2013). Also, post-translational modifications may modify 
PTENs activity, stability, localization and conformation by phosphorylation, 
acetylation, oxidation, SUMOylation and ubiquitination, and defects in any of these 
mechanisms has the ability to influence the cells PTEN status and its interaction with 
other proteins (Hopkins, Hodakoski et al. 2014, Collaud, Tischler et al. 2015).  
1.5.3 PTEN as a prognostic or predictive marker in breast cancer 
There is conflicting evidence as to the value of PTEN as a useful prognostic marker 
in breast cancer. In vitro experiments show that suppressing PTEN function elevates 
activated Akt and increases drug resistance towards certain chemotherapeutics, and 
also sensitizes cancer cells to mTOR inhibition (Grunwald, DeGraffenried et al. 2002, 
Steelman, Navolanic et al. 2008). Clinically, loss of PTEN protein expression in 
metastatic breast cancer was associated with inferior survival compared to patients 
with PTEN positive tumors when treated with cyclophosphamide/methotrexate/5-FU 
or cyclophosphamide/doxorubicin/5-fluoracil (Wang, Hao et al. 2017). In another 
trial in patients with early breast cancer, lack of PTEN IHC staining was associated 
with higher tumor grade and earlier recurrence, but no difference in survival (Bose, 
Chandran et al. 2006). In yet another trial, PTEN IHC staining level was not 
associated with any survival impact among patients with early breast cancer 
(Panigrahi, Pinder et al. 2004). 
While PTEN loss is associated with worse prognosis and higher tumor grade, PTEN 
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loss is not commonly found to be predictive of response to breast cancer treatment. In 
several clinical trials, PTEN loss was not predictive of response to breast cancer 
treatment in early breast cancer (Panigrahi, Pinder et al. 2004, Saal, Johansson et al. 
2007, Lazaridis, Lambaki et al. 2014). In contrast, in HER2 positive breast cancer, 
PTEN loss predicted lack of response to trastuzumab-based therapy (Nagata, Lan et 
al. 2004, Esteva, Guo et al. 2010, Rimawi, De Angelis et al. 2017), whereas another 
trial found no prognostic or predictive value of PTEN loss with respect to the benefit 
of HER2 targeted treatment (Perez, Dueck et al. 2013). 
PTEN loss may be predictive of response to specific targeted inhibitors involving 
PI3K-Akt-mTOR signaling. In a panel of human cancers, loss of PTEN or PIK3CA 
mutations predicted response to the mTOR inhibitor everolimus (in the absence of 
concomitant KRAS/BRAF mutations) (Di Nicolantonio, Arena et al. 2010). In an 
elegant example of how PTEN loss leads to therapy resistance Juric et.al. treated a 
patient with a PIK3CA mutated metastatic breast cancer with BYL719, a PI3Kα 
inhibitor. Initially the malignant disease responded well to treatment, but eventually 
resistant metastases developed. All metastases had acquired ESR1 and BRCA2 
mutations and a single copy loss of PTEN, but in addition the metastases showed a 
parallel evolution of complete PTEN loss, and the metastases presented six different 
types of PTEN deletions on the remaining allele. Metastases with complete PTEN 
loss were not sensitive to PI3Kα inhibition, while the metastases showing PTEN 
expression were sensitive (Juric, Castel et al. 2015).  
It is clear that the utility of PTEN expression as a biomarker warrants further 
investigations, particularly in the future testing of drugs targeting the PI3K-Akt-
mTOR pathway.  
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1.6 Noncoding RNA 
After the completion of the human genome project (McPherson, Marra et al. 2001) it 
became evident that the numbers of protein-coding genes are far less then expected. It 
is estimated that up to 90% of the genome is transcribed (Djebali, Davis et al. 2012), 
but still less than 2% of the genome encodes the ~22 000 protein-coding mRNAs 
(Collins, Lander et al. 2004).  "Noncoding RNA" is mRNA that is transcribed from 
the DNA, but not expressed as proteins, and it was therefore assumed that they had 
no function. Noncoding RNA was thought of as evolutionary leftovers and previously 
labeled as "junk RNA" (Palazzo and Lee 2015). The majority of genomic research 
effort thus far has focused on the protein-coding part, and much less is known 
regarding the function of non-coding genes. Thus, the function of these non-coding 
genes represents a huge gap in our knowledge, and there is much left to discover. 
Although not protein-coding, it has become clear that non-coding RNAs have many 
important functions. The functional importance of non-coding RNAs can be 
demonstrated by Xist RNA. Xist initiates the chromosomal X inactivation in females 
after fertilization, to avoid overexpression of X-chromosome genes. Females have 
two X-chromosomes and males only one, and to avoid overexpression of X-
chromosome genes in females, one of the chromosomes is silenced. Xist is 
transcribed from the inactive X-chromosome and coats its chromatin, repressing 
expression of the entire chromosome (Wutz, Rasmussen et al. 2002, Lee and 
Bartolomei 2013).   
Non-coding RNA is grouped in different classes according to size and function, such 
as microRNAs (~22 nt), small RNAs (<200nt), long RNAs or lncRNAs (>200nt), 
small interfering RNAs (siRNA), pseudogenes, circular RNAs and piRNAs to name a 
few (Palazzo and Lee 2015). They are involved in multiple genomic processes such 
as splicing, regulation of gene expression through antisense base pairing, guiding 
DNA synthesis, and in regulating methylation (Cech and Steitz 2014). LncRNA can 
also function as "address codes", by directing protein complexes, genes and 
chromosomes to specific localizations (Batista and Chang 2013). A more thorough 
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description of different mechanisms of non-coding RNA functions can be found in a 
review by Asgrand et.al (Angrand, Vennin et al. 2015) 
1.6.1 Non-coding RNAs and their role in cancer 
While there are around 20 000 protein-coding mRNAs, there are approximately 8 000 
pseudogenes, around 60 000 lncRNAs (Iyer, Niknafs et al. 2015), 200 000 circular 
RNAs (Liu, Li et al. 2016) and almost 2 000 human microRNAs that have been 
reported (mirbase.org). LncRNAs are not as highly expressed as protein-coding 
mRNAs, but they are more tissue-specific, indicating highly specialized functions 
(Gloss and Dinger 2016). It is estimated that in the human genome there are at least 
19 000 functional lncRNAs (Hon, Ramilowski et al. 2017), many of which are 
deregulated in cancer. Deregulation of ncRNA networks is common in cancer, and 
there has been identified ncRNAs acting as both tumor suppressors and oncogenic 
drivers in the majority of cancer types (Anastasiadou, Jacob et al. 2017). 
Overexpression of lncRNAs like HOTAIR (Gupta, Shah et al. 2010) and MALAT1 
(Tian and Xu 2015) have a negative prognostic impact in cancer. The non-coding 
RNA BRCAT is overexpressed in ER positive breast cancer, and is implicated in 
tamoxifen resistance in breast cancer cell lines (Iyer, Niknafs et al. 2015). Since the 
spectrum of non-coding RNAs may vary between different types of cancer and each 
non-coding RNA may function differently depending on the biological process which 
is studied, it is indeed a huge challenge to decipher if and what role each non-coding 
RNA has in any particular cancer (Fu 2014). However, the field of non-coding RNAs 
is rapidly growing and will shed further light on to the regulatory mechanisms 
governing cancer, which could lead to the discovery of novel non-coding RNA-based 
therapies (Fang and Fullwood 2016). 
1.6.2 MicroRNA 
MicroRNAs are evolutionary conserved short nucleotides approximately 22 
nucleotides long single-stranded RNA. They can influence protein expression by 
binding to complementary regions of mRNA transcripts on sites known as 
"MicroRNA response Elements" (MRE), resulting in translational repression or 
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mRNA decay (Macfarlane and Murphy 2010). Around half of mammalian 
microRNA genes are located within introns of non-coding or protein-coding genes, 
and some overlap exons of non-coding RNAs. Their expression may be 
transcriptionally linked to these genes, while the other microRNAs have dedicated 
gene loci (Rodriguez, Griffiths-Jones et al. 2004). MicroRNAs are transcribed by 
RNA polymerase II as primary miRNAs (pri-miRNAs), which are cleaved and 
processed by Microprocessor (consisting of i.a. DROSHA and DGCR8) into pre-
miRNAs. Pre-miRNAs can then be exported from the nucleus for further processing 
by DICER1, which results in mature miRNAs. The guide strand gets incorporated 
into the microRNA-induced silencing complex (RISC) which consists of i.a. 
Argonaute and DICER1, and the miRISC complex binds to target mRNAs based on 
various degrees of sequence complementarities (Lin and Gregory 2015). MicroRNA 
deregulation in cancer is common, and low expression of the miRNA processing 
genes DROSHA and DICER1 are correlated to poor clinical outcome in ovarian 
cancer (Merritt, Lin et al. 2008). The expression of microRNAs are generally lower in 
tumor tissue than in normal tissue (Lu, Getz et al. 2005). However, the effect of 
specific microRNAs are highly context-dependent, and a microRNA can act as a 
tumor suppressor in one cancer type, while it promotes tumor progression in another 
(Svoronos, Engelman et al. 2016). Global microRNA expression differs between 
different cancer types (Lu, Getz et al. 2005, Rosenfeld, Aharonov et al. 2008) and the 
pattern of global microRNA expression can also be used to classify breast cancer 
intrinsic subtypes (Kurozumi, Yamaguchi et al. 2017). MicroRNAs that are 
associated with or induce cancer are considered to be "oncomiRs".  Overexpression 
of microRNAs targeting tumor suppressors (such as miR-21a and miR-20 targeting 
PTEN) act as oncomiRs, while loss of expression of microRNAs targeting oncogenes 
will also promote cancer progression (Kurozumi, Yamaguchi et al. 2017). However, 
it is complicated to determine if a specific microRNA generally acts a tumor 
suppressor or an oncogene since several microRNAs have been reported as both 
(Svoronos, Engelman et al. 2016). The specificity of microRNA expression will 
induce different downstream effects and can act as a oncogene in one system, while it 
acts as a tumor suppressor in another (Svoronos, Engelman et al. 2016).  
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1.6.3 Pseudogenes and the ceRNA hypothesis 
Pseudogenes are non-coding RNAs that show sequence similarities of more than 75% 
to a protein-coding gene. Due to a lack of functional start-codons, frame shifts or gain 
of internal stop-codons, pseudogenes produce no protein when transcribed, and they 
are considered as evolutionary remnants of their parental functional genes (Harrison 
and Gerstein 2002). Pseudogenes can evolve in two ways. First, through DNA 
duplication of the DNA sequence of a gene where modifications like mutations, 
deletions, insertions or frame shift renders the transcript non-coding. This is the 
duplicated or non-processed pseudogenes. Second, pseudogenes can evolve through 
retrotransposition, where a transcribed and spliced mRNA is reintegrated in the 
genome including its poly-AAA tail, but without a proper regulatory promoter region. 
This is the processed pseudogenes (Harrison and Gerstein 2002). The sequence 
similarities and the lower transcription levels than their parental genes make 
pseudogenes very hard to study, but massive parallel sequencing has revealed that 
more than 7000 pseudogenes are expressed in humans (Iyer, Niknafs et al. 2015). An 
indication of whether a gene is functional or not is their degree of phylogenetic 
preservation, and in many cases pseudogenes are preserved across species. Around 
80% of the processed pseudogenes are specific for primates, pointing to them being a 
recent event in evolution. One functional role for pseudogenes described so far is 
regulation of gene expression of its parental gene by acting as an anti-sense transcript 
which blocks translation (Muro, Mah et al. 2011, Groen, Capraro et al. 2014). 
In 2010, Poliseno et.al. published the pivotal paper "A coding-independent function 
of gene and pseudogene mRNAs regulate tumour biology." where they described a 
new mechanism for gene regulation, by which mRNAs which share binding sites for 
specific microRNAs or MicroRNA Response Elements (MREs) compete for the same 
pool of microRNAs (Poliseno, Salmena et al. 2010). By overexpressing the MREs 
containing the 3`UTR end of the PTEN pseudogene, entitled PTENP1, or 
overexpressing the KRAS pseudogene KRAS1P, they found increased PTEN and 
KRAS mRNA levels respectively in prostate cancer. This means that both the non-
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Figure 5. a) MicroRNAs bind to MicroRNA Response Elements (MREs) on the 3'UTR 
part of mRNAs causing mRNA translational repression and degradation. b) ceRNAs 
harboring shared MRE competes for microRNAs, which promote mRNA translation 
and protein expression.   
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coding pseudogenes and the protein-coding PTEN/KRAS mRNA transcripts exerted  
biological functions through competing endogenous RNA (ceRNA) networks. One 
such network is the PTEN ceRNA network where PTEN mRNA transcripts regulate 
the expression of seemingly unrelated genes through ceRNA interactions, including 
the mRNAs of VAPA, CNOTL, RB1, RUNX1, PDGFRA and STAT3. (Salmena, 
Poliseno et al. 2011, Tay, Rinn et al. 2014). This implicates that ceRNA networks can 
influence cancer genes by regulating tumor suppressors or oncogenes in trans (Figure 
5) (Poliseno and Pandolfi 2015). 
 
The extent at which a specific transcript will be affected by ceRNA interactions are 
highly context-dependent, where the level of mRNAs vs. microRNAs determine the 
outcome (Bosson, Zamudio et al. 2014). Also, a specific ceRNA will exert a different 
outcome depending on the microRNA and mRNA target pool available in the specific 
cell (Figure 6). The potential for downregulation by a microRNA is a function of 
microRNA and target-mRNA abundance. Also, microRNAs with multiple target 
mRNAs downregulate any particular mRNA less than a microRNA with few target 
mRNAs (Arvey, Larsson et al. 2010, Bosson, Zamudio et al. 2014) 
 
 
Figure 6. The relative abundance of microRNA and the number of MREs at each 
mRNA influence the potential for ceRNA interaction. High microRNA and low 
ceRNA concentration promote mRNA translational repression and degradation, 
while low microRNA and high ceRNA expression promotes protein translation. 
miRNA	
ceRNA	
mRNA	 3´	5´	 mRNA	 3´	5´	
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The concept of ceRNAs have been disputed (Thomson and Dinger 2016), and some 
have argued that for ceRNA interactions to occur, there must be similar abundance of 
the target mRNA and microRNA (Denzler, Agarwal et al. 2014). Also, the 
microRNAs need to be expressed in high quantity, and experimentally in vivo 
overexpression of a particular ceRNA did not influence ceRNA targets or mediate 
downstream physiological effects in the liver (Denzler, Agarwal et al. 2014). For 
ceRNA interactions to occur in vivo, the ceRNA must be highly expressed or contain 
dozens of binding sites for any particular microRNA. However, microRNA and 
lncRNA expression levels are highly deregulated in cancer, which could make 
malignant cells more receptive to ceRNA interactions. Also, by computational 
identification of ceRNA-ceRNA networks in normal and breast invasive carcinoma, it 
was revealed that the "sponge activity" of lcnRNAs is disrupted in carcinoma 
compared to normal tissue due to altered microRNA:mRNA ratios (Paci, Colombo et 
al. 2014, Conte, Fiscon et al. 2017). This indicates that this biological mechanism 
may be important for cancer development and progression. 
1.6.4 PTENP1 
While the PTEN gene is located on chromosome 10q23, the pseudogene PTENP1 is 
located on chromosome 9p21.3, and 1.2kb of its 3.9kb long genomic sequence has a 
98% sequence homology to the coding region of PTEN (Whang, Wu et al. 1998, 
Juehui Liu 1999). PTENP1 is a processed pseudogene which is transcribed in all 
normal tissues, but it lacks a start codon and thus far no PTENP1 protein has been 
identified (Juehui Liu 1999, Karro, Yan et al. 2007). Variants of PTENP1 are present 
in several species, but only in a minority of mammals, 48 out of 65 mammals lack the 
pseudogene (Tang, Ning et al. 2016). Species that contain variants of PTENP1 
include some primates, a few rodents (not mice), pigs, but not goat, sheep or bovines, 
and no carnivores. This demonstrates that PTENP1 have originated through several 
gene duplications and have a "birth and death" evolution pattern (Nei and Rooney 
2005). Intriguingly, the naked mole rat that is known for its resistance to developing 
cancer has 17 copies of PTENP1. ceRNA crosstalk between PTEN and PTENP1was 
demonstrated by Poliseno et.al through the shared MREs of miR-20a, 19b, 21, 26a 
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and 214 (Figure 7). Across different species there are conserved binding sites for 
miR-19b, 26a and 20 at the 3´UTR part of PTENP1, indicating that ceRNA crosstalk 

















Figure 7. Shared binding sites/MREs on PTEN and PTENP1 mRNA transcript. 
(Poliseno, Salmena et al. 2010) Reprinted with permission from Nature Publishing 
group. (Poliseno, 2010) © 2010. 
 
PTENP1 can also be transcribed in antisense as isoform α and β. The β isoform pairs 
with the PTENP1 transcript to form RNA:RNA complexes, thereby affecting its 
stability and ceRNA function (Johnsson, Ackley et al. 2013). The PTENP1 antisense 
α transcript can pair with the promoter-associated RNA PTEN 5′ UTR-containing 
transcripts, and guide DNMT3a to the PTEN promoter which epigenetically regulate 
PTEN transcription (Lister, Shevchenko et al. 2017). Both sequence and secondary 
structure of noncoding RNA and its target gene can influence regulation by the 
noncoding RNA (Lister, Shevchenko et al. 2017). This adds yet another layer of 
complexity to the function of PTENP1. 
Discovery of PTENP1 and analytical pitfalls 
Historically, Whang et.al (Whang, Wu et al. 1998) examined the frequency of PTEN 
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mutations in prostate cancer by RT-PCR and sequencing of a panel of cell lines. 
Surprisingly, in all cell lines tested, including the PTEN null PC3 cell line, a RT-PCR 
product with the correct size for PTEN appeared. A more thorough examination 
revealed that this product was not PTEN, but rather genomic PTENP1. Also, 10 out 
of 11 sequence variants previously reported as PTEN mutations were in fact base 
substitutions present in the pseudogene DNA sequence. This stresses the need for 
both DNAse treatment before cDNA synthesis, and a strict selection of primers to 
avoid detecting the pseudogene when reporting the mutational status of the PTEN 
gene (Whang, Wu et al. 1998).   
There has also been some controversy regarding PTEN promoter hypermethylation, 
given the sequence homology between PTEN and PTENP1. This became evident in 
our group in earlier work on PTEN methylation (Vidar Staalesen and Ranjan 
Chrisanthar, unpublished data). While assessing methylation profiles of the PTEN 
promoter in breast cancer patients, there was conflicting evidence as to its 
methylation status. PTENP1 share 91% sequence identity with a 921 bp CpG island 
in the PTEN promoter, and it became evident that the assay used to assess PTEN 
promoter methylation was undistinguishable from the PTENP1 promoter. By using 
an assay able to distinguish between the two they found the PTENP1 promoter to be 
methylated rather than the PTEN promoter in several tumor biopsies, prompting the 
question of PTENP1´s biological relevance in breast cancer. Previously, studies have 
been published wherein PTENP1 promoter methylation might be mistaken for PTEN 
methylation (Salvesen, MacDonald et al. 2001, Zysman, Chapman et al. 2002), 
rendering the clinical relevance of PTEN promoter methylation status unclear 
(Hesson, Packham et al. 2012). After a reexamination, Hesson et.al. found the 
PTENP1 promoter and not the PTEN promoter to be frequently methylated in cancer 
cell lines. However, the relevance of PTENP1 promoter methylations remains to be 
answered. Of notice, due to sequence similarities it is recommended to use allelic 
bisulphite sequencing to correctly identify methylation status of the gene/pseudogene 
in regions with a high degree of homology (Hesson, Packham et al. 2012). 
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2. Aims of Study  
Loss of PTEN protein expression is frequently observed in human breast cancer, but 
the mechanisms governing PTEN expression remains to be elucidated. In particular 
the role of pseudogene PTENP1 to regulate PTEN expression in breast cancer has 
not been addressed previously. Furthermore, the role of PTEN and PTENP1 to 
regulate PI3K-Akt-mTOR signaling and its importance to chemoresistance in breast 
cancer is unknown. The overall aim of this thesis was to examine the role of PTENP1 
and PTEN gene expression, PTEN protein expression and PI3K-Akt-mTOR signaling 
towards treatment response and survival outcome in patients with locally advanced 
breast cancer. Further, we wanted to examine the role of PI3K-Akt-mTOR signaling 
in anthracyline-based chemotherapy resistance, and evaluate if specific inhibitors 
targeting the PI3K-Akt-mTOR pathway could be used therapeutically to potentiate 
treatment or counteract chemoresistance. Finally, we wanted to assess the biological 
impact of PTENP1 by up- and downregulating its expression in preclinical models of 
breast cancer.  
 
2.1 Paper 1 
It has been established previously by our research group as well as by others, that 
patients with locally advanced breast cancers harboring TP53 mutations are at 
increased risk of resistance to anthracyclines and mitomycin-based chemotherapy and 
have a worse survival outcome. However, not all patients with TP53 mutated tumors 
progress on treatment, and not all patients experience breast cancer recurrence, 
despite TP53 tumor mutations.  
On the protein level, the tumor suppressor p53 promotes the expression of the PTEN 
tumor suppressor (Stambolic, MacPherson et al. 2001). In addition, PTEN protects 
p53 from degradation (Mayo, Dixon et al. 2002). Furthermore, PTEN is an important 
tumor suppressor and inhibitor of the growth-promoting PIK3-Akt-mTOR pathway. 
 37 
Loss of PTEN expression is frequently observed in human breast cancer (Millis, 
Ikeda et al. 2016) and the negative prognostic impact of PTEN loss has been 
demonstrated (Wang, Hao et al. 2017). However, staining for PTEN expression by 
IHC is prone to interobserver variation, and alternative methods to assess PTEN 
expression objectively, such as PTEN gene expression by qPCR, could be a better 
method. Further, the expression of PTENP1 and its role in treatment response and 
survival in human breast cancer has not been established previously.  
The aims of this study were; 
1. To determine the prognostic and predictive value of PTEN gene expression in 
patients with locally advanced breast cancer treated with chemotherapy.  
2. To assess how TP53 mutation status influences the prognostic and predictive 
impact of PTEN gene expression.  
3. To examine protein expression of PTEN and PI3K-Akt-mTOR signaling by 
IHC and correlate the findings to treatment outcome. 
4. To examine the correlation between PTEN protein and PTEN mRNA 
expression in breast cancer. 
5. To examine the expression of PTENP1 in breast cancer, and correlate the 
expression levels to PTEN expression level, as well as treatment outcome and 
survival. 
 
2.2 Paper 2 
Upregulated PI3K-Akt-mTOR signaling is observed more frequently in hormone 
receptor positive breast cancers, and inhibition of this pathway augments the response 
to endocrine therapy clinically (Baselga, Campone et al. 2012). However, upregulated 
PI3K-Akt-mTOR signaling is also observed when resistance to chemotherapy 
develops (Avan, Narayan et al. 2016). Accordingly, in this preclinical study we 
wanted to examine how PI3K-Akt-mTOR signaling is affected by short-term and 
long-term anthracycline treatment in ER positive and negative human breast cancer. 
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Then we wanted to assess the potential of PI3K-Akt-mTOR inhibitors to counteract 
chemoresistance. In particular, we wanted to examine the response to acute 
doxorubicin exposure in doxorubicin-naïve and doxorubicin-resistant cell lines. 
Furthermore, we wanted to examine whether an Akt inhibitor could be used to 
augment the response to doxorubicin.  
The following aims were defined: 
1. Create in-house doxorubicin-resistant breast cancer cell lines 
2. Explore how PI3K-Akt-mTOR signaling is influenced by an acute exposure to 
doxorubicin in doxorubicin-naïve and resistant cell lines. 
3. Design and perform a preclinical trial using agents targeting PI3K-Akt-mTOR 
signaling alone and combined with doxorubicin. This is in order to examine if 
inhibition of PI3K-Akt-mTOR signaling is an effective therapy by it self, and 
also if it can be utilized to augment the response to chemotherapy. 
4. Compare PI3K-Akt-mTOR signaling in biopsies taken before and after 
neoadjuvant anthracycline treatment in patients with locally advanced breast 
cancer and examine if differences in mRNA levels is related to treatment 
outcome in two patient subgroups; 1-Short term response; biopsies collected 
before and 24 hours after the first anthracycline exposure. 2-Long term 
response; biopsies collected before and after 16 weeks of doxorubicin 
treatment. 
 
2.3 Paper 3 
Previously PTENP1 was shown to adsorb miRNAs targeting PTEN for degradation, 
thereby increasing PTEN mRNA and protein expression in prostate cancer cell lines 
(Poliseno, Salmena et al. 2010). However, the role of PTENP1 in breast cancer has 
not been defined.  
In this paper we wanted to examine whether PTENP1 exhibits a functional role in 
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breast cancer. Further, we wanted to assess whether overexpression of PTENP1 in 
breast cancer affects PTEN and downstream AKT-mTOR signaling in breast cancer 
in vivo and in vitro. Also, we wanted to examine whether PTENP1 up-or 
downregulation influences doxorubicin sensitivity. 
To address these questions the following aims were defined: 
1. Create a lentiviral vector containing PTENP1 to make breast cancer cell lines 
stably overexpress PTENP1 in order to examine the ceRNA effect of PTENP1 
overexpression on PTEN, PI3K-Akt-mTOR signaling and proliferation both in 
vitro and in vivo. 
2. Evaluate whether PTENP1 overexpression affects the expression levels of 
known microRNAs which are shared between PTEN and PTENP1. 
3. Examine the effect of PTENP1 downregulation by siRNA on PI3K-Akt-
mTOR signaling 




3. Methodological considerations 
 
3.1 Patient material 
The Bergen Breast Cancer Group has systematically collected tumor biopsies from 
patients with locally advanced breast cancer included in neoadjuvant clinical studies 
since the early 1990´s. The tumor biopsies were taken directly from open surgery or 
in the outpatient clinic, snap-frozen in nitrogen, and subsequently stored at N2 until 
DNA/RNA extraction, or embedded in paraffin for IHC analyses. High quality 
samples combined with long-term follow up data for all patients included in the trials 
makes this biobank a valuable resource for breast cancer research. In addition, we 
have close to 100% follow-up regarding patient data and survival outcome, which is 
unique compared to many international studies where follow-up is hampered since 
patients commonly switch hospitals, as well as regulations causing loss of insight into 
patient data for the researcher. Another advantage with our studies is the fact that the 
clinical trials have been conducted in the same defined patient population, providing 
homogenous data throughout the last three decades with respect to patient and tumor 
characteristics, which makes it easier to compare results between patient cohorts 
using our own historical controls. Importantly though, neoadjuvant treatment has 
changed extensively during these 27 years.  
One disadvantage with these studies is the fact that the treatment is not compared to a 
control arm with standard treatment of care. This is due to the relatively small 
number of patients with locally advanced breast cancer diagnosed each year in 
Norway, making it very difficult to conduct such a randomized trial within a 
reasonable time frame. Even so, the purpose of this thesis was not to compare the 
efficacy of the different treatment regimens, but rather to identify mechanisms 
contributing to therapy resistance. Another limitation in our trials is the amount of 
tumor tissue available from biopsies. In many cases we only have access to True-
Cut/needle biopsies. This makes it difficult to obtain enough sample material for all 
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the parameters one might want to analyze, and information from DNA and RNA 
analyses have been prioritized, whereas available tissue for proteinanalysis was in 
many cases limited. 
The Doxorubicin cohort consists of patients with locally advanced breast cancer, 
recruited to a clinical trial running from 1991-1997 to evaluate the efficacy of low-
dose doxorubicin 14 mg/m2 body surface as first line monotherapy, administrated 
weekly for 16 weeks (Aas, Borresen et al. 1996, Geisler, Lonning et al. 2001, 
Eikesdal, Knappskog et al. 2014). Tumor biopsies were collected before starting 
therapy, and after 16 weeks of therapy. The Doxorubicin trial was a single-armed 
phase 2 trial including patients at one cancer center, Haukeland University Hospital. 
The FUMI cohort consists of patients with locally advanced breast cancer, enrolled 
in a clinical trial running from 1993 to 2001 to evaluate a combined 5-fluorouracil (5-
FU) and mitomycin treatment regimen (Geisler, Borresen-Dale et al. 2003). Primary 
treatment consisted of 5-FU 1000mg/m2 on day 1 and 2, and mitomycin C 6mg/m2 
administered on day 2 in a three-week interval for four cycles. The FUMI trial was a 
single-armed phase 2 trial including patients at one cancer center, Haukeland 
University Hospital. 
The Epi Tax cohort consists of patients with locally advanced breast cancer enrolled 
in a clinical trial running from 1997 to 2003 to identify biomarkers of drug resistance 
towards epirubicin or taxanes. Patients were randomized to one of two treatment arms 
and given either epirubicin 90 mg/m2 or paclitaxel 200 mg/m2 every three weeks 
(Chrisanthar, Knappskog et al. 2008, Chrisanthar, Knappskog et al. 2011). If the 
disease progressed on the first treatment, the patients were switched to the opposite 
treatment regimen. The EpiTax trial was a national phase 2 trial, including patients 
from all health regions of Norway. 
The Dose Dense cohort consists of patients with locally advanced breast cancer, 
enrolled in a clinical trial running from 2007 to 2016, where patients received dose 
dense epirubicin 60 mg/m2 for four cycles followed by docetaxel 100 mg/m2 for four 
cycles, administered every two weeks. The Dose Dense trial was a single-armed 
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phase 2 trial including patients at one cancer center, Haukeland University Hospital. 
Tumor biopsies were collected before and after starting epirubicin and docetaxel 
treatment, and at surgery. The results from the trial have not been published thus far.  
3.1.1 Statistics 
To perform survival analysis we used date at diagnosis as the start point and last 
follow-up date as the end point.  An "event" was defined as the time of recurrence of 
disease (to calculate recurrence-free survival; RFS), death due to breast cancer (to 
calculate disease-specific survival; DSS) or death regardless of cause (to calculate 
overall survival; OS) if exact cause of death was not available. Censoring was used 
when a patient was lost to follow-up and outcome was unknown, or when a patient 
was withdrawn from the study. The last registered patient contact was used as the 
censoring data point. Kaplan Meyer plots were calculated in order to visualize 
survival for patient groups with specific characteristics i.e. patients with high PTEN 
expression versus low PTEN expression. These plots display survival probability, i.e. 
the cumulative probability of an individual to not have experienced the "event" up to 
a specific time point.  
To compare survival or "time to event" between groups, we have used both the log-
rank test (Kaplan and Meier 1958) and Cox regression (Cox 1972). Both methods 
produce similar results, but with small differences. Log-rank tests the null hypothesis 
that there is no difference in survival times between groups at all times in the Kaplan 
Meyer plot based on a Chi square statistics. Cox regression describes the effect of a 
variable on survival by comparing the hazard ratio between the two groups, where the 
hazard is the risk of experiencing the event within a specific time point. Unlike log-
rank, Cox regression also allows for adjustment for multiple variables. 
One element for discussion is the fact that we transformed a continuous variable 
(gene expression) into a categorical variable (PTEN high or low), where the choice of 
cut-off was the median gene expression in each cohort. This transformation of the 
data was performed to make our comparisons between groups more robust, and to 
avoid overinterpretation of differences between patient subgroups. By selecting a 
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different cut-off value calculating hazard ratios using a continuous variable, the 
results could be different. Particularly, PTENP1 gene expression was much lower 
than PTEN expression, and by comparing high/low gene expression based on the 
median expression instead of for instance the top 10% versus the low/non-expressing 
tumors, one might miss potential correlations between PTENP1 expression and 
survival. 
 
3.2 In vitro and in vivo models of disease 
It is important to realize the potential and limitations of our model systems, and the 
statistician George E. P. Box stated it eloquently as; "All models are wrong, but some 
are useful" (Box and Norman 1987). Breast cancer cell lines are fast growing and 
there is easy access to a wide variety of well characterized cell lines to be purchased, 
making them highly accessible. Also, a large number of experiments can be 
performed within a short time frame. Importantly, cell lines derived and expanded 
from human tumors are subjected to a huge selective pressure, and the fastest 
growing cells in vitro may not represent the cells with the greatest malignant potential 
in their native environment. Over time as cell lines are passaged, they display genetic 
drift and changes in phenotype. Molecular portraits of breast cancer cell lines and 
breast tumors reveal that the expression levels of proteins in cell lines do not 
necessarily represent the protein expression in breast tumors (Cifani, Kirik et al. 
2015). They may also become cross-contaminated by other cell lines, and thereby 
produce misleading results (Liscovitch and Ravid 2007, Capes-Davis, 
Theodosopoulos et al. 2010, Torsvik, Rosland et al. 2010, Weifeng Ke 2011). 
Because of the risk of misidentified and cross-contaminated cell lines resistant to 
anthracyclines we created our own doxorubicin-resistant cell lines (Liscovitch and 
Ravid 2007, Nardone 2008, Capes-Davis, Theodosopoulos et al. 2010). 
When growing tumor cells in vitro you have a system with a low level of complexity, 
enabling you to focus on a single cell type in an artificial but controllable 
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environment. This is very useful when you want to examine for instance the effect of 
up- and downregulation of specific genes on growth or sensitivity to treatment. By 
growing tumor cells in vivo, you add several layers of complexity to the system, 
where the tumor cells grow in between the host´s vascular system, immune cells, 
extracellular matrix, fibroblasts and adipocytes. The tumor and host cells can interact 
through cell-cell contact and through cytokines, growth factors, hormones, matrix 
metalloproteinases and other secreted proteins (Ungefroren, Sebens et al. 2011, 
Balkwill, Capasso et al. 2012). All of this can influence the growth and survival of 
the tumor cells, and can cause discrepancy between in vitro and in vivo experiments. 
Also, therapeutic effects on cell growth or drug sensitivity can be profoundly 
influenced when the experiment is transferred from an in vitro setting to an in vivo 
setting.  
Before any drug can be utilized in patients, it has to be tested preclinically in animals 
to assess safety and potential effects. Mice have a short life span, are easy to breed, 
handle and house. By using mice one can test and screen multiple drugs within a 
relatively short time frame and this is particularly useful for early stage drug 
screening to evaluate antitumor effects in a more biologically relevant manner, as 
compared to in vitro cell culture experiments (Ruggeri, Camp et al. 2014). When in 
vivo xenograft models are used, wherein cancer cells are injected to initiate tumors, 
one lacks the intratumoral heterogeneity of spontaneously arising malignancies. 
Another alternative is to utilize Patient Derived Xenografts (PDX) where tissue 
pieces from the patient are implanted in mice to encompass both the heterogeneity 
within a solid tumor and to implant at the same time both the malignant and non-
malignant components of the tumor that cooperate during cancer progression. But 
also PDX models are subjected to selective pressure when transplanted to a new host, 
and only a subset of tumors are able to grow successfully in mice.  
In this work we used both C3H mice and NOD/SCID mice as tumor hosts, and breast 
cancer cell lines were orthopically implanted in the mammary fat pad. All 
experiments where approved by and conducted according to guidelines by the 
Norwegian State Commission for Laboratory Animals. For the murine breast cancer 
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cell line C3HBA, it was possible to transplant tumor cells to syngeneic C3H mice 
living in a non-sterile environment. In contrast, the MDA-MB-231 and MCF7 cell 
lines are derived from human breast cancers, and the immunodeficient NOD/SCID 
mouse strain had to be used to avoid cross-species anti-tumor immunity (Ito, 
Hiramatsu et al. 2002). In contrast to C3H, the NOD/SCID mice are bred and kept in 
an aseptic environment.  
 
3.3 Other methodological considerations  
Analysis of mRNA vs. protein expression: While small variations in PTEN mRNA 
expression can influence the susceptibility to develop tumors (Alimonti, Carracedo et 
al. 2010), protein levels measured by IHC may not be accurate enough to pinpoint 
small variations in protein expression caused by gene expression changes. Many 
factors can influence IHC staining, all the way from tissue acquisition, handling, time 
and concentration of fixation and antigen retrieval, all or which can impact the 
accessibility and presence of epitopes (Leandro Luongo de Matos). The choice and 
validation of antibody, presence of background staining as well as interobserver 
variability between researchers when staining results are interpreted can also 
influence IHC staining quantification.  
PTEN-PTENP1 mRNA similarities: The PTEN mRNA and PTENP1 mRNA 
transcripts are encoded by a 1.2kb region which have a 98% sequence homology, and 
only a few nucleotides differentiate between the transcripts in this region (Whang, 
Wu et al. 1998). This makes it challenging to separate the transcripts by RT-PCR. 
Thus, PCR primer pairs need to be selected carefully (Juehui Liu 1999). We included 
a cell line with a known PTEN deletion, but preserved PTENP1 in the assessment of 
PTENP1 and PTEN primer pairs. Further, all primers were quality controlled by 
Sanger sequencing of the PCR products using a cell line known to express both PTEN 
and PTENP1 transcripts.  
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Cell lines, mice and methods to examine the impact of PTENP1 deregulation:  
Mice lack the PTENP1 gene (Tang, Ning et al. 2016), and by introducing PTENP1 in 
a murine breast cancer cell line, we hypothesized that biological changes caused by 
upregulating the pseudogene PTENP1 would be more profound than in a human cell 
line with prior PTENP1 baseline expression. We first tried to create a lentiviral vector 
that contained the entire PTENP1 transcript, but this produced a very low virus titer, 
probably due to the size of the plasmid being too large. The packaging-limit for 
lentiviral particles are around 11-12 kb insert between the long terminal repeat (LTR) 
retroviral promoter regions, and there is a drop in titer of 1 log for every 2 kb of insert 
(Kumar, Keller et al. 2001). The 11 kb pWPI plasmid already contains 6 kb between 
the LTR regions, which includes the GFP- and the translational promoting IRES-
sequence. By reducing the size of the cloned fragment to only include the 3´UTR part 
of PTENP1, we got a high titer of functional virus capable of transducing our cell 
lines with acceptable efficiency. Although we did not transduce the complete 
PTENP1 gene, the transduced PTENP1 3´UTR contained the MREs, enabling us to 
study the ceRNA function of PTENP1 (Poliseno, Salmena et al. 2010).  
Similar to other non-coding RNAs, PTENP1 is not as highly expressed as protein-
coding mRNAs (Gloss and Dinger 2016). This makes knockdown experiments 
difficult. To be able to study downregulation of PTENP1 compared to 
downregulation of PTEN, one must also find cell lines expressing both. After an 
initial screen of several different breast cancer cell lines we found that MDA-MB-231 
and MCF7 expressed both wt PTEN and PTENP1. These cell lines were therefore 
initially chosen based on this, and because they are known to be tumorigenic in mice.  
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4. Summary of Results 
 
4.1 Paper 1  
In this paper, PTEN and PTENP1 expression levels in locally advanced breast cancer 
were examined in tumor biopsies from the Doxorubicin, FUMI and Epi/Tax 
neoadjuvant clinical trials. The correlations between gene expression levels and 
treatment response or survival were assessed in the Doxorubicin, FUMI and Epi/Tax 
patient cohorts. The mutational status of TP53 and PIK3CA were established, 
together with ER status and HER2 status where tissue was available for such 
analyses. In the EpiTax cohort, TMA sections were available for immunostaining, 
and the expression of PTEN, phosphorylated AKT (Ser473), phosphorylated S6K 
(Ser371, Thr389) and phosphorylated 4EPB1 (Thr70) were examined, and the 
correlation to recurrence-free (RFS) and disease specific survival (DSS) was 
established by Cox regression. 
There was a weak positive correlation between PTEN mRNA expression and PTEN 
staining in the 166 tumors where both RNA and TMA sections were available. 
Despite this, there was no correlation between low PTEN mRNA expression and lack 
of PTEN staining. Also, there was no correlation between low PTEN mRNA 
expression and increased downstream signaling staining of pAkt or pS6K.  
Furthermore, absence of PTEN staining did not correlate to increased staining of 
downstream signaling of phosphorylated Akt or S6K. Akt phosphorylation was 
however significantly more prevalent in tumors with PI3KCA mutations. 
We then evaluated whether high or low intratumoral expression of PTEN or PTENP1 
mRNA influenced survival and response to treatment. We found that a high 
intratumoral PTEN expression level was associated with shorter disease-specific and 
recurrence-free survival for all cohorts combined. However, high PTEN expression 
was only associated with worse survival in patients with TP53 wt tumors, and not for 
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patients with TP53 mutated tumors.  
There was a significant correlation between PTEN and PTENP1 gene expression, 
indicating a co-regulation, but high or low PTENP1 expression was not associated 
with survival as an independent biomarker.  
Also, none of the IHC protein staining’s performed was associated with survival 
outcome. 
With regards to prediction of treatment response, we found no association between 
pretreatment PTEN or PTENP1 mRNA expression levels and response to therapy. 
This was regardless of TP53, ER, PI3KCA or HER2 status. Activating PIK3CA 
mutations alone also did not influence response to doxorubicin, 5-FU/mitomycin, 
epirubicin or paclitaxel treatment. Furthermore, protein staining for PTEN, pAKT, 
pS6K and p4EPB1 did not predict response to any of the treatment regimens. 
In summary, Paper 1 demonstrates that high intratumoral gene expression of PTEN in 
locally advanced breast cancer is associated with inferior survival outcome, but only 
for patients with tumors harboring TP53 wt status.  
 
4.2 Paper 2 
Here we examined the role of Akt with respect to anthracycline resistance in breast 
cancer. We also evaluated whether Akt inhibition using the small molecule inhibitor 
A-443654 could be used to increase the efficacy of doxorubicin in doxorubicin-naïve 
and doxorubicin-resistant breast cancer cell lines, followed by a preclinical trial. 
In the ER positive cell lines MCF7 and T47D, increased Akt phosphorylation (pAkt) 
was observed after a single dose of doxorubicin in doxorubicin-naïve cells, while no 
pAkt alteration was observed in the ER negative MDA-MB-231 cell line. Increased 
baseline pAkt was seen after long-term doxorubicin treatment in both the MCF7 and 
MDA-MB-231 cell lines. However, no further pAkt increase was induced if an 
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additional high, single dose of doxorubicin was given to the doxorubicin-resistant 
MCF7, whereas pAKT increased in the doxorubicin-resistant MDA-MB-231. PTEN 
expression was not affected by doxorubicin treatment.  
The increased Akt phosphorylation in doxorubicin-resistant cells suggests that adding 
an Akt inhibitor after doxorubicin treatment might be beneficial in the treatment of 
ER positive tumors. Also, that a delayed administration of Akt inhibitor might be 
beneficial in the treatment of ER negative tumors after prior exposure to doxorubicin. 
Based on these assumptions we tested the ATP-competitive Akt inhibitor A-443654. 
A-443654 binds to the ATP-binding site, which causes a transient increase in S473 
phosphorylation in Akt and disrupts its ability to phosphorylate downstream targets 
(Luo, Shoemaker et al. 2005). The doxorubicin-resistant ER positive MCF7 cell line 
was more sensitive to A-443654 treatment than its doxorubicin-naïve parental cell 
line, while this was not observed for the doxorubicin-resistant ER negative MDA-
MB-231 cell line.  
After 2 hours of A-443654 treatment pAkt increased in the doxorubicin-naïve MDA-
MB-231 and MCF7 cell lines in a dose-dependent manner. The doxorubicin resistant 
cell lines also showed increased pAkt, although not as profound as the doxorubicin-
naïve parental cell lines. After 24 hours of A-443654 treatment, pAkt remained 
upregulated while total Akt decreased in both the doxorubicin naïve and resistant 
MDA-MB-231 and MCF7 cell lines. 
In a preclinical trial, we orthotopically implanted NOD SCID mice with either MDA-
MB-231 or MCF7 breast cancer cells. When measureable tumors had developed, the 
mice was grouped into five treatment arms and received either sham treatment, 
doxorubicin, Akt inhibitor, combination treatment of Akt inhibitor and doxorubicin, 
or a delayed combination treatment where the Akt inhibitor treatment commenced 
after the second dose of doxorubicin. The Akt inhibitor had little effect in the MDA-
MB-231 tumors as monotherapy, and two doses of doxorubicin halted tumor growth 
more than two weeks of continuous A-443654 treatment. In contrast, in MCF7 
tumors A-443654 monotherapy caused tumor regression, similar to that of 
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doxorubicin alone. The combination of doxorubicin with delayed A-443654-
treatment significantly inhibited tumor growth of MDA-MB-231 tumors compared to 
sham treatment, but no more than doxorubicin monotherapy. In MCF7 tumors there 
was a superior response to the combination treatment when A-443654 and 
doxorubicin treatment commenced simultaneously compared to sham treatment or A-
443654 monotherapy. 
The clinical relevance of AKT1 expression with respect to anthracycline resistance 
was examined in two patient cohorts after short-term and long-term exposure to 
anthracyclines. Tumor biopsies were extracted before and 24 hours after treatment in 
the recently completed dose-dense trial (NCT00496795), and while AKT1 mRNA 
levels increased in the ER positive tumors that responded to treatment, no change was 
observed in the non-responder group. Paradoxically, the mRNA levels of PTEN as 
well as AKT1 increased concomitantly in the ER positive responder group. After 16 
weeks of anthracycline treatment, no significant change was seen in AKT1 mRNA 
levels in neither group, but PTEN mRNA increased in the non-responder group, and 
most prominently in the ER negative tumors. 
In short, an initial activation of Akt characterizes ER positive breast cancers exposed 
to anthracyclines that respond to treatment. Also, when resistance to anthracyclines 
has developed, estrogen receptor positive cancer cells exhibit a particular sensitivity 
to Akt inhibition.  
 
4.3 Paper 3 
The PTEN pseudogene (PTENP1) has been shown previously to adsorb microRNAs 
targeting PTEN for degradation in prostate cancer cell lines (Poliseno, Salmena et al. 
2010). Here we examined how PTENP1 influences tumor progression in ER positive 
and negative breast cancer through ceRNA interactions. PTENP1 overexpression 
increased PTEN protein in the ER negative breast cancer cell lines C3HBA and 
MDA-MB-231, and in the non-tumorigenic ER negative MCF10a cell line. However, 
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in the ER positive MCF7 and T47D cell lines, there was no influence on PTEN 
protein expression when PTENP1 was overexpressed.  
When examining the effect of PTENP1 overexpression on cell proliferation we found 
that PTENP1 decreased proliferation in C3HBA, whereas no change was observed in 
MDA-MB-231. In contrast, PTENP1 increased cell proliferation in the ER positive 
MCF7 and T47D. By implanting the PTENP1-overexpressing cell lines C3HBA, 
MDA-MB-231 and MCF7 in mice, we found the same growth pattern as indicated by 
the cell proliferation results. While PTENP1 overexpression decreased tumor growth 
in the C3HBA cell line, PTENP1 overexpression had no effect on tumor growth in 
MDA-MB-231. However, a decrease in metastatic propensity was observed in mice 
with MDA-MB-231 tumors, transduced with PTENP1. Finally, PTENP1 transduction 
increased tumor growth in the ER positive MCF7 tumors.  
In contrast to the in vitro findings, PTENP1 overexpression did not affect PTEN 
protein expression in any of the cell lines in vivo. Also, there was no effect of 
PTENP1 overexpression with respect to downstream PI3K-Akt signaling measured 
by western blotting in the ER negative C3HBA or MDA-MB-231 cell lines. In the 
ER positive MCF7 cell line we observed increased Akt phosphorylation in PTENP1 
overexpressing tumors, but there was no effect on downstream S6K activation. This 
points to alternate pathways responsible for the change in tumor growth. 
Due to the lack of effect on PI3K-Akt signaling by PTENP1 transduction in tumor 
tissue, we expanded our search with a global gene expression microarray to identify 
other genes that might be influenced by PTENP1 overexpression in vivo. Since mice 
lack the PTENP1 gene, we chose the C3HBA murine cell line. By examining a 
PTENP1-naïve system we expected to observe stronger gene expression alterations 
induced specifically by PTENP1 overexpression, as compared to a biological system 
wherein PTENP1 is present and expressed at baseline. Using a mouse-specific 
microarray, we found that the gene most profoundly upregulated by PTENP1 in vivo 
was TCFAP2C, which encodes the protein AP2γ. This is a protein that can inhibit 
breast cancer growth, and is important for maintenance of a luminal phenotype (Cyr, 
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Kulak et al. 2014). Based on this we examined the PTENP1 overexpressing tumors 
for AP2γ. We found AP2γ to be upregulated in C3HBA and MDA-MB-231, and 
weakly downregulated in the PTENP1 overexpressing MCF7 tumors.  
Because of the known interaction between AP2γ and ERα, we also examined whether 
PTENP1 overexpression influenced ERα levels. In the ER negative tumors C3HBA 
and MDA-MB-231, no change in ERα expression was observed subsequent to 
PTENP1 overexpression. Strikingly, both ERα and ESR1 gene expression was 
significantly decreased in the PTENP1 overexpressing ER positive MCF7 tumors.  
We then examined if PTENP1 overexpression influenced the level of the five verified 
microRNAs shared between PTEN and PTENP1; hsa-miR-19b-3p, hsa-miR-20a-5p, 
hsa-miR-21-5p, hsa-miR-26a-5p and hsa-miR-214-3p (Poliseno, Salmena et al. 
2010). The five microRNAs were expressed in all the three cell lines C3HBA, MDA-
MB-231 and MCF7, but PTENP1 overexpression did not influence the expression of 
any of the examined microRNAs, except hsa-miR-26a which increased subsequent to 
PTENP1 overexpression in the MCF7 cell line. 
We also examined whether PTENP1 influenced sensitivity towards doxorubicin. 
Interestingly, MCF7 became more resistant to doxorubicin when PTENP1 was 
silenced by siRNA, where knockdown of PTENP1 did not influence the sensitivity to 
doxorubicin in MDA-MB-231.  In contrast, PTENP1 overexpression sensitized 
MDA-MB-231 to doxorubicin, but had no effect on the doxorubicin sensitivity in the 
ER positive MCF7 and T47D cell lines. 
To search for similar associations in patient breast cancer biopsies, we downloaded 
the Breast Invasive Carcinoma (TCGA, Provisional) dataset from the TCGAs 
database cBioportal.org. This dataset was selected because it had the largest number 
of breast cancer samples reporting both protein levels by RPPA and mRNA levels by 
sequencing. Due to the sequence similarities between PTEN and PTENP1 we wanted 
to avoid using data from microarrays, where recognition sites for these two genes 
may overlap. In the TCGA dataset we found that PTENP1 upregulated tumors 
expressed higher levels of PTEN mRNA as well as PTEN protein compared to 
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tumors with low or no PTENP1 expression. Furthermore, there was lower ERα 
expression in PTENP1 upregulated tumors, whereas no difference in TFAP2C was 
found. AP2γ protein was not present in the RPPA array from this dataset and could 
therefore not be assessed. 
Overall, the main finding in this paper is that the PTENP1 3`UTR transcript exerts a 
biological function in breast cancer, with opposite effects on tumor growth in ER 




The current work merges preclinical and clinical research data to examine the 
relevance of PTEN, PTENP1 and PI3K-Akt-mTOR signaling in breast cancer. 
Functional experiments were conducted preclinically to examine further the clinical 
findings we observed, and the results presented demonstrate that PTEN and PTENP1, 
as well as PI3K signaling are actively involved in breast cancer progression, and 
response to breast cancer therapy.  
Our finding that a high intratumoral PTEN expression predicts worse survival in 
patients with preserved TP53 is surprising considering that loss of PTEN protein has 
been characterized as an important protumorigenic event, which is frequently 
observed in a variety of cancers (Steck, Pershouse et al. 1997, Leslie and Foti 2011, 
Millis, Ikeda et al. 2016). p53 is a transcriptional regulator of PTEN (Stambolic, 
MacPherson et al. 2001, Agrawal and Eng 2006, Pappas, Xu et al. 2017), and in line 
with this we found PTEN and TP53 mRNA expression levels to correlate. We 
established a weak correlation between PTEN protein and PTEN mRNA expression 
in our patient cohorts, and there was no significant prognostic impact of lack of 
PTEN staining. The weak correlation between PTEN protein and mRNA indicates 
that the mechanisms behind the negative impact of high PTEN mRNA expression 
levels may occur at the mRNA or post-translational level.   
PTEN mRNA share MREs with several mRNA transcripts involved in cancer 
progression. A ceRNA network has been characterized where both PTEN and 
PTENP1 are involved as well as other key genes involved in human cancer 
progression, such as ZEB2, CNOT6L, VAPA and VCAN (Poliseno and Pandolfi 2015).  
In another study, RUNX1, STAT3, VEGFA and RB1 were identified as PTEN ceRNAs 
(Sumazin, Yang et al. 2011). At high PTEN mRNA transcript levels, PTEN interacts 
with microRNAs and influences the expression level of the microRNA targets within 
this network. PTEN may also act as a ceRNA to p53-regulating transcripts such as 
RNF38, TP53INP1 and HIPK2, which may influence p53 by ubiquitylation, 
phosphorylation and transcription respectively (Zarringhalam, Tay et al. 2017). This 
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is particularly interesting in view of our results where high PTEN expression was 
prognostic only for TP53 wt tumors. This adds a layer of complexity to expression 
studies, and is important to keep in mind when evaluating candidates for therapy 
resistance or oncogenicity based on protein or RNA expression studies. 
Simultaneously, in normal cells there exist no perfect correlation between mRNA 
expression and protein expression levels. We estimate that 30-80% of variation in 
protein expression is caused by variations in mRNA expression levels, and lack of 
correlation can be caused by post-transcriptional or post-translational regulation such 
as mRNA degradation, microRNA regulation, protein degradation and protein 
secretion or measurement errors (Vogel and Marcotte 2012, Kosti, Jain et al. 2016). 
On a global scale, mRNA levels correlate to protein levels, but due to a large 
variation in tissue specific post-transcriptional regulation, this correlation varies 
between tissues (Franks, Airoldi et al. 2017). Also, in cancer tissues the mRNA-
protein correlation is lower than in normal tissues (Kosti, Jain et al. 2016), indicating 
that deregulated post-transcriptional processes are common in cancer as well.  
A high expression of PTEN mRNA cannot be used to guide treatment options in 
breast cancer based on its lack of predictive power herein, but these results points to 
biological mechanisms involving PTEN to be involved in worse survival for patients 
with locally advanced breast cancer. These alternate mechanisms may be ceRNA 
interactions, and more specifically interactions acting on p53 stability and activation.  
In Paper 2 we focused on mechanisms of chemoresistance to explore candidate 
therapeutic targets in the PI3K-Akt-mTOR pathway. While PTEN protein levels were 
not affected by 24 hours doxorubicin treatment, we found that Akt was activated after 
24 hours exposure to an IC30 dose of doxorubicin. Akt was also activated without 
doxorubicin treatment after long-term treatment where chemoresistance had 
developed, indicating a role for Akt activation in resistance to anthracyclins. 
Upregulation of AKT1 was a common response 24 hours after anthracycline treatment 
in ER positive human breast cancers that responded to treatment, whereas no increase 
in AKT1 was seen after 16 weeks of treatment in the responder group. Oncogene-
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induced senescence is a protective mechanism against tumor progression in normal 
cells in the event of an oncogenic mutation; accordingly, most oncogenic mutations 
never give rise to tumors. Both PTEN loss and Akt overexpression has been shown to 
cause oncogene-induced senescence through Rb and p53 (Courtois-Cox, Jones et al. 
2008). Chronic Akt activation in breast cancer could cause oncogene-induced 
senescence and apoptosis by downregulating MDM2 and increasing p53 (Nogueira, 
Park et al. 2008, Astle, Hannan et al. 2012). Interestingly, 24h after the first 
anthracycline treatment AKT1 increased in 6 of the tumors that responded to 
treatment, and only 2 out of the 6 harbored a TP53 mutation. Among the ER positive 
tumors, after 16 weeks there was no difference in AKT1 level between the responder 
groups.  
In light of the above findings, and since doxorubicin-resistant ER positive cell lines 
exhibited increased sensitivity to Akt inhibition, Akt inhibitors may become useful as 
a second line treatment when resistance has developed. This was observed in another 
preclinical trial using the Akt inhibitor MK-2206, where a synergistic response to Akt 
inhibition was achieved when Akt inhibition was combined with multiple 
chemotherapeutics, including doxorubicin (Hirai, Sootome et al. 2010). The response 
was sequence dependent, where Akt inhibitor + docetaxel treatment was less effective 
if given simultaneously, and more effective if the Akt inhibitor was given after 
docetaxel. However, the clinical benefit of Akt inhibitors in this setting remains to be 
defined in ongoing clinical trials (Avan, Narayan et al. 2016). Akt is important for 
insulin signaling and glucose homeostasis, and a known side effect of Akt inhibition 
is hyperglycaemia and hyperinsulinaemia (Brown and Banerji 2017). In our 
preclinical trials, the mice treated with Akt inhibitor lost 7% of weight during 14 days 
of treatment and developed sore skin at the injection site. This precluded long-term 
treatment with this particular drug. However, other ATP-competitive Akt inhibitors 
have been developed recently which are orally available and better tolerated (Avan, 
Narayan et al. 2016).  
When suppressing Akt constitutively, the cell initiates feedback mechanisms, and 
prolonged Akt inhibition increases receptor tyrosine kinase (RTK) expression 
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upstream of Akt. Thus, combining Akt inhibitors with HER2 inhibitors have yielded 
promising results in vivo (Chandarlapaty, Sawai et al. 2011). Intermittent dosing has 
also been shown to be beneficial, by relieving feedback mechanisms, and increasing 
the patients tolerance for the drug (Davies, Greenwood et al. 2012).  
PIK3CA mutations, PTEN loss/mutations or HER2 amplification correlate to 
response to Akt inhibition, whereas RAS mutations are associated with resistance 
(Davies, Greenwood et al. 2012). This is in line with our results where MCF7 tumors 
was more sensitive to Akt inhibitor treatment than MDA-MB-231 tumors, given that 
MCF7 harbors a PIK3CA mutation and MDA-MB-231 harbors a RAS mutation 
(www.broadinstitute.org/ccle). The RAS-ERK pathway is an alternative/escape 
pathway when Akt inhibition fails to cause apoptosis. The RAS-ERK pathway is 
located downstream of oncogenic PIK3CA, and inhibition of Akt also activates ERK 
signaling through feedback mechanisms. Marie Will et.al observed that apoptosis was 
induced only if both Akt and ERK were inhibited, and that a pulsatile dosage of Akt 
and ERK inhibitors increased the efficacy and decreased the toxicity of such drugs 
(Marie Will 2014). It is clear that choosing inhibitors and combinations of inhibitors 
is a difficult exercise. To achieve a substantial therapeutic gain one should monitor 
the response using different inhibitors and dose schedules in order to adapt treatment 
to counteract feedback mechanisms causing resistance. 
The relevance of the pseudogene PTENP1 in breast cancer has not been examined 
functionally before. The role of PTENP1 as a protector of PTEN was established in 
prostate cancer (Poliseno, Salmena et al. 2010), and the role of PTENP1 has been 
examined in several cancer types. PTENP1 is expressed in the majority of cancer 
subtypes, and PTEN and PTENP1 expression is highly correlated. PTENP1 was 
associated with decreased proliferation and tumor growth in squamous cell 
carcinomas of the head & neck (Liu, Xing et al. 2017). In endometrial cancer, no 
correlation was observed between PTENP1 expression and response to treatment or 
survival, but the authors reported a trend towards a lower frequency of disease 
progression in patients with PTENP1-expressing tumors (Ioffe, Chiappinelli et al. 
2012). In gastric cancer, PTENP1 expression was lower than in adjacent normal 
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tissue, and interestingly high PTENP1 expression was associated with lower tumor 
size, lower invasion depth and fewer lymph node metastasis (Guo, Deng et al. 2016, 
Zhang, Guo et al. 2017). In clear-cell renal carcinoma, lack of PTENP1 expression 
correlated to worse survival outcome (Gan Yu 2014). 
In contrast to previous work in other types of cancer, in Paper 3 we found a diverging 
role of PTENP1 in breast cancer, depending on breast cancer subtype. 
Overexpression of PTENP1 did not affect PTEN protein levels in the ER positive cell 
lines, but ERα protein expression was reduced in the PTENP1 overexpressing MCF7 
tumors. PTENP1 reduced growth in the ER negative cell lines and increased 
proliferation in the two ER positive cell lines tested. Hsa-mir-26a is known to target 
and downregulate ESR1 in addition to PTEN and PTENP1 (microRNA.org), and this 
microRNA was upregulated by PTENP1 overexpression in all the three cell lines 
tested. Importantly, while expression levels are low, the tissue specificity of 
noncoding RNAs is high. Actually, noncoding RNA expression is more tissue-
specific than mRNA and protein expression (Gloss and Dinger 2016). Thus, it is 
plausible that PTENP1 can have different downstream effects in different subtypes of 
breast cancer. Among noncoding RNAs the context is highly important, and the 
microRNA-mRNA titration ratio is important for possible outcomes of deregulation 
of one spesific ceRNA (Johnsson, Ackley et al. 2013, Bosson, Zamudio et al. 2014).  
Although we did not find high PTENP1 expression to be of any prognostic value in 
Paper 1, the subgroup of TNBC with high PTENP1 expression deviated from all the 
other subgroups with longer survival, although not statistically significant in these 
patient cohorts (Online resource 3). However, combining these clinical observations 
in Paper 1 with the functional assessments in Paper 3, where PTENP1 expression 
sensitized MDA-MB-231 to doxorubicin, indicates that PTENP1 sensitizes cancer 
cells to anthracyclin, that there is a protective role of the pseudogene PTENP1 in ER 
negative breast cancer. The protective role in ER negative breast cancer is probably 
mediated via increased PTEN, while other mechanisms are invoked in ER positive 




PTEN loss is common in cancer (Millis, Ikeda et al. 2016) and is associated with 
metastatic events (Juric, Castel et al. 2015) and endocrine resistance (Shoman, 
Klassen et al. 2005). Despite this, all tumors we evaluated expressed PTEN mRNA 
and few had PTEN mutations. There was also a weak correlation between PTEN 
mRNA expression and PTEN protein staining measured by IHC. This indicates that 
posttranscriptional modifications could be responsible for the lack of PTEN protein 
staining. Having a high intratumoral PTEN mRNA expression was shown to be a 
negative prognostic marker for long term survival in metastatic breast cancer, but 
only for patients with TP53 wt tumors. PTEN mRNA levels however did not predict 
response to treatment, regardless of TP53 status. Accordingly, a high intratumoral 
PTEN mRNA levels is associated with worse survival, but is not a predictive factor to 
guide breast cancer treatment.  
Paper 2 
We found that activation of Akt is a common response to anthracycline treatment, 
and that inhibition of Akt yields a therapeutic benefit. However, the benefit is time-
and context-dependent. Also, there are different mechanisms involved in short-term 
and long-term response to chemotherapy. We observed that 24 hours after the first 
chemotherapy dose, in patients with ER positive tumors, increased AKT1 mRNA 
levels was associated with subsequent response to therapy. Also, the in vitro study 
demonstrated that persistent exposure to doxorubicin activated Akt extensively, and 
increased the sensitivity to Akt inhibition in doxorubicin-resistant MCF7.  
The patients that could benefit from adding an Akt inhibitor to treatment are the 
patients who already have a high constitutive Akt signaling, or that have previously 
been exposed to anthracyclines. Accordingly, using Akt inhibitors to enhance the 
effect of chemotherapy should be explored in anthracycline-resistant breast cancers, 
and in particularly ER positive breast cancer. 
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Paper 3 
During the recent years, the biological function of non-coding RNAs in cancer 
progression has been a rapidly expanding area of research. Non-coding RNAs were 
mostly considered inactive evolutionary leftovers that were accidentally transcribed. 
In Paper 3 we observed that in breast cancer the pseudogene PTENP1 has a "Janus 
face"; i.e. PTENP1 overexpression suppressed tumor growth in the ER negative 
C3HBA murine tumor model and the MDA-MB-231 human tumor model, while it 
increased tumor growth in the ER positive MCF7 human tumor model. Non-coding 
RNA transcription is highly cell-specific in normal cells, and we have shown a 
diverging response in different breast cancer subtypes. In ER negative breast cancers 
PTENP1 increased the level of AP2γ, a transcription factor involved in maintaining a 
luminal phenotype. In addition, upregulating PTENP1 dramatically reduced ERα 
expression in MCF7 tumors. The notion that PTENP1 expression may decrease ERα 
expression in breast cancer was strengthened based on data extraction from the 
TCGA database. There we found that breast cancers having upregulated  PTENP1 
expression had a lower ERα expression than tumors without upregulated PTENP1 
expression.  
In short, the non-coding pseudogene PTENP1 has a biological effect that affects 
breast cancer progression through ceRNA interactions, which is governed by the 
hormone receptor status of the tumor.  
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7. Future perspectives 
The work presented in this thesis show that high intratumoral expression of PTEN 
mRNA is a negative prognostic marker in patients with preserved p53 function. 
Based on PTEN´s role as a tumor suppressor, this is rather counterintuitive and the 
mechanisms responsible remain to be elucidated. Although PTEN mRNA and PTEN 
protein levels were positively correlated, PTEN protein expression was not 
prognostic in our cohorts of patients with breast cancer. In most studies, lack of 
PTEN protein staining is associated with treatment resistance and aggressive 
malignancies (Wang, Hao et al. 2017), and it is generally accepted that PTEN loss is 
important in tumor development and progression (Wikman, Lamszus et al. 2012, 
Juric, Castel et al. 2015). However, PTEN is also involved in DNA repair and 
protects cells from genotoxic stress, and in that context, PTEN upregulation could 
promote chemoresistance by halting cell proliferation (Bassi, Ho et al. 2013).  
In Paper 1 we found PTEN protein and PTEN mRNA levels to be weakly correlated, 
but several biopsies with high PTEN mRNA had no PTEN staining. Only 25% of 
cancer biopsies show a correlation between loss of the PTEN protein and PTEN 
mRNA (Zhang, Zhang et al. 2013), indicating that deregulated post-translational 
mechanisms mediate PTEN loss despite ongoing PTEN gene expression. This may in 
part be caused by ceRNA interactions, but also by deubiquitylating enzymes that 
interact with PTEN and destabilize or translocate the PTEN protein between the 
cytoplasm and nucleus. It would be of interest to examine the mechanisms causing 
these tumors to express high PTEN mRNA but little or no PTEN protein, as this may 
represent novel "druggable" targets.  
Intriguingly, it has been reported that a high PTEN mRNA expression in lung 
adenocarcinoma is an adverse prognostic factor, but only in female patients (Inamura, 
Togashi et al. 2007). This raises several questions, such as the mechanisms and 
growth factors governing the adverse response in women, and whether hormone 
levels are imposing the negative impact of high PTEN expression. Based on our 
findings in breast cancer and that in lung cancer above, it seems that the hormonal 
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environment wherein these cancers develop may dictate the biological effect of 
PTEN.  Investigating this further could have therapeutic implications in both breast 
cancer treatment and lung cancer.    
Another possible reason for low correlation between PTEN mRNA expression and 
PTEN protein expression is the formation of alternative splice variants. Splice 
variants of PTEN is differentially expressed in cancer vs. normal tissues, they are also 
increasingly expressed in aged blood and EBV-transformed lymphoblastoid cell lines, 
and may be a cellular response to stress (Liu, Malaviarachchi et al. 2010). 
Furthermore, p53 promotes altered PTEN splice variants when overexpressed 
(Agrawal and Eng 2006), and p53 is thereby not only functioning as a transcriptional 
regulator of PTEN, but is also involved in the post-transcriptional regulation of PTEN 
through splicing. Agrawal et.al demonstrated that ectopically overexpressing p53 
induced PTEN splice variants SV-5b and 5c that increased cyclin D1 promoter 
activity. Accordingly, it would be of interest to examine the expression of PTEN 
splice variants in the patient cohorts where we analyzed PTEN expression to evaluate 
whether the expression of SV-5b or 5c is associated with worse survival in patients 
harboring tumors with preserved p53 function. 
Turning to PTEN, the PI3K-Akt-mTOR pathway and chemoresistance, we 
established that cell lines made resistant to anthracyclines expressed a higher degree 
of phosphorylated Akt than its parental chemotherapy-naïve cell line when exposed 
to an acute dose of anthracyclines. This makes Akt a promising druggable candidate 
using small molecule inhibitors to directly target drug resistance. The Akt inhibitor 
A-443654 tested in this work is not a drug that should be pursued further in its current 
form. This is due to the severe side effects of the compound. Severe weight loss, 
probably due to induced hyperglycaemia, prevented prolonged use of the drug 
regardless of its anti-cancer effect. However, other Akt inhibitors have been 
developed which can be taken orally and with tolerable side effects. There are several 
phase 2 clinical trials testing Akt inhibitors, particularly as a mode to resensitize 
platinum resistant ovarian cancer to treatment (Brown and Banerji 2017). It would be 
of interest to assess whether these newer and less toxic Akt inhibitors exhibit the 
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same increased cytotoxicity to anthracyclin-resistant breast cancer cell lines, 
compared to chemotherapy-naïve parental cell lines, and whether they could be used 
in combination with anthracyclines to counteract acquired chemoresistance.  
During the recent years, massive parallel sequencing has increased our knowledge not 
only about the genomic landscape of cancer, but also the transcriptome. The number 
of non-coding RNAs transcribed, transcends the number of protein coding RNAs. 
Their tissue, cell and developmental expression specificity tell us that they are 
critically important in regulation, but their specific function is yet to be revealed 
(Gloss and Dinger 2016). PTENP1 is but one of many noncoding RNAs. When we 
add proteomics, epigenomics and metabolomics, including all the possible 
interactions between RNAs and proteins, the complexity of "big data" becomes far 
too great to manage individually. To be able to construct models, navigate them and 
understand signal transduction in cancer and resistance to therapy, we will become 
more dependent on utilizing collective databases and systems biology as a tool (Nam 
2017). This will change translational research, moving from hypothesis-testing to 
hypothesis-generating research where we can make clinical predictions for individual 
phenotypes (Biesecker 2013). These predictions however, must be tested by bench 
science for validity but provides exciting opportunities for elucidating biological 
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Abstract
Purpose PTEN is an important tumor suppressor in breast
cancer. Here, we examined the prognostic and predictive
value of PTEN and PTEN pseudogene (PTENP1) gene
expression in patients with locally advanced breast cancer
given neoadjuvant chemotherapy.
Methods The association between pretreatment PTEN and
PTENP1 gene expression, response to neoadjuvant
chemotherapy, and recurrence-free and disease-specific
survival was assessed in 364 patients with locally advanced
breast cancer given doxorubicin, 5-fluorouracil/mitomycin,
or epirubicin versus paclitaxel in three phase II prospective
studies. Further, protein expression of PTEN or phospho-
rylated Akt, S6 kinase, and 4EBP1 was assessed in a
subgroup of 187 tumors.
Results Neither PTEN nor PTENP1 gene expression level
predicted response to any of the chemotherapy regimens
tested (n = 317). Among patients without distant metas-
tases (n = 282), a high pretreatment PTEN mRNA level
was associated with inferior relapse-free (RFS; p = 0.001)
and disease-specific survival (DSS; p = 0.003). Notably,
this association was limited to patients harboring TP53
wild-type tumors (RFS; p = 0.003, DSS; p = 0.009).
PTEN mRNA correlated significantly with PTENP1
mRNA levels (rs = 0.456, p\ 0.0001) and PTEN protein
staining (rs = 0.163, p = 0.036). However, no correlation
between PTEN, phosphorylated Akt, S6 kinase or 4EBP1
protein staining, and survival was recorded. Similarly, no
correlation between PTENP1 gene expression and survival
outcome was observed.
Electronic supplementary material The online version of this
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material, which is available to authorized users.
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Conclusion High intratumoral PTEN gene expression was
associated with poor prognosis in patients with locally
advanced breast cancers harboring wild-type TP53.
Keywords Locally advanced breast cancer ! PTEN ! p53 !
Prognosis ! Predictive factors
Introduction
Mutations in the TP53 tumor suppressor gene, encoding the
p53 protein, are associated with lack of response to anthra-
cycline- and mitomycin-containing chemotherapy as well as
poor prognosis in breast cancer [1–7]. However, some
patients experience lack of response to these chemothera-
peutic compounds despite a preserved tumor p53 function,
pointing to additional resistance mechanisms [8]. Apart from
p53, PTEN is an important tumor suppressor which is fre-
quently inactivated in breast cancer, thus enabling increased
signaling of the crucial growth-promoting PI3K-Akt-mTOR
pathway [9, 10]. PI3K-Akt-mTOR signaling is involved in
resistance to endocrine- and HER2-directed therapy clini-
cally [9, 11], as well as resistance to chemotherapy in pre-
clinical trials [12, 13]. This suggests that PTEN expression
may influence response to cancer treatment.
While PTEN somatic mutations are rare, PTEN protein
expression is frequently lost in breast carcinomas, pointing
to transcriptional and post-transcriptional regulation as
possible mechanisms [14, 15]. Of notice, PTEN and p53
reciprocally interact to preserve each other’s protein levels
[16]. Further, in vitro data from prostate cancer cell lines
suggest that PTEN pseudogene (PTENP1) mRNA tran-
scripts may regulate the PTEN expression level by com-
peting for PTEN-degrading micro RNAs (miRNAs) [17].
The aim of the present study was to assess the prognostic
role of pretreatment PTEN and PTENP1 gene expression
levels in patients with locally advanced breast cancer, stratified
by TP53mutations status, and the predictive role of PTEN and
PTENP1 gene expression levels toward chemotherapy
response. In addition, we examined protein expression levels
of PTEN as well as key signaling molecules in the PI3K-Akt-
mTOR pathway [9]. For this purpose, we used tumor material
collected from patients with locally advanced breast cancer
treated with different chemotherapy regimens in phase II trials
conducted between 1991 and 2007 [1–5].
Methods
Patient material
Pretreatment tumor samples were available from patients
with locally advanced breast cancer (T3/T4 and/or N2/N3)
included in three neoadjuvant phase II trials described in
detail previously [1, 3–5, 18] and outlined in Fig. 1. Dates
of enrollment of the first participants to the trials were
18/1-91 (Study 1), 1/6-93 (Study 2), and 24/11-97 (Study
3). In Study 1, patients were given neoadjuvant doxoru-
bicin, 14 mg/m2 qW for 16 weeks. In Study 2, each patient
received 5-fluorouracil 1000 mg/m2 and mitomycin 6 mg/
m2 (FUMI) q3w for 12 weeks. In Study 3, patients were
randomized to either epirubicin 90 mg/m2 (Arm A) or
paclitaxel 200 mg/m2 q3w (Arm B), administered in 4–6
courses. Further, in Study 3, patients with suboptimal
tumor response to either drug switched to the opposite
chemotherapy regimen [5, 18].
Response rates (according to the The Union for Interna-
tional Cancer Control criteria), TNM status, estrogen
receptor (ER), and TP53 mutation data have been reported
previously [1, 5, 18], and are summarized in Table 1, along
with the current assessment of PIK3CA and HER2 status.
Follow-up data were available for[10 years or up to time of
death for all patients in the trials. A total of 317 patients
were assessed for chemotherapy response with respect to
gene and protein expression. Among these, 282 patients with
stage 3 disease at diagnosis were used for survival analysis.
Tumor samples
In each protocol, tumor samples were collected by incisional
biopsies prior to commencing cancer therapy. Samples were
snap frozen and stored in liquid nitrogen until DNA/RNA
analysis. In the present investigation, tumor RNA was avail-
able from 325 patients; 81 patients from Study 1, 32 patients
from Study 2, and 212 patients from Study 3. Among patients
with tumor RNA available, seven lacked response data and 43
had primary metastatic disease, leaving 318 patients for
response evaluation and 282 patients for survival analysis
with respect to gene expression results (Fig. 1).
Pretreatment formalin-fixed paraffin-embedded (FFPE)
tumor tissue was available from 193 patients in Study 3 as
tissue microarrays (TMAs), but due to the lack of tumor
tissue in some core biopsies or staining artifacts, incl.
missing cores, only 187 patients could be evaluated for any
particular protein. Among patients with TMA tumor tissue
available, seven lacked response data, 18 had primary
metastatic disease, whereas one patient did not undergo
breast surgery and was unfit for calculation of recurrence-
free survival, leaving 179 patients for response evaluation
and 169 patients for survival analysis with respect to pro-
tein staining results (Fig. 1).
Basic genomic procedures
Procedures, primers, and antibodies used for RNA and
DNA analysis are described in detail in Online Resource 1.
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Immunohistochemistry (IHC) and in situ
hybridization (ISH)
Procedures used for IHC and ISH analysis are described in
detail in Online Resource 1. The antibodies used for pro-
tein analysis were monoclonal anti-Akt (phosphorylated
Ser 473), monoclonal anti-HER2 (4B5, Dako), polyclonal
anti-PTEN, polyclonal anti-S6 kinase (S6K, phosphory-
lated Ser 371, Abcam), mouse monoclonal anti-S6K
(phosphorylated Thr 389), and polyclonal anti-4EBP1
(phosphorylated Thr 70). All antibodies were developed in
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Fig. 1 Flow chart depicting the number of patients with locally
advanced breast cancer recruited in Studies 1–3, and the number of
samples available from each trial for RNA and immunohistochem-
istry (IHC) analysis. In Study 3, patients randomized to either
epirubicin or paclitaxel were switched to the opposite regimen if
tumor regression on the first regimen was insufficient; survival
analysis was performed for all patients randomized to each regimen
(intention-to-treat) and separately for those patients without crossover
(w/o cross) to the opposite regimen. aPatients with stage IV disease
were excluded from survival analysis. bOne patient with progressive
disease (PD) never became tumor-free, and recurrence-free or
disease-free survival could therefore not be assessed. FFPE forma-
lin-fixed paraffin-embedded tissue, IHC immunohistochemistry
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Table 1 Baseline patient and
tumor characteristics
Treatment Study 1a Study 2a Study 3Ab Study 3Bb
Doxorubicin FUMI Epirubicin Paclitaxel
Patients 90 34 119 121
Accrual 1991–1997 1993–2001 1997–2003 1997–2003
Age (years)
Range 32–88 37–82 28–70 25–70
Median 64 67 49 48
T stage
T2c 3 2 1 1
T3 54 15 99 90
T4 33 17 18 30
N stage
N0d 30 9 52 45
N1 34 14 48 59
N2 26 11 17 17
N3 0 0 1 0
M stage
M0 78 24 109 106
M1 12 10 10 15
ER
Negative 13e 11e 52 49
Positive 77 23 66 69
Unknown 0 0 1 3
HER2
Negativef 24 27 63 66
Positive 6 6 30 28
Unknown 60 1 26 27
TP53
TP53 wtg 64 16 84 89
TP53 mut. 26 18 23 25
Unknown 0 0 12 7
Responseh
PD 5 9 10 14
SD 45 13 49 47
PR 31 10 56 47
CR 0 0 4 5
Unknown 0 0 0 8
TMAi
Stage 3 0 0 88 81
Stage 4 0 0 7 11
RNA/DNAj
Stage 3 71 22 90 99
Stage 4 10 10 9 14
PTENk
PTEN wt 0 0 80 99
PTEN mut. 0 0 2 2
Unknown 0 0 27 4
PIK3CAl
PIK3CA wt 26 20 82 92
PIK3CA mut. 4 12 25 22
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otherwise. Immunostaining was evaluated by two inde-
pendent researchers, and given a semi-quantitative score of
0 (no staining) to 3 (strong staining). Whereas both nuclear
and cytoplasmic staining were assessed for PTEN, cyto-
plasmic staining was scored for 4EBP1, and nuclear
staining for Akt and S6K. In a combined PI3K pathway
analysis, absent PTEN protein staining, phosphorylated
Akt staining, phosphorylated S6K staining, and PIK3CA
mutation were each given a score of one each, and ‘‘PI3K
pathway activation’’ was defined as a score of two or
higher.
Statistics
Correlation analysis between PTEN mRNA expression
level and PTEN staining was performed using Spearman’s
rho. Mann–Whitney test was used for comparison of
mRNA or protein staining levels between tumor subgroups.
The Chi-square test was used to assess the correlations
between PIK3CA mutation status and phosphorylation
status of Akt, S6 K, 4EBP1 proteins or between PIK3CA
mutations and response to chemotherapy. Chi-square test
was also used to assess the correlation between IHC
staining and chemotherapy response. Survival data were
assessed by Cox regression analysis calculating hazard
ratios for each parameter. For Kaplan–Meier plots, patient
subgroups were compared by the log-rank test. Due to a
smaller number of patients, the survival data from Studies
1 to 2 were analyzed in concert, as described previously
[1]. Recurrence-free (RFS) and disease-specific survival
(DSS) were defined as time from inclusion in the trial until
breast cancer recurrence or death due to breast cancer,
respectively. Deaths for reasons other than breast cancer, or
patients still alive at the time of analysis, were treated as
censored observations. PTEN and PTENP1 gene expres-
sion values were sorted for each of the three trials sepa-
rately and divided by the median value into two groups
defined as PTEN or PTENP1 ‘‘low’’ (i.e., below the med-
ian) and ‘‘high’’ (i.e., above the median). Multivariate
analysis was performed using Cox regression to evaluate
the independent prognostic impact of PTEN, PTENP1,
TP53, PIK3CA, HER2, and ER status in this cohort of
locally advanced breast cancers. Statistical analyses were
performed using the SPSS 22/PASW 17.0 and Graph Pad
Prism v6 software packages. All p-values reported are two-
tailed, and p\ 0.05 was considered statistically significant.
Results
PTEN, PTENP1, and TP53 gene expression
Baseline patient and breast cancer characteristics from
Studies 1-3 are summarized in Table 1. PTEN gene
expression by quantitative/real-time PCR (qPCR) was
detectable in all 318 tumors with a defined treatment
Table 1 continued
Treatment Study 1a Study 2a Study 3Ab Study 3Bb
Doxorubicin FUMI Epirubicin Paclitaxel
Unknown 51 0 12 7
a Data from Studies 1–2 were pooled for statistical analysis due to a low number of patients in Study 2
b Data from Study 3 were split into Study 3a (epirubicin) and 3b (paclitaxel), based on the primary
chemotherapy given
c T2 tumors only included if axilla stage N2. T stage and all subsequent tumor characteristics given for
stage 3 and 4 combined
d N stage by clinical assessment alone
e ER negative if tumor ER concentration\10 fmol/mg in Study 1–2. ER assessed by standard IHC in Study
3
f For Studies 1–2; HER2 assessment available from a subset of the tumors by in situ hybridization only. For
Study 3: HercepTest IHC was performed on all tumors, and HER2 in situ hybridization for tumors with
staining score 2 by IHC
g TP53 mutation status, whole exome assessed by Sanger sequencing. wt wild-type, mut mutation
h Progressive disease (PD), stable disease (SD), partial response (PR), complete response (CR)
i Subset of patients from whom formalin-fixed paraffin-embedded (FFPE) tumor tissue was available for
protein analysis to correlate against gene expression results (PTEN), response rates (stage 3 and 4 disease),
or survival (stage 3 only)
j Subset of patients from whom tumor RNA was available for gene expression analysis to correlate against
response rates (stage 3 and 4 disease) or survival (stage 3 only)
k Subset of patients from whom tumor DNA was available for PTEN mutation analysis
l Subset of patients from whom tumor DNA was available for PIK3CA mutation analysis to correlate
against response rates (stage 3 and 4 disease) or survival (stage 3 only)
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response (Fig. 2a). In contrast, PTENP1 expression was
undetectable in 96 tumors (30%; Fig. 2b). There was a
significant, albeit not uniform correlation between PTEN
and PTENP1 mRNA expression levels (rs = 0.456,
p\ 0.0001; Fig. 2c). Whereas PTEN mutations were
identified in four out of 183 breast cancers (2.2%), PIK3CA
mutations were found in 63 out of 220 (29%), and TP53
mutations in 92 out of 253 (36%) tumors analyzed
(Table 1). Among the four tumors with PTEN mutations,
two had PTEN gene expression above and two below the
median (data not shown). No significant differences in
PTEN or PTENP1 gene expression were observed in sub-
groups stratified by ER, HER2, PIK3CA, or TP53 mutation
status or by comparison of triple-negative breast cancer
(ER/PGR/HER2 negative; TNBC) vs. non-TNBC (data not
shown). TP53 gene expression was undetectable in seven
out of 273 tumors (2.5%), and a significant correlation was
observed between TP53 and PTEN gene expression in
these 273 tumors from Studies 1 to 3 where both transcripts



















































Fig. 2 a Gene expression of
PTEN in locally advanced




Studies 1–3 combined. Sorted
by response group and
increasing PTEN levels. b Gene
expression of PTEN pseudogene
(PTENP1) in locally advanced
human breast cancers prior to
starting neoadjuvant
chemotherapy, sorted by
response group and increasing
PTEN levels (same as a).
c Scatter plot depicting the
correlation between PTEN and
PTENP1 gene expression in
breast cancers from the
epirubicin/paclitaxel,
doxorubicin, FUMI trials
combined. d Scatter plot
depicting the correlation
between PTEN gene expression
and PTEN protein expression in
breast cancers from the
epirubicin/paclitaxel,
doxorubicin, FUMI trials
combined. PTEN and PTENP1
mRNA levels in a–d are
depicted as the mean gene
expression of three separate
real-time RT-PCR runs, as a
fraction of RPLP2 expression,
and corrected for cDNA pool.
Gene expression in a–b is not
depicted beyond eight times the
RPLP2 expression to visualize
better differences between the
tumor samples. PD progressive
disease, SD stable disease, PR
partial response, CR complete
response
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between TP53 and PTEN mRNA levels remained signifi-
cant (rs = 0.150, p\ 0.05), if 47 out 212 tumors with
known TP53 or PTEN mutations (Study 3) were excluded
from the analysis.
PTEN and PI3K pathway protein expression
IHC staining results for PTEN, and phosphorylated Akt
(Ser 473), S6K (Ser 371 or Thr 389), and 4EBP1 (Thr 70)
are summarized in Online Resource 2. High-quality
immunostaining was observed for all antibodies used, apart
from phosphorylated S6K (Thr 389) which yielded poor
staining of the tissue microarrays. At the same time, it has
been established previously that phosphorylation at the
S6K Ser371 phosphorylation site is essential for Thr389
phosphorylation [19], indicating that the staining results for
Ser371 should correlate to Thr389 staining. A weak cor-
relation (rs = 0.163, p = 0.036) was established between
PTEN gene expression and the corresponding PTEN pro-
tein staining level in 166 tumors from which both RNA and
TMA tissue blocks were available (Fig. 2d). However,
there was no correlation between a low PTEN gene
expression level and increased Akt (Ser 473) or S6K (Ser
371 or Thr 389) phosphorylation in breast cancers from
which both RNA and IHC tissue samples were available
for such comparisons (n = 163). Also, there was no cor-
relation between the absence of PTEN protein staining and
increased Akt (Ser 473) or S6K (Ser 371 or Thr 389)
phosphorylation by comparison of IHC tissue samples
(data not shown). ‘‘PI3K pathway activation,’’ defined as
two or more of the following: absent PTEN staining,
phosphorylated Akt, phosphorylated S6K, and/or PIK3CA
mutations, was observed in 117 out of 159 breast cancers in
Study 3. PTEN gene expression was significantly higher
(p = 0.028) in tumors with pathway activation, compared
to tumors without pathway activation (data not shown).
However, if split into ER-positive or ER-negative tumors,
PTEN gene expression was not significantly higher in
neither group in tumors with pathway activation. Akt
phosphorylation was significantly more prevalent in tumors
harboring PIK3CA mutations (27 out of 38 tumors), as
compared to PIK3CA wild-type tumors (55 out of 132
tumors; p = 0.002, data not shown). However, there was
no correlation between PIK3CA mutation status and the
proportion of tumors with phosphorylation of S6K
(Ser371), S6K (Thr389), or 4EBP1 further downstream in
the PI3K pathway. In TNBC, a high frequency of absent
PTEN staining, and low level of Akt-S6K-4EBP1 phos-
phorylation was observed, as expected for this breast can-
cer subtype (Online Resource 2). However, there was no
significant difference in PTEN staining between TNBC and
non-TNBC tumors (data not shown).
Predictive variables toward chemotherapy response
No association was recorded between pretreatment PTEN
or PTENP1 gene expression and response to neither of the
chemotherapies given (n = 320 patients with stage 3/4
disease), irrespective of TP53 mutation, PIK3CA mutation,
HER2 or ER status (data not shown). Furthermore, no
association between PIK3CA mutation status and response
to chemotherapies was detected across the three trials
(n = 267). Finally, the protein staining intensity for PTEN
(n = 179), phosphorylated Akt (n = 178), S6K (Ser 371,
n = 173), S6K (Thr 389, n = 183), and 4EBP1 (n = 175),
yielded no predictive information toward chemotherapy
response among patients in Study 3.
Prognostic impact of PTEN gene expression
Excluding patients with stage 4 disease from the analysis,
high PTEN gene expression, defined as a PTEN mRNA
level above the median, was associated with significantly
shorter RFS (hazard ratio (HR) for recurrence 1.78, 95%
confidence interval (CI) 1.26–2.50, p = 0.001), and DSS
(HR for breast cancer-specific death 1.72, 95% CI
1.20–2.47, p = 0.003) across the pooled cohort of patients
with stage 3 disease (n = 282, Fig. 3a–d). Among tumors
wild-type for TP53, a high PTEN level remained a negative
prognostic marker, with inferior RFS as well as DSS (HR
1.82, 95% CI 1.22–2.72, p = 0.003 and HR 1.78, 95% CI
1.16–2.73, p = 0.009, respectively; Figs. 3c, d, 4a, b). In
contrast, no significant association between outcome and
PTEN gene expression level was observed in patients with
tumors harboring TP53 mutations (Fig. 3c, d, 4c, d). These
findings were consistent across each individual trial (On-
line Resource 3).
If stratified by ER status, high intratumoral PTEN gene
expression was associated with inferior RFS (HR 2.20,
95% CI 1.41–3.44, p = 0.001) and DSS (HR 2.18, 95% CI
1.34–3.54, p = 0.002) among patients with ER-positive
tumors only; no effect was observed among patients har-
boring ER negative tumors (Fig. 3c, d). Moreover, the
negative prognostic impact of a high PTEN level was
evident only in ER-positive tumors harboring wild-type
TP53 (Fig. 3c, d), with inferior RFS (HR 2.37, 95% CI
1.41–3.97, p = 0.001) and DSS (HR 2.30, 95% CI
1.31–4.04, p = 0.004). No prognostic impact of PTEN
mRNA level was recorded in patients with ER-negative
tumors, irrespective of TP53 status (Fig. 3c, d). In contrast,
PTEN gene expression above the median was associated
with inferior survival outcome among both HER2 negative
(RFS; HR 1.69, 95% CI 1.07–2.69, p = 0.026, DSS; HR
1.63, 95% CI 0.99–2.65, p = 0.053) and HER2-positive
tumors (RFS; HR 2.52, 95% CI 1.07–5.91, p = 0.034,
DSS; HR 3.16, 95% CI 1.19–8.39, p = 0.021, Fig. 3c, d).
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Finally, the negative prognostic impact of high PTEN
mRNA levels was observed exclusively for PIK3CA wild-
type tumors (RFS; HR 1.89, 95% CI 1.23–2.91, p = 0.004,
DSS; HR 1.94, 95% CI 1.33–3.07, p = 0.005), with no
impact of PTEN level in PIK3CA mutated tumors (Online
Resource 3).
Patients with stage 4 disease (n = 44) were excluded
from the above survival analysis. However, a high PTEN
gene expression was associated with significantly shorter
DSS (HR for breast cancer-specific death 2.06, 95% CI
1.08–3.01, p = 0.027) also for patients with primary
metastatic disease (data not shown).
Validation using the cancer genome atlas (TCGA)
public dataset
To validate our findings in another patient cohort, PTEN
gene expression data were extracted from the cBioPortal
database [20, 21], and normalized to RPLP2 expression in
the same dataset. These gene expression data are based on
a 
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RNA sequencing in the Breast Invasive Carcinoma (Cell
2015) analysis [22], which are in whole based upon data
generated by the TCGA Research Network: http://cancer
genome.nih.gov/. Patient outcome for 816 patients with
primary breast cancer was compared for tumors with PTEN
mRNA levels above or below the median. A negative
prognostic impact of high PTEN gene expression was
observed for overall survival (OS) (HR 1.59, 95% CI
1.10–2.29, p = 0.014), but not for RFS (Fig. 4e, f). Among
tumors wild-type for TP53, a high PTEN level remained a
negative prognostic marker, with inferior OS (HR 2.03,
95% CI 1.25–3.30, p = 0.004; Fig. 4e, f). In contrast, no
prognostic value was established for PTEN gene expression
in tumors harboring TP53 mutations. DNA sequencing data
from the same cohort identified PTEN mutations in 42
tumors (5.1%), and 13 tumors thereof exhibited PTEN gene
expression above and 29 tumors exhibited PTEN gene
expression below the median. A weak negative correlation
(rs = -0.090, p = 0.010) was established between the
presence of PTEN mutations and the corresponding PTEN
gene expression level in the 816 tumors from the TCGA
dataset.
Other prognostic variables
No survival difference was observed between patients with
tumor PTENP1 gene expression above or below the med-
ian within the pooled cohort of patients with stage 3 dis-
ease, nor within any of the subgroups (Online Resource 4).
Also, there was no prognostic impact of PTENP1 mRNA
level in patients with stage 4 disease (data not shown).
Similarly, no prognostic impact of either PIK3CA mutation
status (n = 238), PTEN protein expression level
(n = 168), phosphorylated Akt (n = 167), S6K (n = 162),
or 4EBP1 (n = 165) assessed by immunohistochemistry
was recorded with respect to RFS and DSS for patients
with stage 3 disease (Online Resource 5). Further, in
patients with stage 4 disease where tissue was available for
IHC (n = 18), no correlation was observed between PTEN
protein expression and DSS (data not shown).
Multivariate analysis
Multivariate analysis revealed PTEN expression level and
TP53 mutation status to be independent prognostic vari-
ables for RFS as well as DSS (Table 2). No significant
interaction between PTEN mRNA level and TP53 status
with respect to outcome was recorded (Table 2).
Discussion
TP53 inactivating mutations are associated with resistance
to anthracycline- and mitomycin-containing chemotherapy
and poor prognosis in patients with locally advanced breast
cancer [1–7]. Among TP53 wild-type breast cancers
revealing primary resistance to anthracyclines, mutations in
the p53 upstream activator CHEK2 [23] or low expression
levels of ATM [24] have been observed. Yet, additional
factors are known to influence p53 activation in response to
genotoxic stress [25, 26]. One such factor is the PTEN
protein encoded by the PTEN gene [10]. In the present
bFig. 4 a–d Recurrence-free (RFS) and disease-specific survival
(DSS) after neoadjuvant chemotherapy in patients with locally
advanced breast cancer after neoadjuvant epirubicin, paclitaxel,
doxorubicin, or 5-FU/mitomycin (FUMI), Studies 1–3 combined.
Groups are split by PTEN gene expression above or below the
median, and stratified by TP53 mutation status. Censored values are
marked with ?. n indicates the number of patients used for the
survival analysis. e–f Forest plot for the association between tumor
PTEN gene expression level and recurrence-free (e) or overall
survival (f) in patients with early breast cancer with data extracted
from the The Cancer Genome Atlas (TCGA) Breast Invasive
Carcinoma (Cell, 2015) cohort. Results are presented as individual
hazard ratios (HRs) with corresponding 95% confidence intervals
(CIs). HR[ 1 indicates that the survival of patients with tumor PTEN
gene expression above the median (PTEN high) is shorter than that of
patients with PTEN low tumors, while HR\ 1 indicates the opposite.
RFS recurrence-free survival, OS overall survival, wt wild-type, mut
mutated
Table 2 Prognostic indicators of survival by multivariate analysis
Variable Recurrence-free survival Disease-specific survival
HR (95% CI) p value Events/patients HR (95% CI) p value Events/patients
PTEN low 1.00 0.040 57/147 1.00 0.005 51/146a
PTEN high 1.48 (1.02–2.14) 80/135 1.69 (1.17–2.42) 70/135
TP53 wt 1.00 0.001 98/216 1.00 0.040 86/215a
TP53 mut 1.75 (1.24–2.46) 39/66 1.51 (1.02–2.24) 35/66
Interaction PTEN*TP53 0.927 0.776
The parameters included in the multivariate analysis were PTEN gene expression (high vs. low) and TP53 mutation status (wild-type vs. mutated)
wt wild-type, mut mutated, HR hazard ratio, CI confidence interval
a One case censored before the earliest event in a stratum for disease-free survival
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work, we provide data demonstrating the negative prog-
nostic role of high PTEN gene expression levels in tumor
tissue from patients with locally advanced breast cancer.
Notably, the prognostic role of PTEN was observed
exclusively in patients whose tumors contain preserved
TP53 wild-type status, in accordance with the known
functional crosstalk between PTEN and p53
[16, 25, 27–29]. Moreover, our data suggest that the bio-
logical impact of PTEN in human breast cancer is mediated
via mRNA interactions, given a lack of prognostic impact
of PTEN protein staining, and a lack of correlation between
PTEN and PI3K-Akt-mTOR signaling activity.
To the best of our knowledge, the prognostic role of
PTEN gene expression by qPCR has not been assessed in
patients with breast cancer previously. In a study of 70
patients with stage 2 breast cancer, a gene expression
profile of ‘‘PTEN loss,’’ including reduced PTEN gene
expression, was predictive of poor survival, whereas PTEN
protein staining had no prognostic value [30]. However,
PTEN gene expression was categorized only as up- or
downregulated in this microarray analysis, with no further
quantification [30]. Another study found PTEN gene
expression to be significantly higher in 93 human breast
cancer samples as compared to healthy breast tissue;
however, the potential impact on survival was not assessed
[31].
While our clinical data are provocative to suggest a
negative prognostic role of high intratumoral PTEN gene
expression in patients with stage 3 breast cancer, our
findings were confirmed by mining the TCGA dataset, to
extract RNA sequencing data from 816 patients with stage
1–3 breast cancer [22]. Again, inferior overall survival was
observed among patients with high intratumoral PTEN
mRNA levels, and in particular, for patients with TP53
wild-type tumors. In this validation cohort, recurrence-free
survival did not differ for patients with high versus low
PTEN levels, as opposed to our findings. This could be
attributed to a high proportion of stage 1–2 breast cancer in
the TCGA cohort (74%), with a better prognosis, regardless
of PTEN gene expression, compared to patients with high-
risk stage 3 disease in our trials.
The biological reason why high PTEN gene expression
was associated with an inferior prognosis in our clinical
material remains to be elucidated. While a weak correlation
between PTEN gene expression and PTEN protein staining
was observed, PTEN protein levels had no prognostic
impact, pointing to biological interactions at the mRNA
level as a probable reason.
Firstly, PTEN and p53 influence each other at the
transcriptional level as well as through protein interaction
[25]. Apart from binding to and stabilizing the p53 protein
[16], PTEN inhibits MDM2 transcription, thus reducing
MDM2-mediated p53 degradation [27]. Furthermore, p53
binds to the genomic PTEN locus and increases PTEN
transcription [28, 29]. Notably, while we found PTEN and
TP53 to correlate at the mRNA expression level, this was
observed among tumors harboring wild-type TP53 only.
Similar, PTEN expression correlated to outcome only
among TP53 wild-type tumors. Interestingly, in vitro data
indicate that nuclear PTEN modulates the response to
genotoxic stress by control of DNA repair in cancer cells
with preserved p53 function [32]. While the role of PTEN
as a regulator of PI3K cytoplasmic signaling has been
extensively studied, the role of nuclear PTEN to influence
cell cycle arrest and DNA repair remains less defined
[33, 34]. However, the prognostic impact of PTEN protein
staining did not differ if nuclear staining was assessed
separately, as opposed to combined nuclear and cytoplas-
mic staining in the current patient cohort.
Secondly, PTEN mRNA share miRNA binding sites
with multiple gene transcripts implicated in cancer pro-
gression [35], and high PTEN gene expression could skew
the balance between these transcripts in a pro-tumorigenic
manner by adsorbing miRNAs which would otherwise
target and degrade important oncogenes [36]. Moreover,
PTEN and the protein non-coding PTEN pseudogene
(PTENP1) share multiple miRNA binding sites [17], and
altering the PTEN mRNA level could influence PTENP1
degradation by competing for the same miRNAs [17, 35].
PTEN and PTENP1 could even interact via PTENP1
antisense transcripts which bind to the PTEN promoter and
reduce PTEN mRNA expression [37]. While being protein
non-coding, PTENP1 transcripts are biologically active and
tumor suppressive in various solid cancers [17, 38–40].
Loss of PTENP1 on chromosome 9p was identified in 11
out of 118 human breast cancers in data extracted from
array-based comparative genomic hybridization databases
by Poliseno et al. [17].
To the best of our knowledge, we present the first
analysis of PTENP1 gene expression in human breast
cancer. We found PTENP1 to be expressed in 222 out of
318 human breast cancer samples analyzed. However, the
positive correlation between PTEN and PTENP1 transcript
levels established in the current report, and the known
tumor inhibitory role of PTENP1, do not indicate that the
negative prognostic impact of high PTEN levels is medi-
ated via its pseudogene. Accordingly, no prognostic impact
of PTENP1 was observed in univariate analysis in our
patient cohort.
Thirdly, methodological issues associated with
immunohistochemistry, such as formalin fixation, antigen
retrieval, antibody specificity, and inter-observer variabil-
ity could explain the lack of strong correlation between
PTEN mRNA and PTEN protein levels. In comparison,
PTEN mRNA analysis was performed using a standardized
qPCR assay with specific primers and validated PCR
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products which were quantified independently of the
observers.
PTEN is a known inhibitor of the growth-promoting
PI3 K-Akt-mTOR pathway [9, 41], and lack of PTEN
protein expression is generally associated with increased
PI3K-Akt-mTOR signaling [9, 42]. While a significant
association between PTEN and phosphorylated Akt by IHC
was established previously in 655 breast cancers [43], such
an association was not observed in another patient cohort
[44], and there was no correlation between the loss of
PTEN staining and increased Akt phosphorylation in nei-
ther of these two trials [43, 44]. In our current TMA
analysis, negative PTEN staining was not associated with
increased Akt or S6K phosphorylation levels in 163 locally
advanced breast cancers, clearly indicating a lack of bio-
logical interaction between PTEN and the PI3K-Akt-
mTOR pathway in this setting.
The lack of prognostic impact of PTEN protein
expression among 168 patients in the current study is in
accordance with several large clinical trials in early breast
cancer [30, 43–46]. In the recent CLEOPATRA trial in
HER2-positive metastatic breast cancer, a low PTEN pro-
tein expression was associated with worse OS, but at the
same time an improved progression-free survival, whereas
the presence of PIK3CA mutations was a definite negative
prognostic marker [47]. In the BOLERO-2 trial, patients
with ER-positive metastatic breast cancer experienced the
same survival benefit from adding the mTOR inhibitor
everolimus to exemestane, regardless of ‘‘PI3K activa-
tion’’, defined as low PTEN staining, or AKT1, PIK3CA,
PIK3R1 or PTEN mutations [48]. Finally, the prognostic
impact of PIK3CA in breast cancer is not well established
[49], and our data are consistent with the findings in a
recent study, reporting no influence of PIK3CA mutation
status on survival outcome among 1008 patients with
breast cancer at high risk of relapse [50].
Conclusions
We establish that high PTEN gene expression in locally
advanced human breast cancers is a marker of poor prog-
nosis, across three neoadjuvant trials with 282 patients.
Furthermore, the prognostic impact of PTEN gene
expression is evident only among patients with TP53 wild-
type breast cancers. This should be examined further to
assess whether the outcome of patients with these breast
cancer characteristics could be improved by alternative
therapeutic measures in the future.
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Online Resource 1. 
Basic genomic procedures 
RNA was extracted from breast cancer samples using either Trizol (Invitrogen) (Studies 1-2) or the Qiagen 
RNeasy protocol (Study 3). RNA concentrations were measured by a NanoDrop spectrophotometer (Thermo 
Scientific), and cDNA was made from 500 ng of RNA using Transcriptor Reverse Transcriptase kit w/random 
hexamers (Roche). DNA for PTEN and PIK3CA analysis was extracted using the Qiagen DNeasy kit. 
 
Real-time qPCR was performed using dual labeled hydrolysis probes (TIB MOLBIOL). The Light Cycler 480 
(Roche) was used to detect the PCR products. Lack of gene expression was defined as lack of gene amplification 
after 37 cycles. Gene of interest was given as a ratio to the housekeeping gene RPLP2, and as a mean of three 
independent runs, normalized to a cDNA pool of 6 breast cancer cell lines. PTEN was amplified much earlier 
than PTENP1 during the qPCR procedure, demonstrating higher absolute levels of PTEN than PTENP1 
transcripts. The relative PTENP1/RPLP2 gene expression was therefore divided by 98 (2rCp) since PTENP1 
appeared on average 6.62 cycles after PTEN (ΔCp) on real-time RT-PCR. 
 
For each of the three trials patients were sorted based on increasing PTEN or PTENP1 gene expression in the 
tumors, and the groups were split by gene expression above or below the median.  
 
Gene expression of PTEN and the known transcribed, processed PTENP1 [1] was analyzed using cDNA 
produced from DNAse-treated RNA. Due to the 98% sequence homology between PTEN and PTENP1 [1], the 
specificity of all PCR reactions was verified by Sanger sequencing.  
 
PTEN 3´UTR primers from [2]: 
PTEN_F2:   CTTCTCCATCTCCTGTGTAATCAA 
PTEN_R2:   GTTGACTGATGTAGGTACTAACAGCAT 
PTEN_FAM:   FAM6-CCAGTGCTAAAATTCA-BBQ 
 
PTENP1 3´UTR: 
PTENP1_F18:  TGCAGTTAGCTAAGAGAAGTTTCTG 
PTENP1_R20:  CCATTCCCCTAACCCAAATAC 
 27 
PTENP1_FAM:  FAM6-AGGGTTTTGCTGCATTCTTGCAT-BBQ 
 
RPLP2: 
RPLP2_F  GACCGGCTCAACAAGGTTAT 
RPLP2_R  CCCCACCAGCAGGTACAC 
RPLP2_Cy5  Cy5-AGCTGAATGGAAAAAACATTGAAGACGTC-BBQ 
 
TP53: 
TP53_F     CGAGCACTGCCCAACAA    
TP53_A     GCCTCATTCAGCTCTCGGAA   
TP53_TM     FAM6-CACGGATCTGAAGGGTGAAATATTCTCCA—BBQ 
 
Hot-spot PIK3CA mutations in exons 10 and 21 (previously exon 9 and 20) [3] were assessed in 275 pre-
treatment breast cancer samples from Studies 1-3; tumor DNA was used as PCR template with the primers listed 
below. PTEN mutation status was assessed in 183 pre-treatment breast cancer samples from Study 3, using 
cDNA as the template for nested PCR with the primers listed below. PCR products were analyzed at Center for 
Medical Genetics and Molecular Medicine, Haukeland University Hospital, by Sanger sequencing using the 
BigDye v1.1 reaction mix (Applied Biosystems).  
 













PI3KCA_ex21_seqR   AGAAAATGAAAGCTCACTCTG 
PI3KCA_ex21_seqF0 GGAGATGTGTTACAAGGCTTATCTA 
PI3KCA_ex21_seqR2  GCATTGAACTGAAAAGATAACTGAGAAA 
 
PTEN sequencing primers (nested PCR): 
PTEN outerF     TCCAGAGCCATTTCCATC 
PTEN outerR   TGTCAAAACCCTGTGGATG 
 
PTEN inner primerF    CTCCTCCTTTTTCTTCAGC 
PTEN inner primerR CAAGAGGGATAAAACACCAT 
 
PTEN sequencingF  GAGTAACTATTCCCAGTCAGAGG 
PTEN sequencingR AACTGAGGATTGCAAGTTCC 
 
Immunohistochemistry (IHC) and in situ hybridization (ISH) 
Tissue microarrays (TMAs) were created from Study 3 with quadruplicate 1 mm cores from formalin-fixed 
paraffin embedded (FFPE) tumor material collected at the time of diagnosis. Briefly, tumor sections (4 µm) from 
the TMAs were de-paraffinized and rehydrated, before antigen retrieval at 98°C for 1 hour in DAKO Target 
Retrieval Buffer (pH 6.0 or 9.0). After blocking with diluted goat serum for 30 min, the slides were incubated 
overnight (+4°C) with the primary antibody. After blocking endogenous peroxidase activity for 15 min with 
DAKO peroxidase block, a biotinylated goat anti-rabbit secondary antibody was applied for 30 min (Vector 
Laboratories). The antigen-antibody complex was revealed with avidin-biotin-peroxidase (ABC) for 30 min 
according to the manufacturer’s instructions (Vectastain® ABC Kit, Vector). The immune reaction was 
visualized by incubation with diamino-benzidine tetrahydrochloride (Vector). The sections were then 
counterstained with haematoxylin (Fisher), dehydrated and mounted with Entellan (Electron Microscopy 
Services). Parallel sections were run for all the experiments without primary antibody, to assure the specificity of 
the immune reactions.  
 
 29 
HER2 assessment was performed according to international guidelines [4], using the Ventana-Roche HercepTest 
and the INFORM HER2 Dual ISH DNA Probe Cocktail (Roche) assays. Briefly, HER2 immunostaining 
(HercepTest) scores 0 and 1 were classified as HER2 negative, score 2 as equivocal and score 3 as HER2 
positive. Biopsies with equivocal results were analyzed by dual-color dual-hapten brightfield in situ 
hybridization (DDISH, Ventana-Roche) using the INFORMER HER2 Dual ISH DNA Probe Cocktail, the 
UltraView Red ISH DIG Detection and ultraView SISH DNP Detection Kits. HER2 and chromosome 17 
centromere (CEP17) were counted in 20 tumor cell nuclei and specimens with equivocal ratio HER2/CEP17 
(1,8-2,2) an additional 20 nuclei were counted. A ratio below 1.8 was considered negative for Her2, and above 
1.8 was considered HER2 amplified and therefore HER2 positive. 
 
References: 
1. Dahia PL, FitzGerald MG, Zhang X, Marsh DJ, Zheng Z, Pietsch T, von Deimling A, Haluska FG, Haber DA, 
Eng C (1998) A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene 
16 (18):2403-2406. doi:10.1038/sj.onc.1201762 
 
2. Poliseno L, Salmena L, Zhang J, Carver B, Haveman WJ, Pandolfi PP (2010) A coding-independent function 
of gene and pseudogene mRNAs regulates tumour biology. Nature 465 (7301):1033-1038. 
doi:10.1038/nature09144 
 
3. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, 
Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) High frequency of mutations of the 
PIK3CA gene in human cancers. Science 304 (5670):554. doi:10.1126/science.1096502 
 
4. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous 
M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale 
G, Hayes DF, American Society of Clinical O, College of American P (2013) Recommendations for human 
epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of 
American Pathologists clinical practice guideline update. J Clin Oncol 31 (31):3997-4013. 
doi:10.1200/JCO.2013.50.9984 
 
High PTEN gene expression is a negative prognostic marker in human primary breast cancers with 
preserved p53 function 
 
Breast Cancer Research and Treatment 
 
Authors: 
Synnøve Yndestad1,2, Eilin Austreid1, Stian Knappskog1,2, Ranjan Chrisanthar3, Peer Kåre Lilleng4,5, Per 
Eystein Lønning1,2, Hans Petter Eikesdal1,2* 
 
Author details: 
1Section of Oncology, Department of Clinical Science, University of Bergen, Bergen, Norway. 
2Department of Oncology, Haukeland University Hospital, Bergen, Norway. 
3Section of Molecular Pathology, Department of Pathology, Oslo University Hospital, Oslo, Norway.  
4Department of Pathology, Haukeland University Hospital, Bergen, Norway.  






























Online Resource 2.  
  
  All samples ER+ ER- TNBC TP53 wt TP53 mut PIK3CA wt PIK3CA mut 
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Immunohistochemistry results for PTEN and phosphorylated Akt (pAkt, Ser473), S6K (pS6K, Ser371 or 
Thr389) and 4EBP1 (p4EBP1, Thr70) proteins. Staining was performed on tissue microarray sections of 
pretreatment breast cancer samples from Study 3, and results are summarized for all samples, or 
subgrouped based on estrogen receptor (ER) status, triple negative breast cancer status (TNBC; 
ER/PGR/HER2 negative breast cancer), TP53 or PIK3CA mutation status. (c) = cytoplasmic staining. (n) 
= nuclear staining. *PTEN (c+n) score is given as (c+n)/2. 
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Online Resource 3 
a-b Forest plot for the association between tumor PTEN gene expression level and recurrence-free (a) or disease-
free survival (b) in patients with locally advanced breast cancer. Results are presented as individual hazard ratios 
(HRs) with corresponding 95% confidence intervals (CIs) for Study 1 (doxorubicin trial), Study 2 (FUMI trial) 
and Study 3 (epirubicin/paclitaxel trial) combined (i.e. all cohorts) or split by subgroups. HR>1 indicates that the 
survival of patients with tumor PTEN gene expression above the median (PTEN high) is shorter than that of 
patients with PTEN low tumors, while HR<1 indicates the opposite. RFS: recurrence-free survival, DSS: 
disease-specific survival, wt: wildtype, mut: mutated, ER: estrogen receptor, PGR: progesterone receptor, 
TNBC: triple negative breast cancer (ER/PGR/HER2 negative breast cancer), *for patients in Study 1 and 2 PGR 
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Online Resource 4 
a-b Forest plot for the association between tumor PTEN pseudogene (PTENP1) gene expression level and 
recurrence-free (a) or disease-free survival (b) in patients with locally advanced breast cancer. Results are 
presented as individual hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) for Study 1 
(doxorubicin trial), Study 2 (FUMI trial) and Study 3 (epirubicin/paclitaxel trial) combined (i.e. all cohorts) or 
split by subgroups. HR>1 indicates that the survival of patients with tumor PTENP1 gene expression above the 
median (PTENP1 high) is shorter than that of patients with PTENP1 low tumors, while HR<1 indicates the 
opposite. RFS: recurrence-free survival, DSS: disease-specific survival, wt: wildtype, mut: mutated, ER: 
estrogen receptor, PGR: progesterone receptor, TNBC: triple negative breast cancer (ER/PGR/HER2 negative 
breast cancer), *for patients in Study 1 and 2 PGR status was not available, and TNBC was defined as ER/HER2 
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Online Resource 5 
a-b Forest plot for the association between tumor protein staining by immunohistochemistry (IHC) and 
recurrence-free (a) or disease-free survival (b) in patients with locally advanced breast cancer. Results are 
presented as individual hazard ratios (HRs) with corresponding 95% confidence intervals (CIs), based on tissue 
microarray staining and survival data from Study 3 (epirubicin/paclitaxel trial). HR>1 indicates that the survival 
of patients with protein staining is shorter than that of patients without protein staining in the tumors, while 
HR<1 indicates the opposite. Number of samples analyzed per protein vary due to technical issues during tissue 
microarray staining. *One case censored before the earliest event in a stratum. RFS: recurrence-free survival, 
DSS: disease-specific survival, wt: wildtype, mut: mutated, ER: estrogen receptor, pAkt: phosphorylated Akt 
(Ser 473), pS6K (Ser 371): phosphorylated S6 kinase (Ser 371), pS6K (Thr 389): phosphorylated S6 kinase (Thr 
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ABSTRACT
Anthracyclines are key components of human breast cancer chemotherapy. Here, 
we explored the role of Akt signaling in anthracycline resistance.
The antitumor activity of doxorubicin and Akt inhibitor A-443654 alone or 
combined was examined in estrogen receptor (ER) positive and negative human breast 
cancer cell lines. Further, we examined mRNA changes induced by anthracyclines in 
locally advanced breast cancers biopsied before and after treatment in two clinical 
trials.
Doxorubicin increased Akt phosphorylation in ER positive MCF7 and T47D cell 
lines, with no effect in ER negative MDA-MB231 breast cancer cells. A-443654 was 
significantly more cytotoxic in doxorubicin-resistant compared to doxorubicin-naïve 
MCF7. This difference was not observed in MDA-MB231. Among 24 patients, AKT1 
gene expression increased 24 hrs after the initial epirubicin exposure in ER positive 
tumors responding to therapy (n=6), as compared to ER positive non-responders 
(n=7) or ER negative tumors (n=11). In contrast, AKT1 mRNA changes after 16 weeks 
of doxorubicin were unrelated to clinical response and ER status (n=30).
In conclusion, rapid Akt activation was observed in ER positive breast cancers 
which responded to anthracyclines. Increased cytotoxicity of A-443654 in doxorubicin-
resistant MCF7 cells indicates a possible role for Akt inhibitors in ER positive breast 
cancers where chemoresistance evolves.
INTRODUCTION
Phosphatidylinositol-4,5-bisphosphate 3-kinase 
(PI3K)-Akt-mammalian target of rapamycin (mTOR)-S6 
kinase (S6K) signaling (in short: PI3K signaling) is 
upregulated in 25% of human breast cancers and has 
been associated with resistance to endocrine as well as 
HER2 directed therapy [1–3]. PIK3CA, encoding the 
p110α subunit of PI3K, harbors activating mutations in 
up to 45% of luminal A breast cancers [4], which are 
typically estrogen receptor (ER) positive tumors. Thus, 
therapeutic inhibition of the PI3K signaling pathway with 
the mTOR inhibitor everolimus can be used to counteract 
acquired resistance to aromatase inhibitors and prolong 
survival among patients with ER positive breast cancer 
[3]. Moreover, activating PIK3CA mutations are observed 
in ER negative breast cancer as well [4], and mTOR 
inhibition, combined with trastuzumab and paclitaxel, 
prolonged progression-free survival significantly 
among patients with hormone receptor negative, HER2 
positive breast cancer [5]. However, the potential to treat 
chemoresistant breast cancer by inhibiting PI3K signaling 
has not been thoroughly addressed thus far.
Phosphatase and tensin homolog (PTEN) is the 
main endogenous inhibitor of PI3K activation [6]. While 
experimental studies revealed loss of PTEN function to 
be associated with reduced sensitivity to doxorubicin 
in breast and prostate cancer models, chemosensitivity 
was restored by concomitant mTOR inhibition [7, 8]. 
Furthermore, increased Akt phosphorylation is observed in 
doxorubicin-resistant ER positive, but not in ER negative 
breast cancer cell lines [9–11]. In line with this, inhibitors 
of the PI3K-Akt-mTOR pathway can be employed to 
enhance anthracycline sensitivity in ER positive breast 
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cancers [10, 11] Whereas the introduction of Akt inhibitors 
in clinical trials has been slower than PI3K and mTOR 
inhibitors [12], the key position of Akt as a signal hub for 
important pro-tumorigenic pathways [6] makes such trials 
highly relevant.
In the present work we assessed the in uence of 
doxorubicin treatment on PTEN and Akt-mTOR-S6K 
signaling, and the interaction between doxorubicin and the 
Akt inhibitor A-443654 in ER positive and negative human 
breast cancer cell lines in vitro and in vivo. In particular, 
cell lines made resistant to doxorubicin by continous drug 
exposure were compared with doxorubicin-na ve cells to 
decipher the role of Akt-mTOR-S6K signaling in breast 
cancer chemoresistance. Furthermore, the short-term and 
long-term changes in PTEN and AKT1 gene expression 
subsequent to anthracycline exposure were assessed in 
patients with locally advanced breast cancers.
RESULTS
Influence of doxorubicin treatment on Akt 
activity and PI3K signaling in doxorubicin-naïve 
breast cancer cell lines
A sublethal concentration of doxorubicin (24 hrs 
exposure) was established by the W T-1 assay, to facilitate 
subsequent assessment of increased cytotoxicity when the 
A-443654 Akt inhibitor was introduced. The IC30 was 
approximately 1.5-2.0 M for M 231 and M F  and 
0.5-1.0 M for T4  ( upplementary Figure 1A). ased 
on this, doxorubicin was used at a concentration of 1.5 
M for M 231, 2 M for M F  and 0.  M for T4  
for the in vitro experiments. Each experimental setup was 
conducted in three parallel cell cultures.
oxorubicin increased phosphorylated Akt (p-Akt) 
in the ER positive M F  and T4  human breast cancer 
cell lines (Figure 1 , upplementary Figure 1 ). In 
contrast, p-Akt was not in uenced by doxorubicin in 
the ER negative M 231 cell line (Figure 1A). Whereas 
doxorubicin had no impact on PTEN protein levels in 
neither cell line, mTOR phosphorylation levels increased 
in M 231 and decreased in M F  cells (Figure 1A-
1 ), although not significant by densitometry (Figure 
1E-1F). Phosphorylated S6K was weakly expressed in 
both cell lines, and a non-significant decrease in 6K 
phosphorylation levels was observed in the M F  cell line 
after doxorubicin exposure (Figure 1A-1 ).
AKT1 mRNA levels as determined by P R 
analysis remained unaltered 24 hours after doxorubicin 
exposure in all three cell lines (Supplementary Figure 2A). 
While PTEN mRNA levels decreased in M 231 cells, no 
change was observed in M F  and T4  cells subse uent 
to doxorubicin treatment (Supplementary Figure 2A). 
The reason why decreased PTEN mRNA levels did not 
translate into decreased PTEN protein levels in M 231 
cells exposed to doxorubicin remains to be elucidated, 
but the rapid changes in gene expression induced by 
the chemotherapy could take longer to translate into a 
change in protein levels, due to a half-life of more than 
8 hrs for PTEN [13]. Furthermore, there is no strong 
correlation between PTEN mRNA and PTEN protein 
levels in human breast cancer, which could be explained 
by post-transcriptional and post-translational mechanisms 
modifying protein expression and stability [14].
Influence of doxorubicin treatment on Akt 
activity and PI3K signaling in doxorubicin-
resistant cell lines
We performed the same experiments as outlined 
above in M 231 and M F  cells made resistant to 
doxorubicin through long-term doxorubicin exposure (see 
Methods & materials).
While doxorubicin exposure for 24 hours increased 
AKT1 gene expression in doxorubicin-resistant MCF7 
cells, no significant change in AKT1 expression was 
observed subse uent to doxorubicin expression in 
M 231 cells ( upplementary Figure 2 ). Notably, 
PTEN gene expression was profoundly reduced 24 hrs 
after doxorubicin exposure in doxorubicin-resistant 
M 231, whereas a minor PTEN increase was observed 
in doxorubicin-resistant MCF7 cells (Supplementary 
Figure 2 ). While p-Akt increased at the protein level 
in doxorubicin-resistant compared to doxorubicin-na ve 
M 231 cells, no change in downstream signaling was 
observed. The level of p-Akt was increased in doxorubicin-
resistant M 231 cells, compared to doxorubicin-na ve 
cells, but without any changes in downstream signaling 
(Figure 1A, 1C). In doxorubicin-resistant MCF7 cells, 
the protein levels of PTEN, p-Akt, mTOR and p-mTOR 
were higher compared to doxorubicin-na ve cells (Figure 
1 , 1 ). However, an additional pulse of doxorubicin 
treatment did not change PTEN or Akt-mTOR-S6K 
protein levels further in doxorubicin-resistant M 231 or 
M F  cells, compared to sham treatment (Figure 1 - ).
Akt inhibition in doxorubicin-naïve and resistant 
MB231 and MCF7 cell lines
Next, we examined the cytotoxicity of the Akt 
inhibitor A-443654, alone or combined with doxorubicin, 
in the ER negative M 231 and ER positive M F  
cell lines. Moreover, based on the increased Akt 
phosphorylation levels observed in the doxorubicin-
resistant cell lines, we compared the doxorubicin-na ve 
and resistant cell lines with respect to Akt inhibitor 
cytotoxicity.
First, it was established that the IC30 concentration 
of A-443654 was 1.0 M in M 231 and 0.5 M in the 
MCF7 cell line (Supplementary Figure 2C). A-443654 is 
a known ATP competitive inhibitor of Akt, which causes 
a transient increase in Akt phosphorylation at S473 [15]. 
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In line with this, 2 hrs exposure to A-443654 increased 
Akt phosphorylation in a dose-dependent manner in 
M F  as well as M 231 cells (Figure 2A-2 ). The 
induction of Akt by A-443654 in ER negative M 231 
cells was not in uenced by doxorubicin resistance 
(Figure 2A). However, in ER positive M F  cells, 
the induction of Akt phosphorylation by A-443654 
was significantly less prominent in doxorubicin-
resistant compared to doxorubicin-na ve cells (Figure 
2 ), suggesting that long-term doxorubicin exposure 
exhausts the ability to activate Akt and could in uence 
the response to A-443654. Of notice, the baseline 
phosphorylation level of Akt in doxorubicin-na ve 
M 231 differed in Figure 1A and 2A, possibly due to 
the use of different dissolvents given to control cells 
in the two experiments  HPM  was used as dissolvent 
Figure 1  oxorubicin treatment of doxorubicin-naïve and doxorubicin-resistant human breast cancer cell lines  A-B  
Western blots of PTEN and Akt-mTOR- 6K signaling in M 231 and M F  breast cancer cells in vitro, either doxorubicin-na ve A-B  or 
doxorubicin-resistant (C- , dox-res). rug exposure lasted 24 hrs, at either 1.5 M for M 231 and 2 M for M F  or an e uivalent volume 
of M O (stock solvent for doxorubicin) for control wells, three independent experiments per group. Whole cell lysate, 30 g protein 
loaded per lane. -F  ensitometries for western blots A-  depict the relative protein expression, normali ed to actin. Phosphorylated 
Akt (p-Akt) and mTOR (p-mTOR) were normali ed to actin and thereafter to total Akt and mTOR, respectively. ars represent the mean 
protein expression for experiments performed in triplicate ± SEM. **p<0.01
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Figure 2  Akt inhibitor treatment of doxorubicin-naïve and doxorubicin-resistant human breast cancer cell lines  A-B  
Western blots of Akt phosphorylation induced by increasing doses of the Akt inhibitor A-443654, 0-10 M, 2 hrs exposure in doxorubicin-
na ve or doxorubicin-resistant M 231 A  and MCF7 B  human breast cancer cells in vitro. Whole cell lysate, 30 g protein loaded per 
lane. ensitometries for western blots A-B  depict the relative protein expression, normali ed to actin and total Akt. Phosphorylated Akt 
increased significantly in doxorubicin-na ve (dox-na ve), compared to doxorubicin-resistant M F  cells (dox-res), at AKTi concentrations 
above 0.5 M. p 0.05. C-  Western blot analysis of Akt and downstream signaling in doxorubicin-na ve or doxorubicin-resistant M 231 
C  and MCF7  human breast cancer cells, after 24 hrs exposure to A-443654 (M 231  1 M, M F  0.5 M) in vitro. ensitometries for 
western blots C-  depict the relative protein expression, normali ed to actin. ars represent the mean protein expression in experiments 
performed in triplicate ± SEM.
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for A-443654 (Figure 2A), whereas M O was the 
dissolvent for doxorubicin (Figure 1A).
To decipher the consequence of Akt inhibition in a 
wider time frame, Akt phosphorylation and downstream 
signaling was assessed after 24 hrs of A-443654 (IC30) 
exposure (Figure 2 -2 ). As compared to 2 hrs, total 
Akt was profoundly reduced after 24 hrs, suggesting the 
Akt inhibitor may induce protein degradation. In parallel, 
phosphorylated Akt remained upregulated after 24 hrs 
of doxorubicin exposure in the doxorubicin-na ve as 
well as the doxorubicin-resistant M F  and M 231 cell 
lines, which is in accordance with the reported activity 
of A-443654 [16]. With respect to downstream signaling, 
it was clearly reduced by A-443654 in the doxorubicin-
na ve M F  cell line, with decreased K3 and 6K 
phosphorylation and increased 4E P1 protein levels 
(Figure 2 ), and the same signaling inhibition was 
observed in the doxorubicin-resistant M F  cell line. 
The in uence of A-443654 on Akt downstream signaling 
was less pronounced in the M 231 cell line (Figure 
2 ). Whereas reduced K3 and increased 4E P1 
phosphorylation was observed in doxorubicin-na ve 
M 231, Akt inhibition had no in uence on phosphorylated 
6K. In doxorubicin-resistant M 231, A-443654 reduced 
6K and increased 4E P1 phosphorylation, in accordance 
with protein synthesis inhibition, but at the same time 
phosphorylated K3 protein levels increased, indicating 
glycogen synthase and cell cycle activation. All in all, 
these results point to a stronger dependence on Akt 
downstream signaling for cell proliferation in MCF7 than 
in M 231 breast cancer cells when doxorubicin resistance 
evolves.
Indeed, the Akt inhibitor exhibited significantly 
increased cytotoxicity in doxorubicin-resistant compared 
to doxorubicin-na ve M F  cells (Figure 3 ). In contrast, 
the cytotoxicity of A-443654 was significantly reduced 
in doxorubicin-resistant compared to doxorubicin-na ve 
M 231 cells (Figure 3A). The cytotoxicity of A-443654 
was not augmented by doxorubicin in neither cell line 
(Figure 3A-3 ).
f cacy of doxorubicin and Akt inhibition in 
doxorubicin-naïve MB231 and MCF7 xenografts 
in vivo
The efficacy of sham treatment, A-443654 or 
doxorubicin, alone or in combination, was assessed 
in NO I  mice implanted orthotopically with 
doxorubicin-na ve M 231 or M F  human breast cancer 
(n 5-6 mice group).
The Akt inhibitor A-443654 was ineffective as 
monotherapy in M 231 tumors in mice, but inhibited 
tumor growth significantly in M F  tumors (Figure 
4A-4 ). oxorubicin treatment yielded significant 
tumor inhibition in both cancer subtypes. In M 231, 
the combination of doxorubicin and A-443654 inhibited 
tumor growth significantly compared to A-443654 or sham 
treatment, but only if A-443654 was postponed for a week 
after commencing doxorubicin administration (treatment 
group ). In contrast, co-administration of A-443654 
and chemotherapy (treatment group A) diminished the 
tumor growth inhibition induced by doxorubicin alone. 
In MCF7, the combination of doxorubicin and A-443654 
yielded significant tumor growth inhibition as compared to 
A-443654 or sham treatment, but only if the Akt inhibitor 
and doxorubicin were administered concomitantly 
(treatment group A). In both breast cancer models there 
was no significant difference in tumor response between 
doxorubicin alone and doxorubicin combined with 
A-443654.
Subcutaneous Akt inhibitor injections caused a 
7% weight loss after 14 days of treatment, which was 
comparable to combined treatment with doxorubicin and 
A-443654. However, the observed weight loss precluded 
further extension of the A-443654 treatment period, to 
assess whether long-term Akt inhibiton could augment 
the efficacy of doxorubicin. nfortunately, two mice in 
the doxorubicin and one mouse in the doxorubicin and 
A-443654 group (A) had to be euthanized and taken out of 
the MCF7 trial due to accidental injection of doxorubicin 
into the gut wall and subsequent gut necrosis.
In a separate experiment, mice exposed to the 
same treatment regimens as above were euthani ed 
after 14 days and tumor tissue extracted for molecular 
analysis (doxorubicin-na ve M 231  n 3 mice
group and M F  n 2 mice group). As monotherapy, 
A-443654 or doxorubicin yielded a heterogenous 
increase in Akt phosphorylation in MCF7 and to 
a lesser extent in M 231 xenografts, although not 
significant by densitometry (Figure 4 -4 ). ombined 
treatment with A-443654 and doxorubicin increased 
Akt phosphorylation in M F  xenografts significantly, 
whereas the phosphorylation level of Akt in M 231 
was unaffected by the combination regimen (Figure 4C-
4 ). While Akt phosphorylation increased substantially 
subsequent to 24 hours of A-443654 treatment in vitro 
(Figure 2A-2 ), this increase was less pronounced 
in M 231 and M F  xenografts after two weeks of 
A-443654 treatment (Figure 4 -4 ).
Potential effects of Akt inhibition was further 
monitored by analyzing downstream target effects (S6K 
phosphorylation status). In doxorubicin-na ve M 231 
tumors, protein analysis demonstrated significantly reduced 
S6K phosphorylation after treatment with doxorubicin alone 
or combined with A-443654 (Figure 4C). In doxorubicin-
na ve M F  tumors, A-443654 or doxorubicin, either 
alone or in combination, reduced mTOR phosphorylation 
(Figure 4 ). ene expression analysis of PTEN, AKT1 
and S6K in tumors extracted 14 days after commencing 
therapy (Supplementary Figure 3) demonstrated a 
significant decrease in AKT1 in MCF7 tumors subsequent 
to doxorubicin exposure, but apart from this no definite 
Oncotarget6www.impactjournals.com/oncotarget
differences between the treatment groups were observed in 
neither M F  nor M 231.
ene ex ression changes induced by 
anthracyclines in human breast cancers
Next, to compare with the preclinical results, we 
examined how anthracyclines affected acute and chronic 
tumor gene expression by analyzing breast cancer samples 
obtained before and 24 hours after the first epirubicin 
(60 mg m2 i.v.) course, or before and after 16 weeks 
of weekly doxorubicin (14 mg m2 i.v.). All 24 tumors 
collected in the dose dense epirubicin trial (ClinicalTrials.
gov N T004 6 5)expressed PTEN, AKT1 and S6K, 
before and or after treatment ( upplementary Figure 4). 
Among the patients treated with epirubicin, AKT1 gene 
expression increased significantly (p 0.016) in tumors that 
subsequently regressed on treatment (PR; n=9), whereas 
no change was observed in tumors that did not respond 
( , P  n 15, Figure 5A). The mRNA levels of PTEN 
and S6K did not change significantly, neither among 
responders nor non-responders (Figure 5A). Stratifying 
patients according to ER status, neither AKT1, PTEN nor 
S6K mRNA levels were in uenced by epirubicin exposure 
among ER negative tumors (n 11), independent of clinical 
response to therapy (Figure 5 ). Interestingly, among the 
ER positive tumors (n 13), AKT1 (p=0.040) as well as 
PTEN levels (p 0.03 ) increased significantly in patients 
who responded to therapy (n=6); whereas no change 
in neither AKT1 nor PTEN levels was observed among 
the non-responders (n , Figure 5 ). Furthermore, S6K 
decreased significantly (p 0.02 ) in ER positive tumors 
that did not respond to therapy (n , Figure 5 ).
After a median follow-up of 69 months, six out 
of 24 patients from the dose dense trial had developed 
breast cancer recurrence; no difference in gene expression 
changes between patients relapsing and those not relapsing 
was observed ( upplementary Figure 4).
To assess potential long-term effects of 
anthracycline treatment, tumor samples collected from 30 
patients with locally advanced breast cancers, before and 
after 16 weeks of doxorubicin [30, 31], were examined for 
long-term gene expression changes of PTEN and AKT1 
(Supplementary Figure 5). Analysing all patients together, 
no change in neither AKT1 nor PTEN expression was 
observed. However, stratifying patients based on response 
to therapy, PTEN expression increased significantly 
(p 0.033) among non-responders (patients having a P  
or  on therapy  n 1 ), in particular among ER negative 
non-responders (n 4  p 0.026  Figure 6A-6 ). In contrast, 
Figure 3  Cytotoxicity of A- 3  and doxorubicin in doxorubicin-naïve and doxorubicin-resistant human breast 
cancer cell lines  In vitro cytotoxicity of doxorubicin (1 M), Akt inhibitor A-443654 at I 30 concentration, or the combination, in 
doxorubicin-na ve or resistant M 231 A  and MCF7 B  cells, after 24 hrs drug exposure. W T-1 cell proliferation assay, absorbance 
read at optical density (O ) 450 nm, normali ed to readings in control wells exposed to e uivalent volumes of M O (doxorubicin stock 
solvent) and HPM  (dissolvent for A-443654). ars depict the mean  EM. p 0.01, p 0.001
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Figure  he influence of A- 3  and doxorubicin on tumor gro th in vivo  A-B  Tumor growth of M 231 and M F  
breast cancer in NO I  mice, given doxorubicin ( O ) 1.25 mg kg i.p. W twice (red arrows), Akt inhibitor A-443654 (AKTi) 3. 5 
mg mg kg I  14 days (green lines) or the combination. AKTi treatment commenced either at the first A  or at the second B  doxorubicin 
in ection. Tumor volume is displayed as the mean  EM for each group, relative to tumor volume on the day treatment started. p 0.05, 
**p<0.01. C-  Western blots for PTEN and Akt-mTOR- 6K signaling in M 231 C  and MCF7  tumors, harvested the last day of 
A-443654 treatment. Whole cell lysate, 30 g protein loaded per lane. The sample order on the blot pictures has been rearranged to enhance 
readability. ensitometries for western blots C-  depict the relative protein expression, normali ed to actin. Phosphorylated Akt (p-Akt) 
and mTOR (p-mTOR) were normali ed to actin and thereafter to total Akt and mTOR, respectively. ars represent the mean protein 
expression for experiments performed in duplicate  or triplicate C  ± SEM. *p<0.05
Oncotarget8www.impactjournals.com/oncotarget
while 22 out of 30 patients had relapsed during a median 
follow-up of 235 months, gene expression changes did not 
correlate to long-term outcome (Supplementary Figure 5).
The mutation status of PIK3CA and TP53 was 
assessed in all the above tumor samples ( upplementary 
Figure 4 and Supplementary Figure 5). The low number 
of tumors harboring PIK3CA mutations precluded any 
correlation analysis between PIK3CA mutation status 
and the gene expression changes observed. Among 
tumors assessed before and 24 hours after the initial 
epirubicin course, no difference in PTEN or AKT1 
gene expression was observed regardless of response to 
Figure  AKT1, PTEN and S6K gene ex ression in human breast cancers before and 2  hrs after e irubicin ex osure  
A  ox plots of gene expression of PTEN, AKT1 and S6K normalized to RPLP2 in human breast cancer samples, before and 24 hrs after 
the first epirubicin dose, from patients in the dose dense trial. B  ox plots from the same patient cohort as in A , but depicted separately 
for estrogen receptor (ER) positive and ER negative breast cancers. p 0.05
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Figure  AKT1 and PTEN gene ex ression in human breast cancers before and after 1  eeks of doxorubicin 
treatment  A  ox plots of gene expression of PTEN and AKT1 normalized to RPLP2 in human breast cancer samples, before and after 
16 weeks of doxorubicin treatment, from patients in the doxorubicin trial. B  ox plots from the same patient cohort as in A , but depicted 
separately for estrogen receptor (ER) positive and negative breast cancers. p 0.05
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chemotherapy, if subdivided into TP53 wt (n=16) and 
TP53 mutated tumors (n ). pregulated AKT1 24 hrs 
after the first epirubicin exposure was observed in six 
out of 13 ER positive breast cancers which subse uently 
regressed on this treatment (Figure 5); and four out of 
these six tumors where AKT1 increased harbored wt 
TP53 status (Supplementary Figure 4).
In tumors examined before and after 16 wks of 
doxorubicin, if split by TP53 mutation status (TP53 
wt; n=15, TP53 mutated; n=15), PTEN increased 
significantly after treatment (p 0.02) in tumors harboring 
TP53 mutations that did not respond to doxorubicin 
treatment (n ), whereas no change was observed among 
responders (n=7) or among TP53 wt tumors (data not 
shown). Also, there was no significant change in AKT1, 
among responders or non-responders to doxorubicin, if the 
subgroups were split by TP53 mutation status.
DISCUSSION
Patients with ER positive as well as ER negative 
breast cancer obtain improved survival from ad uvant 
polychemotherapy [1 ], but the benefit of chemotherapy is 
less in typical luminal A tumors with strong ER expression 
compared to other subtypes [18]. The mutational 
landscape of breast cancer subtypes differ substantially, 
with a high prevalence of activating PIK3CA mutations in 
ER positive, luminal or HER2-enriched tumors, whereas 
inactivating TP53 mutations are commonly observed in 
ER negative subtypes [4]. Moreover, while activating 
AKT1 mutations are rare in human breast cancers, they 
occur more frequently among luminal or HER2-enriched 
(2-4%) than basal-like tumors (0%) [4], suggesting a 
selection pressure towards increased Akt signaling in 
these neoplasms. Accordingly, the PI3K-Akt-mTOR 
pathway has been targeted therapeutically to counteract 
acquired resistance to endocrine therapy and combined 
trastuzumab-chemotherapy in clinical trials [1, 3, 5, 19]. 
However, the importance of PI3K-Akt-mTOR signaling to 
chemoresistance has not been fully elucidated.
Here, we systematically explored alterations in this 
pathway in response to anthracycline and or Akt inhibition 
in ER positive and negative breast cancer cell lines 
and their concomitant xenografts and to anthracycline 
treatment in human breast cancers.
We established that the Akt inhibitor A-443654 
reduces cell proliferation both in the ER positive M F  
and the ER negative M 231 cell line in vitro. However, 
Akt inhibition yielded tumor regression in MCF7 and not 
M 231 in vivo, and doxorubicin significantly augmented 
this tumor response only in MCF7 xenografts. Of notice, 
A-443654 caused significant weight loss which was 
intolerable beyond 14 days, and we therefore could 
not explore its full potential alone or combined with 
anthracyclines. Toxicity was a similar problem in the first 
clinical trials testing Akt inhibitors, although next generation 
compounds seem better tolerated [20] and should be tested 
in long-term combination schedules with anthracyclines. 
Importantly, the combined efficacy of A-443654 and 
doxorubicin was dependent on timing, where concomitant 
administration of the Akt inhibitor and chemotherapy was 
required for optimal tumor regression in MCF7 xenografts. 
In contrast, co-administration of A-443654 with doxorubicin 
reduced the efficacy of doxorubicin in M 231 xenografts. 
oxorubicin yielded rapid upregulation of phosphorylated 
Akt in MCF7 cells in vitro, whereas long-term exposure 
and induction of doxorubicin resistance was required 
to upregulate phosphorylated Akt in M 231. This may 
explain the different efficacy with respect to timing between 
doxorubicin and the Akt inhibitor in the two cell lines.
Previous studies have revealed A-443654 to act as 
an ATP competitive inhibitor of Akt  as such, it increases 
Akt phosphorylation while at the same time inhibiting Akt 
downstream signaling [15, 16]. Accordingly, A-443654 
rapidly increased Akt phosphorylation, which was more 
pronounced in the M F  as compared to the M 231 cell 
line, and suggesting a particular responsiveness of the PI3K-
Akt-mTOR pathway in ER positive breast cancer cells. 
However, the cytotoxicity of A-443654 was comparable 
between M F  and M 231, and similar inhibition of Akt 
downstream signaling was observed in the ER positive and 
ER negative cell lines. In contrast, the activity of A-443654 
was profoundly reduced in doxorubicin-resistant M 231 
cells, where the inhibition of Akt signaling by A-443654 was 
abrogated. Interestingly, doxorubicin resistance enhanced 
the cytotoxicity of A-443654 significantly in M F , with 
maintained inhibition of Akt downstream signaling. The 
mechanisms behind the enhanced activity of A-443654 in 
doxorubicin-resistant MCF7 cells remain to be established. 
However, the baseline Akt phosphorylation level is higher 
in the doxorubicin-resistant MCF7 cell line, as compared to 
doxorubicin-na ve M F  cells, potentially explaining the 
increased cytotoxicity towards A-443654.
In line with previous observations [10, 21], we 
established that doxorubicin exposure increases Akt 
phosphorylation in the ER positive M F  and T4  
human breast cancer cell lines, but not the ER negative 
M 231 cell line. Herein we expand upon these data to 
show that MCF7 cells made resistant to doxorubicin 
exhibit a higher constitutive Akt phosphorylation levels 
which is not affected by further doxorubicin exposure. The 
increased cytotoxicity of Akt inhibition in doxorubicin-
resistant MCF7 breast cancer cells points to a potential 
use of such a drug class in ER positive breast cancer, in 
particular if resistance to anthracycline has developed 
and Akt phosphorylation levels are elevated. Importantly, 
while the Akt inhibitor exhibited increased cytotoxicity 
in doxorubicin-resistant compared to doxorubicin-na ve 
MCF7 breast cancer, we did not examine whether Akt 
inhibitors can be used to reverse doxorubicin resistance, 
but this issue should be addressed in future trials. 
However, upregulated PI3K-Akt-mTOR signaling is 
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clearly associated with chemoresistance, which has 
been shown in various preclinical cancer models, and 
chemotherapy response can be augmented in this setting 
by simultaneous PI3K or Akt inhibition [10, 11, 22–24], in 
particular in ER positive breast cancer [10, 22].
Finally, we provide clinical data demonstrating that 
increased AKT1 gene expression 24 hours after epirubicin 
exposure characteri es ER positive, but not ER negative, 
primary breast cancers that subsequently regress on 
anthracycline treatment. Interestingly, no change in tumor 
AKT1 expression was observed in patients after 16 weeks 
of doxorubicin, suggesting an intermittent Akt response 
where the efficacy of Akt inhibitors could depend on 
timing. Furthermore, an increased AKT1 mRNA level 24 
hrs after the first chemotherapy course could potentially 
be used as a biomarker identifying ER positive tumors 
likely to respond to chemotherapy. The reason why 
elevated AKT1 mRNA is associated with good response 
remains to be elucidated. However, if high AKT1 translates 
into increased Akt activation throughout the duration 
of chemotherapy, chronic Akt activation may promote 
senescence and apoptosis by downregulating M M2 
and increasing p53 in breast cancers with preserved p53 
function [25, 26]. Of notice, among the ER positive 
breast cancers which responded to epirubicin, four out 
of six tumors with upregulated AKT1 after chemotherapy 
harbored wt TP53 status.
In contrast to the patient data, AKT1 mRNA levels 
were not affected in the M 231 and M F  human breast 
cancer cell lines after 24 hrs chemotherapy exposure. The 
reason for this discrepancy remains to be elucidated, but 
could be due to the admixture of tumor cells and stroma 
in patient tumor samples in contrast to the pure tumor cell 
content in the in vitro cultures. nfortunately, we did not 
have patient samples available for proteinanalysis of Akt 
and Akt signaling to compare with the gene expression 
data. Furthermore, the induction of Akt phosphorylation 
by A-443654 which was observed in M 231 and M F  
in vitro, was not detected in the corresponding xenografts. 
Again, the admixture of tumor cells and stroma cells in 
vivo, as well as the heterogeneity between the xenografts 
may explain the lack of correlation between the in vivo 
and in vitro findings. Moreover, the xenografts used for the 
proteinanalysis were extracted after 14 days of treatment 
compared to the 2 hrs and 24 hrs of treatment in the in 
vitro experiments. The reason why decreased PTEN 
mRNA levels did not decrease PTEN protein levels in 
M 231 cells after 24 hrs exposure to doxorubicin also 
remains to be established. Whereas rapid changes in gene 
expression are induced by the chemotherapy, protein 
changes may take longer to develop due to the relatively 
long half-life of PTEN (>8 hrs) [13]. Furthermore, there 
is no strong correlation between PTEN mRNA and PTEN 
protein levels in human breast cancer [14], which could 
be explained by post-transcriptional and post-translational 
mechanisms modifying protein expression and stability.
In conclusion, our data point to upregulated Akt 
expression as a recurrent initial response to anthracyclines 
in ER positive human breast cancers, and in particular, 
among patients who respond to chemotherapy. 
Furthermore, we observed increased sensitivity to 
Akt inhibition in doxorubicin-resistant, compared to 
doxorubicin-na ve, ER positive M F  breast cancer 
cells. Accordingly, the benefit of Akt inhibition is clearly 
context-dependent, with respect to ER status and previous 
anthracycline exposure. Thus far, the role of Akt inhibitors 
to augment the efficacy of chemotherapy in solid tumors 
has not been dealt with to a large extent, despite promising 
preclinical and clinical data [23, 24, 27–29] and should 
be explored further, in particular in ER positive breast 
cancers.
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Cell lines
The ER positive M F  and T4  and the ER 
negative M A-M -231 (M 231) human breast cancer 
cell lines were used for all the preclinical experiments. 
For cell growth conditions and cell line identity, see 
Supplementary methods. oxorubicin (Adriamycin, 
Pfi er) was diluted to 2 mg ml in M O  for cell 
culture experiments, stored as frozen aliquots (-20°C), and 
prepared fresh by dilution in complete cell culture medium 
for each experiment to preserve drug stability. ontrol 
cells were always incubated with an e uivalent volume 
of M O  as cells exposed to medium containing 
doxorubicin. A-443654 (Abb ie) was dissolved in 0.2  
hydroxypropyl methylcellulose (HPMC, Sigma) prior 
to use. For comparison, control cells were given an 
e uivalent volume of HPM  as those cells exposed to 
A-443654.
eneration of doxorubicin-resistant cell lines
oxorubicin-na ve M 231 and M F  cells were 
grown in gradually increasing doxorubicin concentrations 
over several months. When the cells were subcon uent 
they were exposed to growth medium containing twice 
the previous concentration of doxorubicin, and this was 
repeated until a dose was reached, where the cells would 
not expand any further. At this point, the cells had acquired 
resistance to doxorubicin 1.5 M (M 231 dox-res) and 
doxorubicin 0.65 M (M F  dox-res), each by exposure 
for 48 hrs. The cells were maintained in doxorubicin-free 
medium, but exposed to doxorubicin at their resistance 
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dose every two weeks to maintain resistance. ontrol cells 
were propagated in medium with an e uivalent volume of 
M O. To determine the acute response to doxorubicin in 
doxorubicin-resistant cells, the cells were seeded at 3x105 
in 6-well dishes (Nunc) and incubated for 24 hrs until 70% 
con uence. The medium was then replaced by medium 
containing either doxorubicin or M O, and cells were 
incubated for another 24 hrs before the cells was harvested 
and RNA and protein isolated.
In vitro activity and cytotoxicity of A- 3  and 
doxorubicin
ubcon uent M 231 and M F  cells (in T25 
asks), either doxorubicin-na ve or doxorubicin-resistant, 
were exposed to increasing concentrations of Akt inhibitor 
A-443654 or HPM  (control) to assess the in uence on 
Akt phosphorylation, and protein was harvested after 
2 hrs. To evaluate the in uence of the Akt inhibitor on 
Akt phosphorylation and downstream signaling after 24 
hrs, cells were exposed to A-443654 at the I 30 (1 M 
M 231, 0,5 M M F ), before harvesting protein.
To assess the in uence of doxorubicin - Akt 
inhibitor A-443654 on cell viability, 5000 M 231, 1500 
M F  or 20000 T4  cells were seeded per well in 6-
well plates (Falcon), and allowed to attach over night 
in complete medium. Thereafter the drug(s) was added, 
before culturing the cells for another 24 hours. Cell 
proliferation after drug exposure was assessed by the 
W T-1 assay (Roche), as described in the manufacturer s 
manual.
ene ex ression analysis and estern blots
Therapy-induced changes in gene and protein 
expression were assessed using qPCR and western blot 
analyses. etailed methods, primers and antibodies are 
described in Supplementary methods.
In vivo cytotoxicity of A- 3  and doxorubicin
NO I  mice were bred and mouse crossings 
performed inhouse at the Animal Facility, niversity of 
ergen. Adult mice of fertile age were anestheti ed with 
iso urane ( axter) before 1x106 M F  or M 231 cells were 
injected orthotopically in the fourth left inguinal mammary 
gland. The tumors were measured every 3-4 days using 
ernier calipers, and tumor volumes were calculated using 
the formula a2b 2, where a and b are the shorter and longer 
diameter of the tumors respectively. Treatment commenced 
when the tumors had reached 4-6 mm in diameter, and 
the animals were stratified into groups according to tumor 
size. The mice were euthanized if signs of serious distress 
occurred or when the first tumor in any treatment group had 
a tumor diameter exceeding 17 mm.
The maximum tolerable dose (MT ) of doxorubicin, 
given weekly for two following weeks, with or without 
the Akt inhibitor A-443654 was initially assessed in non-
tumor bearing NO I  mice before commencing the 
therapy trial in xenograft-implanted mice. oxorubicin 
was dissolved in 0.  Na l ( axter) and in ected i.p. once 
weekly for two consecutive weeks to establish an MT  of 
1.25 mg kg W. A-443654 was dissolved in HPM  and 
administered subcutaneously at 3. 5 mg kg I  for 14 
consecutive days, based on dosage reported elsewhere 
[16]. In the combination treatment groups, administration 
of A-443654 commenced either upfront (A), 24 hours after 
the first doxorubicin in ection (to treat primary resistance 
due to high Akt signaling), or started as a delayed regimen 
( ) at the same time as the second doxorubicin in ection 
(to counteract doxorubicin-induced acquired resistance 
due to upregulated Akt signaling). Control mice were 
given 0.2  HPM  s.c. and 0.  Na l i.p.
In a separate experiment, three M 231 mice and 
two M F  mice per group were sacrificed at the end of 14 
days of treatment (as given in the treatment trial above) for 
protein analysis. All animals were euthani ed by cervical 
dislocation two hours after the last injection of A-443654 
or sham treatment, and tissue samples from the tumor as 
well as all organs snap-frozen on liquid N2 and stored at 
-80°C.
The animal experiments were performed with the 
approval of and in accordance with guidelines by the 
Norwegian State Commission for Laboratory Animals.
Patient breast cancer sam les
The short-term effect of anthracyclines on PTEN, 
AKT1 and S6K gene expression was assessed in a selected 
cohort of 14 ER positive and 11 ER negative breast 
cancers biopsied before and 24 hrs after receiving their 
first course of epirubicin as part of the dose dense trial  
( linicalTrials.gov N T004 6 5) wherein treatment-
na ve patients with locally advanced breast cancer were 
given dose dense neoad uvant epirubicin 60 mg m2 q2w 
(four courses) followed by docetaxel 100 mg m2 q2w 
(four courses). The presence of pre-treatment PIK3CA 
and TP53 mutations in all tumor samples were examined 
as described in Supplementary methods. One ER positive 
tumor pair was excluded due to poor RNA uality, leaving 
24 tumor pairs for analysis.
Furthermore, to analyze for long-term effects of 
anthracyclines on PTEN and AKT1 mRNA levels, gene 
expression was assessed in paired tumor samples from 
30 patients with treatment-na ve locally advanced breast 
cancer in the doxorubicin trial , biopsied before and 
after 16 wks of neoad uvant doxorubicin 14 mg m2 W 
treatment [30, 31]. rie y, tumor pairs for mRNA analysis 
were available from 24 patients with ER positive and six 
patients with ER negative locally advanced breast cancer.
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The dose dense and doxorubicin clinical trials 
were approved by the Regional Ethical ommittee of the 
Western health region in Norway (reference numbers  
1 2 1-6 . 1 and 0 .06). All patients gave their informed 
consent before inclusion. Accordingly, all procedures 
performed in these clinical trials were in accordance with 
the national ethical standards and with the 1964 Helsinki 
declaration and its later amendments.
tatistics
P  22 PA W 1 .0 and raph Pad Prism v6 
software packages were used for statistical analyses. 
Correlation analysis between AKT1 and PTEN or S6K 
mRNA expression levels was performed using pearman s 
rho. omparison of gene or protein expression levels was 
performed using the Student’s t-test for paired samples 
or two independent samples, as appropriate. All p-values 
reported are two-tailed, and p<0.05 was considered 
statistically significant.
Availability of data and materials
All raw data generated from the experiments 
presented are available from the corresponding author 
upon request. The data subset used for mutational calling 
of TP53 and PIK3CA in the dose dense trial  was 
extracted from whole exome sequencing data, and the 
NA se uences are available from the corresponding 
author upon request.
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Activation of Akt characterizes estrogen receptor positive human 
breast cancers which respond to anthracyclines
SUPPLEMENTARY MATERIALS
SUPPLEMENTARY METHODS
Cell lines and growth conditions
The human breast cancer cell lines MDA-MB-231 
(MB231), MCF7 and T47D were purchased from American 
Type Culture Collection (ATCC, Manassas, VA). The cells 
were grown at 37°C in 5% CO
2
 atmosphere in Roswell Park 
Memorial Institute medium-1640 (RPMI), supplemented 
with non-essential amino acids, 10% fetal calf serum, 100 
ml penicillin, 100 g ml of streptomycin and 400 uM 
L-glutamine (all products: Lonza, Basel, Switzerland). 
Additionally, the RPMI medium for T47D was 
supplemented with human insulin 108 U/ml (Life/Thermo 
Fisher). The cell lines were tested negative for mycoplasma 
using the Mycoplasma Detection Kit Venor GeM (Minerva 
Biolabs) before starting the experiments listed. Also, the 
cell lines were fingerprinted based on short tandem repeat 
( TR) markers with the AmpF TR  Profiler Plus  and 
AmpF TR  Ofiler  P R Amplification Kit, followed 
by capillary electrophoresis on the ABI PRISM® 310 
enetic Analy er and TR allele identification using the 
Peak Scanner Software v1.0 (Applied Biosystems).
Basic genomic procedures
Breast cancer cells were grown on 6-well plates 
(Nunc), under conditions as described above, until 
subcon uency. After exposure to doxorubicin, the cells 
were rinsed gently with warm (37°C) phosphate-buffered 
saline (PBS), and RNA was isolated using the Qiagen 
RNeasy kit, as described in the product manual, followed 
by DNAse (Ambion) treatment.
The human breast cancer biopsies were snap-frozen 
immediately after extraction and stored on liquid nitrogen 
until analysis, while collecting prospectively response rates 
and patient survival data. DNA for mutation analysis was 
extracted by the Qiagen DNeasy kit, and RNA was extracted 
using either Trizol (Invitrogen) (doxorubicin study) or 
mirVana™ miRNA Isolation Kit, with phenol (Ambion) 
(dose dense study), followed by DNAse treatment.
RNA concentrations were measured by a NanoDrop 
spectrophotometer (Thermo cientific), and c NA 
was made from 500 ng of RNA using qScript reverse 
transcriptase and the qScript cDNA SuperMix with a blend 
of random and oligo(dT) primers (QuantaBio).
RT-PCR was undertaken using AmpliTaq Gold 
polymerase (Invitrogen), with reagents as recommended 
by the company, and PCR reactions were run with 30-35 
cycles and the appropriate temperature settings.
Real-time qPCR was performed on a Light 
Cycler 480 (Roche), with the gene of interest given as 
the ratio to housekeeping gene RPLP2, and as a mean 
of three individual runs. Taqman probes were used to 
detect the PCR products for PTEN and RPLP2, whereas 
PowerSYBR®Green (Applied Biosystems) was used for 
AKT1 and S6K. ack of gene expression was defined as 
lack of gene amplification after 35 cycles. ene of interest 
was given as a ratio to the housekeeping gene RPLP2, 
and as a mean of three independent runs, normalized to a 
cDNA pool of 6 breast cancer cell lines.
All P R products were checked for specificity by 
Sanger sequencing.
Primers for RT-PCR and real-time qPCR
RT-PCR:
AKT1: F: TTGGCTGCACAAACGAGGGGAGTAC, 
R: TGCGTTCGATGACAGTGGTCCAC
β-actin: F: AGATGACCCAGATCATGTTTG, 
R: AGGAGCAATGATCTTGATCTTCATTGTG
PTEN: F: TTTCCATCCTGCAGAAGAAGC, 
R: TAAATATGCACATATCATTAC
S6K: F: TGGACCATATGAACTTGGCATG, 
R: CTTTCCATAGCCCCCTTTACC
Real-time qPCR (PowerSYBR®Green):
AKT1: F: TTGGCTGCACAAACGAGGGGAGTAC, 
R: TGCGTTCGATGACAGTGGTCCAC











PIK3CA and TP53 mutation analysis
PIK3CA and TP53 mutation analysis was performed 
on pre-treatment breast cancer samples. All tumor samples 
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in the doxorubicin trial and eight out of 25 tumors in the 
dose dense trial were analyzed by Sanger sequencing. 
rie y, tumor NA was used as P R template to assess 
hot-spot PIK3CA mutations in exons 10 and 21 (previously 
exon 9 and 20) [1] and TP53 mutations (all exons), using 
primers as described previously [2, 3]. PCR products were 
analyzed at Center for Medical Genetics and Molecular 
Medicine, Haukeland University Hospital, by Sanger 
sequencing using the BigDye v1.1 reaction mix (Applied 
Biosystems). The remaining 17 tumors in the dose dense 
trial were analyzed for PIK3CA and TP53 mutations by 
massive parallel whole exome sequencing on an Illumina 
HiSeq 2500, to an average sequencing depth of >200x. 
Somatic mutations were called using the intersect between 
the MuTect and Strelka mutation calling algorithms.
Western blots
Cells and tissues were homogenized and proteins 
lysed in a custom made total protein lysis buffer (50 
mM Tris HCl, pH 7.5, 150 mM NaCl, 0.1% SDS, 1% 
deoxycholate, 1% Triton X-100) containing a protease 
inhibitor cocktail (Roche). Protein concentrations were 
measured by a bicinchoninic acid (BCA) assay (Pierce), 
and 30 g protein was loaded per lane for all the 
immunoblots.
The protein lysates were fractionated using reducing 
SDS-PAGE gel electrophoresis with Mini-PROTEAN 
TGX Precast Gels (Bio-Rad), and transblotted by semi-dry 
technique to nitrocellulose membranes using the Transblot 
Turbo system (Bio-Rad). Thereafter the membranes were 
blocked with 5% bovine serum albumine (Sigma) for 60 
min, before immunoblotting with the primary antibody. 
The immobilized antibody was detected using the 
appropriate horseradish peroxidase-conjugated secondary 
antibody (Promega) and a 1:5 mix of SuperSignal West 
Femto and Pico chemiluminescent solution (Pierce). The 
immunoreaction was visuali ed on a Fu ifilm A  4000. 
Immunoblots for actin were made for all samples to assure 
equal protein loading for total protein analysis.
Densitometry of western blots was performed using 
Gel Analyzer 2010a and the band intensity for each protein 
was normalized to actin. Thereafter phosphorylated Akt 
and mTOR were normalized to total Akt and mTOR, 
respectively.
Antibodies for proteinanalysis
Rabbit anti-actin (Sigma), anti-Akt (pan), anti-
phosphorylated Akt (Ser473), anti-mTOR, anti-
phosphorylated mTOR (Ser2448), anti-phosphorylated 
p 0 6K ( er3 1), anti-phosphorylated K3α  
(Ser21/9) or anti-PTEN and goat anti-4EBP1 (R&D). 
Actin, 4EBP1 and phosphorylated p70 S6K are polyclonal 
antibodies, all other antibodies are monoclonal. All 
primary antibodies were purchased from Cell Signaling, 
unless noted otherwise.
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Supplementary Figure 1: (A) Doxorubicin cytotoxicity in MB231, MCF7 and T47D breast cancer cells, assessed by WST-1 cell 
proliferation assay, after 24 hrs drug exposure. Absorbance was read at optical density (OD) 450 nm, and readings normalized to control 
wells, incubated with an equivalent DMSO (doxorubicin stock solvent) dose as in the wells with the highest doxorubicin dose. Bars depict 
the mean ± SEM. The dotted line indicates the IC30 level. (B) Western blots of PTEN and Akt protein expression in T47D breast cancer 
cells in itro, after exposure to doxorubicin or M O. rug exposure lasted 24 hrs, at 0.  M doxorubicin or an e uivalent volume of 
M O (stock solvent for doxorubicin) for control wells, three independent experiments per group. Whole cell lysate, 30 g protein loaded 
per lane.
SUPPLEMENTARY FIGURES
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Supplementary Figure 2: (A) Gene expression in doxorubicin-naïve MB231, MCF7 and T47D breast cancer cells in itro exposed to 
doxorubicin (M 231  1.5 M, M F  2 M, T4  0.  M), 24 hrs drug exposure. (B) Gene expression in doxorubicin-resistant MB231 
and MCF7 breast cancer cells in itro exposed to doxorubicin (M 231  1.5 M, M F  2 M), 24 hrs drug exposure. ars depict the mean 
gene expression of three parallels ± SEM, normalized to RPLP2, and analyzed by real-time quantitative RT-PCR. *p<0.05. ***p<0.001. 
(C) Cytotoxicity of Akt inhibitor A-443654 in MB231 and MCF7 cells, assessed by WST-1 assay, 24 hrs drug exposure. Absorbance was 
read at optical density (OD) 450 nm, and readings normalized to control wells, incubated with an equivalent dose of HPMC (A-443654 
dissolvent) as in the wells with the highest A-443654 dose. Data points depict the mean ± SEM.
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Supplementary Figure 3: Gene expression in MB231 (A) or MCF7 tumors (B) in NOD/SCID mice, given sham treatment (DMSO 
and HPMC; Controls), doxorubicin (DOX) 1.25 mg/kg i.p. qW twice, Akt inhibitor A-443654 (AKTi) 3.75 mg mg/kg BID 14 days or the 
combination. Tumors were removed and analyzed 14 days after commencing the treatment. Only tumors from treatment group B, wherein 
AKTi treatment commenced at the second doxorubicin injection, were used in the current analysis. Densitometry depicts the relative gene 
expression, normalized to ß-actin. Bars depict the mean ± SEM. *p<0.05.
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u lementary Figure  ene ex ression in human breast cancer sam les before and 2  hrs after the rst e irubicin 
dose (60 mg/m2), in 11 patients with estrogen receptor (ER) negative breast cancer and 13 patients with ER positive 
breast cancer included in the dose dense trial. Bars depict the ratio of gene expression after vs. before epirubicin, based on the 
mean of three separate real-time RT-PCR runs, normalized to RPLP2 and corrected for cDNA pool. PD: Progressive disease after 4 courses 
epirubicin q2w, SD: Stable disease, PR: Partial response. Patients with breast cancers harboring TP53 or PIK3CA mutations, and those with 
breast cancer recurrence are labelled beneath the diagram.
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Supplementary Figure 5: Gene expression in human breast cancer samples before and after 16 weeks of doxorubicin 
qW 14 mg/m2, in six patients with estrogen receptor (ER) negative breast cancer and 24 patients with ER positive 
breast cancer included in the doxorubicin trial. Bars depict the ratio of gene expression after vs. before 16 weeks of doxorubicin, 
based on the mean of three separate real-time RT-PCR runs, normalized to RPLP2 and corrected for cDNA pool. PD: Progressive disease, 
SD: Stable disease, PR: Partial response. Patients with breast cancers harboring TP53 or PIK3CA mutations, and those with breast cancer 
recurrence are labelled beneath the diagram.
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